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Thesis Abstract 
 
Background and Aims 
As a leading cause of morbidity and mortality, diabetes places a significant burden on society 
and presents a growing challenge for national economies. The economic burden of diabetes 
is forecast to grow in coming years, driven by increasing diabetes prevalence and rising 
medical expenditure. Worldwide, there is a lack of robust, comprehensive and comparable 
estimates of costs attributable to diabetes. Cost-effective interventions are required to 
efficiently manage and treat diabetes and curb increasing trends in incidence. Three effective 
interventions spanning the prevention continuum have recently been recommended in Irish 
health policy and can potentially influence the burden of diabetes; a sugar-sweetened 
beverage (SSB) levy, financial remuneration for the provision of structured diabetes care in 
primary care through the ‘cycle of care’ initiative and bariatric surgery.  The overarching aims 
of this thesis were to estimate the economic burden of diabetes in Ireland and to explore the 
potential for current policy approaches to impact on the burden of diabetes.  
Methods 
The economic burden of diabetes was estimated from a societal perspective employing an 
incremental costing approach where possible. Nationally representative data from The Irish 
LongituDinal study of Ageing (TILDA) and the national pharmacy claims database, Health 
Service Executive – Primary Care Reimbursement Service (PCRS), were utilised. Direct costs 
included health service utilisation costs and medication costs while indirect costs included 
productivity losses from reduced labour force participation and premature mortality. The 
impact of diabetes on health service utilisation and productivity were explored using 
multivariable regression models. Trends in pharmaceutical expenditure on diabetes between 
2011 and 2015 were explored. Total expenditure associated with diabetes was calculated by 
extracting data on all diabetes-related items dispensed. A comparative risk assessment was 
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conducted to robustly estimate the potential impact of a reduction in population-level SSB 
consumption on type 2 diabetes incidence. Using data from the Survey of Lifestyle, Attitudes 
and Nutrition (SLAN), the potential impact of a 10% levy on SSBs was explored. An 
assessment of the potential impact of the ‘cycle of care’ and bariatric surgery provision on 
the burden of diabetes was conducted using a cross-sectional analysis of TILDA. 
Results 
Diabetes was associated with excess health service use across the entire health system and 
was also adversely associated with productivity. Compared to those without diabetes, 
people with diabetes have on average 1.49 (95% CI: 1.10, 1.88) additional GP visits annually. 
Diabetes was associated with an 87% increase in out-patient visits, 52% increase in hospital 
admissions and 33% increase in A&E attendances (p<0.001). People with diabetes were 41% 
less likely to be employed than those without diabetes (p<0.001). The total costs of diabetes 
in those aged over 50 years in Ireland was estimated at €545,787,911 (95% CI: 365,597,451 
– 766,782,103) in 2013; €238,155,072 (95% CI: 192,023,954 – 278,959,992) in direct costs 
and €307,632,839 (95% CI: 173,573,497 – 487,822,111) in indirect costs. Over the five-year 
period from 2011 to 2015, the cost of prescription items used specifically in the treatment 
and management of diabetes increased by 18%, reaching €153,621,477 in 2015, with blood 
glucose-lowering medications accounting for 73% of this increase. The introduction of a 10% 
SSB levy is estimated to prevent 0.25% (95% UI: 0.01%,0.5%) of incident type 2 diabetes cases 
in a ten-year period. While the majority of people with type 2 diabetes are covered by the 
‘cycle of care’ initiative, 31.6% (95% CI: 27.8, 35.6) are not eligible. Current eligibility criteria 
do not identity people on the basis of clinical need but rather on income. With fewer than 
50 publicly funded bariatric surgeries taking place annually, current service provision meets 
less than 0.1% of the need. 
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Conclusion  
Diabetes places a substantial burden on the Irish health system as well as the national 
economy. The estimates provide useful information to inform policy-level responses to 
tackle the burden of diabetes. With findings demonstrating increasing pharmaceutical 
expenditure on diabetes in recent years, combined with the increasing prevalence of 
diabetes in Ireland, the economic burden of diabetes is likely to increase. Population-level 
interventions targeting SSB consumption can play a role in the primary prevention of type 2 
diabetes. The potential impact of effective tertiary prevention interventions, as 
recommended and supported by Irish health policy, are limited by inequitable and 
inadequate investment.  
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1. Introduction  
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1.1 Introduction 
Diabetes is one of the most concerning global public health challenges of the 21st century 
(1). As a leading cause of morbidity and premature mortality, diabetes places a significant 
burden on society (2,3). The number of people with diabetes continues to increase, driven 
by population growth and ageing. Between 1980 and 2014, the number of adults with 
diabetes worldwide increased four-fold (4). The global economic burden of diabetes was 
estimated at $1.31 trillion (95% CI: 1.28, 1.36) in 2015, accounting for 1.8% of global Gross 
Domestic Product (GDP) (5). With increasing diabetes prevalence and rising medical 
expenditure, the costs of diabetes are forecast to continue to grow in coming years (6,7). 
Should current trends in diabetes prevalence and mortality continue, it is estimated that by 
2030, the global burden will increase to $2.5 trillion (95% CI: 2.4, 2.6) (7). Medication costs 
have been identified as the primary driver of increasing medical expenditure on diabetes 
(8,9). While empirical evidence is scarce, it is suggested that the observed increase in 
pharmaceutical expenditure can be attributed to a combination of increasing diabetes 
prevalence, advancements in clinical guidelines advocating long-term glycaemic control and 
the upsurge of new expensive medical treatments (8–10).   
Cost-of-illness studies provide important estimates highlighting the economic burden of 
diabetes. Such estimates motivate and inform the implementation of cost-effective 
strategies addressing the burden of diabetes. Worldwide, there is a lack of accurate, 
comprehensive and comparable estimates of costs attributable to diabetes (11). Valid and 
reliable incremental cost estimates for diabetes are required at a regional and country level 
to improve the accuracy of global cost of diabetes estimates (10).  
Diabetes not only places a substantial burden on the health system but is also a concern for 
national economies (5). It highlights the urgent need for cost-effective interventions to 
efficiently manage diabetes and its complications (12). In tandem with this, the prevention 
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of diabetes is essential to curb the increasing prevalence, ensuring that the future costs of 
diabetes are curtailed and improvements in rates of morbidity and mortality are realised in 
economic terms. A public health response to diabetes identifies three areas of prevention 
required to adequately address the burden of diabetes (10,13–18). Primary prevention 
employs a population-wide approach with the aim of intervening before the onset of 
diabetes occurs. Secondary prevention targets those at high risk of developing diabetes, 
while tertiary prevention strategies manage and treat diabetes once it has manifested with 
the aim to prevent diabetes-related complications. Effective interventions for diabetes exist 
across this continuum of prevention.  
Three effective interventions spanning the prevention continuum have recently been 
addressed in Irish health policy and can potentially influence the burden of diabetes in 
Ireland. The primary prevention of diabetes has been addressed in healthy government 
policy tackling SSB consumption (19–21). Two effective tertiary prevention interventions 
have also been recommended; the provision of structured care for people with type 2 
diabetes in primary care supported through an initiative called the “cycle of care” and the 
provision of bariatric surgery (22,23).  
Valid estimates of the potential impact of public health interventions are essential to allow 
policy-makers make informed decisions about the cost-benefit trade-off between them (24). 
Furthermore, where robust evidence on effective interventions exist, the translation of this 
evidence into policy and the subsequent implementation into practice is essential (25). The 
impact of interventions is influenced by policy decisions including legislative change, for 
example, sugar-sweetened beverage (SSB) tax and health system changes such as, drug 
reimbursement decisions or financial remuneration for chronic disease management. 
Although research has provided evidence for preventing or delaying type 2 diabetes, health 
policy decisions influence their potential impact on the burden of diabetes (26).  
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1.2 Aims  
The two main aims of this thesis were to estimate the economic burden of diabetes in Ireland 
and to explore the potential for health policy approaches to impact on the burden of 
diabetes.  
1.3 Objectives 
These aims were addressed by the six specific objectives outlined below; 
1. to provide robust estimates of health service use and direct healthcare costs 
attributable to diabetes in Ireland. 
2. to estimate the total costs, direct and indirect, attributable to diabetes in Ireland. 
3. to explore trends in pharmaceutical expenditure on diabetes between 2011 and 
2015, examining the impact of newer blood glucose-lowering medications. 
4. to provide a robust estimate of the impact of sugar-sweetened beverage 
consumption on type 2 diabetes incidence and subsequently estimate the potential 
impact of public health interventions targeting sugar-sweetened beverage 
consumption.  
5. to investigate the coverage of the cycle of care initiative and to describe the 
population who are not currently eligible. 
6. to estimate the number of people who would potentially benefit from bariatric 
surgery in Ireland based on established clinical criteria. 
1.4 Thesis outline 
This thesis contains nine chapters, six of which are studies addressing the aims and objectives 
outlined above. Figure 1 illustrates the six studies and the corresponding chapters. 
The global burden of diabetes and its implications are presented in Chapter 2. Trends in the 
epidemiology of diabetes are explored, specifically describing trends in prevalence, incidence 
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and diabetes-related morbidity and mortality. The economic burden of diabetes is 
subsequently outlined with a discussion on the variation in methodologies used to estimate 
the cost of diabetes. Finally, the implications of the burden of diabetes are considered, 
identifying key approaches required to address the burden.  
The excess health service use and related costs attributable to diabetes are described in 
Chapter 3.  This study demonstrates the use of robust methods to provide the first estimates 
of excess health service utilisation attributable to diabetes in Ireland. The results are used in 
Chapter 4 to estimate the total economic burden of diabetes in Ireland. This study uses best 
available data and methods to estimate the direct and indirect costs attributable to diabetes 
in Ireland. 
Chapter 5 examines trends in pharmaceutical expenditure on diabetes-related items 
between 2011 and 2015. This study uses data from a national pharmacy claims database and 
highlights the impact of newer blood glucose-lowering medications on expenditure. The 
impact of cost-containment measures implemented over the study period are also assessed.  
The impact of a primary prevention strategy is explored in Chapter 6. This study provides 
robust estimates of the potential impact population-level interventions targeting sugar-
sweetened beverage consumption can have on type 2 diabetes incidence in Ireland. 
Specifically, this study assesses the potential impact of the recently introduced sugar-
sweetened beverage levy in curbing type 2 diabetes incidence.  
Cost-effective interventions are also required to efficiently manage diabetes and related 
complications (10). The potential for two tertiary prevention strategies, as provided for in 
Irish health policy, to influence the burden of diabetes are assessed in Chapters 7 and 8.  
Chapter 9 provides an overall discussion of the main findings, the strengths and limitations 
of the thesis, the implications for policy and suggestions for future research.
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Figure 1.1- Overview of thesis including aims and objectives
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2. Background 
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2.1 Overview 
This chapter presents a brief overview of the societal and economic burden of diabetes, both 
internationally and in Ireland. First, the epidemiology of diabetes and related complications 
is described, specifically examining recent trends. Second, the economic burden of diabetes 
is explored and discussed in the context of increasing diabetes prevalence. Third, the 
implications of the increasing cost of diabetes are outlined with a discussion on prevention 
approaches to address the burden of diabetes. Finally, three prevention strategies 
recommended in Irish health policy are presented, namely reducing sugar-sweetened 
beverage consumption, funding for the structured management of people with type 2 
diabetes in primary care and the provision of bariatric surgery.    
 
2.2 Diabetes – a chronic disease 
Diabetes is a group of metabolic conditions characterised by hyperglycaemia (27). It results 
from defects in insulin secretion whereby the pancreas does not produce enough insulin, or 
from insulin inaction whereby the body cannot effectively use the insulin that is produced, 
or both. The majority of diabetes cases can be classified into one of two groups; type 1 
diabetes or type 2 diabetes (27). It is estimated that five percent of diabetes cases are type 
1, while approximately 90% are estimated to be type 2 diabetes (28,29). The remainder of 
cases include gestational diabetes and other specific types (27). Type 1 diabetes is caused by 
a deficiency in insulin secretion. The pathogenesis of type 1 diabetes is described as a 
complex interplay between environmental factors and microbiome, genome, metabolism, 
and immune systems (30). Type 2 diabetes is characterised by a combination of insulin 
resistance and an inadequate compensatory insulin secretion response. The causes of type 
2 diabetes are better understood than type 1 diabetes, with sedentary lifestyles, physical 
inactivity, dietary intake and obesity identified as risk factors for the disease (1,31). The long-
12 
 
term complications of diabetes have traditionally been categorised as microvascular and 
macrovascular complications (32,33). Microvascular complications include retinopathy, 
neuropathy and nephropathy. Macrovascular complications refer to cardiovascular disease 
and include coronary heart disease, cerebrovascular disease and peripheral arterial diseases. 
More recently, diabetes has also been associated with poor cognitive functioning and mental 
health (34) and some cancers (35,36).  
 
2.3 Global epidemiology of diabetes 
The global age-standardised prevalence of diabetes in adults aged over 18 years was 
estimated at 9.0% (95% CI: 7.2, 11.1) in males and 7.9% (95% CI: 6.4, 9.7)  in females in 2014 
(4). Using data from 751 population-based surveys and studies, the NCD Risk Factor 
Collaboration found significant variation in prevalence estimates across world regions. Age-
standardised prevalence was lowest in north-western European countries at less than 5% 
and highest in Polynesia and Micronesia where prevalence was greater than 20%. Between 
1980 and 2014, diabetes prevalence increased or at best remained unchanged in all countries 
worldwide. Over the 35-year period, the number of adults with diabetes increased four-fold 
reaching an estimated 422 million in 2014 (4). The global increase in numbers of people with 
diabetes was attributed to population growth and ageing, a rise in age-specific prevalence 
rates and an interaction of the two. The prevalence of diabetes increases significantly with 
age (37–39). In high-income countries, diabetes prevalence is highest in those aged 75-79 
years and in those aged 60-74 in middle income countries. In low-income countries, diabetes 
prevalence peaks in the 55-64 age group (40).   
The incidence and prevalence of diabetes in the USA doubled between 1980 and 2008, with 
trends plateauing between 2008 and 2012 (41). Increasing trends in prevalence and 
incidence in European countries has also been observed, with evidence of stabilising 
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incidence rates in recent years (42–45). In the UK, analysis of primary care data reports a 
doubling in prevalence of type 2 diabetes between 2000 and 2013 (42). In this population, 
the incidence of type 2 diabetes also increased over the time period, from 3.69 per 1000 
person-years at risk in 2000 to 3.99 per 1000 in 2013 among men and from 3.06 per 1000 to 
3.73 among women. However, since 2005 there was some evidence of stabilising incidence 
rates. One explanation for declining or stabilising incidence rates in the mid to late 2000s is 
the reduction in the pool of undiagnosed diabetes. In the previous decade, there was an 
intensification of diagnostic activities (43,44). Despite some evidence of stabilising incidence 
rates, prevalence increased in all countries over the time periods studied.  
 
2.4 Epidemiology of diabetes in Ireland 
In the absence of a diabetes register, data on the epidemiology of diabetes in Ireland is 
largely from national surveys and pharmacy claims data. Based on data from four nationally 
representative surveys, the prevalence of diabetes in Ireland is estimated to have increased 
from 2.2% (95% CI: 1.7, 2.7)  of the adult population in 1998 to 5.2% (95% CI: 5.1, 5.3) in 2015 
(46). Over this time, there was no significant increase in the prevalence of diabetes in those 
aged 18-39 years, with prevalence remaining at less than 2%. Among those aged 40-69 years, 
the prevalence almost doubled in both males and females (3.5% [95% CI: 3.4, 3.6] to 6.6% 
[95% CI: 6.5, 6.7] and 2.5% [95% CI:2.4, 2.5] to 4.2% [95% CI: 4.1, 4.3], respectively). Similar 
trends were observed in the 70+ age group, with prevalence increasing from 8.2% (95% CI: 
8.0, 8.3) to 15.1% (95% CI: 14.8, 15.2) in males and 4.7 % (95% CI: 4.5, 4.8) to 10.7% (95% CI: 
10.5, 10.8%) in females. The prevalence of type 2 diabetes in Irish adults aged over 50 years 
has been estimated at 8.4% (95% CI: 7.8, 9.0%) (47). Prevalence was higher among males, 
10.3% (95% CI: 9.4, 11.2%), than females, 6.6% (95% CI: 5.9, 7.5%). Similar estimates for type 
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2 diabetes prevalence were published using national pharmacy claims data in Ireland (48). 
There are no data on trends in incidence rates over time in Ireland. 
 
2.5 Morbidity and mortality  
Diabetes is associated with reduced quality of life, morbidity and premature mortality. In 
2016, diabetes was the eighth leading cause of years lived with disability globally (49). Much 
of the burden can been attributed to diabetes-related complications (50).  
 
2.5.1 Morbidity 
People with diabetes are at increased risk of developing macrovascular and microvascular 
complications. The risk of macrovascular complications in people with diabetes is 2-4 times 
that of the population without diabetes and the risk of microvascular complications is 10-20 
times that in people with diabetes compared to those without, even after adjustment for 
important confounding factors (32,51–53). The prevalence of complications varies greatly 
between studies due to variations in methods employed, study populations and data 
sources.  
There is a paucity of international data on trends in complications with evidence restricted 
to a number of high income countries (32). Such evidence suggests that rates of 
complications have declined over time. Analysis of nationally representative US surveillance 
data demonstrated, that between 1990 and 2010, rates of lower-extremity amputations, 
acute myocardial infarction, stroke, end-stage renal disease and death from hypoglycaemic 
crisis all declined significantly (54). The magnitude of reduction was largest for myocardial 
infarction with 95.6 fewer cases per 10,000 persons per year (95% CI: 76.6, 114.6), followed 
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by stroke (58.9 fewer cases per 10,000 [95% CI: 41.6, 76.2]). Similar declining trends in 
cardiovascular event rates in people with diabetes were observed in Canada (55).  
While study populations, methods of ascertainment and outcome definitions vary across 
studies, published data on trends in lower-extremity amputations indicate declining rates 
over time (32). Lower-extremity amputations have been described as a sentinel outcome for 
evaluating diabetes care as the risk is influenced by the management of clinical measures 
including glycaemic control and blood pressure control, lifestyle factors such as tobacco 
consumption and health system factors such as screening and risk-stratification (56). Rates 
of lower-extremity amputations in the USA declined by half (51.4%, 95% CI: 68.2, 34.5)  
between 1990 and 2010 (54), with similar trends observed in European countries and 
Australia (57–62). Conversely, national trends in rates of lower-extremity amputations in 
Ireland increased non-significantly between 2004 and 2008 (52). However, trends in major 
of lower-extremity amputations remained unchanged while minor of lower-extremity 
amputations rates rose from 96.2 to 127.6 per 100,000 people with diabetes. Minor 
amputations may reflect improved detection and earlier intervention, consequently 
preventing the progression from minor to major amputation (52).  
Diabetic retinopathy is a leading cause of blindness in working age adults (63–65). The global 
prevalence of diabetic retinopathy is estimated at 34.6% (95% CI: 34.5, 34.8) among people 
with diabetes, however estimates are limited by a paucity of data pooled from different 
study populations, at different time points and with varying methodologies (66). Population-
based data from Israel, Scotland, and Germany document reductions in rates of diabetic 
retinopathy and blindness between the years 1999 and 2010 (65,67,68). Trends in blindness 
due to diabetic retinopathy among adults aged 18–69 years in Ireland have been published 
for the years 2004 to 2013 and suggest somewhat similar trends (69). Although there was 
insufficient evidence to confirm a downward trend, incidence of blindness due to diabetic 
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retinopathy decreased from 31.9 per 100,000 population (95% CI: 21.6, 45.7) in 2004 to 14.9 
per 100,000 population (95% CI: 8.2, 25.1) in 2013. The incidence of visual impairment due 
to diabetic retinopathy increased from 6.4 (95% CI: 2.4, 13.9) per 100,000 in 2004 to 11.7 
(95% CI: 5.9, 21.0) per 100,000 in 2013. This may be indicative of local efforts to screen for 
diabetic retinopathy (69). Since 2013, a national diabetes retinopathy screening programme 
has been implemented in Ireland (70). 
 
2.5.2 Mortality  
Diabetes is one of the leading causes of death worldwide (3). It is associated with excess 
mortality, with cardiovascular disease being the most common cause of death in people with 
diabetes (71–76). The Diabetes Atlas Group estimate that in 2013, 5.1 million deaths were 
attributable to diabetes worldwide, with 619,847 deaths in Europe (77). Diabetes has also 
been associated with substantial premature mortality from several cancers, infectious 
diseases, external causes, intentional self-harm, and degenerative disorders (78). 
International country-level data on trends in mortality are, again, limited to a number of 
high-income countries and consistently demonstrate reductions in mortality over the past 
two decades (32,44,54,79,80). All-cause mortality rates and cardiovascular mortality rates in 
the USA reduced by 23% (95% CI: 10, 35) and 40% (95% CI: 23, 54), respectively, between 
1997 and 2006 (79). Similar trends have been observed in Australia between the years 1997-
2010 (81). In Europe, reductions in mortality rates have also been observed over similar time 
periods (43,44,80). Despite this, absolute number of deaths attributable to diabetes 
worldwide are increasing (3,43).  Between 2006 and 2016, absolute number of deaths and 
the total years of life lost from diabetes rose by 31% (95% UI: 28.9, 33.4) and 25% (95% UI: 
23.2, 27.7), respectively (3).   
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2.6 “Winning the battle but losing the war?” 
Declining trends in morbidity and mortality have been more pronounced in populations with 
diabetes compared to those without, resulting in attenuated relative risks for the 
associations between diabetes and poor health outcomes and mortality (43,54,79). While 
such achievements can be attributed to the improvement in risk factor management and 
processes of care for people with diabetes, the absolute burden of diabetes on society and 
health systems continues to increase. Declining mortality rates in people with diabetes 
results in increasing years spent with the condition. The total number of years lived with 
disability due to diabetes has increased globally between 2006 and 2016 (49). Furthermore, 
it is estimated that, due to declining mortality rates in the total population, the lifetime 
probability of developing diabetes has increased for males and females (82,83). Combined 
with ageing populations and increasing incidence, the absolute numbers of people with 
diabetes is increasing (4,84). A small increase in incidence of diabetes, observed in the USA 
between 2000 and 2004, is projected to result in 12 million additional people with diabetes 
by 2050 (84). Despite declining rates of complications, the increasing numbers of people with 
diabetes in the population will translate to growing absolute numbers of cases with diabetes-
related complications (12,13,32). When trends in diabetes-related complications, such as 
lower-extremity amputations, are re-assessed with the total population as the denominator 
less promising trends are evident (13). With significant strides made in the tertiary 
prevention of diabetes, improvements in population health are being negated by the 
increasing numbers of people with diabetes (13). With increasing absolute numbers of 
people with diabetes globally, the societal and economic burden of diabetes is ever more 
concerning.  
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2.7 The global economic burden of diabetes 
The global economic burden of diabetes was estimated at $1.31 trillion (95% CI: 1.28, 1.36) 
in 2015, accounting for 1.8% of global Gross Domestic Product (GDP) (5). Substantial 
variation exists across global regions. The highest absolute economic burden is observed in 
North America, where the costs of diabetes also account for the highest proportion of GDP 
(2.6%). Sub-Saharan Africa has the lowest economic burden in absolute terms, while in South 
Asia the costs of diabetes account for the lowest proportion of GDP (1%) compared to other 
regions. When grouped by income classification, high-income countries contribute the most 
to the global economic burden of diabetes with a total of $800 billion spent on diabetes.  
A large body of literature has quantified the cost of diabetes at the country level (11,85,86). 
Cost-of-illness studies estimate the economic burden of a disease with the aim to identify 
the costs that could potentially be saved if the disease were prevented. These estimates are 
useful in highlighting the economic burden of diabetes (8,87). Three systematic reviews, 
published in 2004, 2014 and 2015, document the large and increasing economic burden of 
diabetes (11,85,86). While the studies identified by Ettaro and colleagues, in 2004, were 
largely focused on the USA and a small number of high-income European countries, by 2015 
there was an emergence of studies from low and middle income countries (11,85). However, 
comparisons in cost estimates across studies are limited by the wide variation in 
methodologies employed (11,85,86,88).  
 
2.8 Variation in cost-of-illness methodology 
Comprehensive cost-of-illness studies include direct and indirect costs. Incurred by the 
health system, society, families and the individual patient, direct costs can consist of 
healthcare costs (for example, health service use, prescription medications and medical 
supplies) and non-healthcare costs (for example, transportation or any informal care) 
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(88,89). Indirect costs, incurred by the individual, families, society and employers, estimate 
the costs of lost productivity associated with a disease (for example, reduced labour force 
participation and premature mortality). While some studies also include the intangible costs 
of a disease, using quality of life measures, this category of costs is often omitted due to the 
difficulty in accurately quantifying quality of life in monetary terms (86). Cost-of-illness 
studies can be conducted from a variety of different perspectives, determining the costs to 
be included. The perspectives may measure costs to society, the government, the health care 
system, private sectors or the individual. Depending on the perspective adopted, cost 
estimates will vary. A societal perspective is the most comprehensive perspective as it 
includes all direct and indirect costs  (89,90).  
 
2.8.1 Prevalence versus incidence-based approaches 
Depending on the epidemiological data used, cost-of-illness studies are either prevalence-
based or incidence-based. A prevalence-based approach estimates the economic burden of 
a disease over a specified period of time, usually a 12-month period or calendar year. This is 
the most commonly used approach, particularly for chronic conditions with a long duration 
(88,91). The incidence-based approach calculates the lifetime costs associated with a disease 
by estimating the number of new cases in a given year, assigning a lifetime cost to each case.   
2.8.2 Defining disease associated costs 
The costing methodologies for cost-of-illness studies can be classified into two overarching 
groups; total disease costs and excess costs, and are detailed in Table 2.1 (11,88). Total 
disease costs estimate the total healthcare expenditure of people diagnosed with the 
disease. On the other hand, excess costs identify costs that are attributable to the disease of 
interest. Within each category, costs can be further categorised by the methodological 
approach employed. While the aim of the study and data availability will ultimately 
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determine the approach utilised, there are a number of advantages and disadvantages to 
each approach. The ideal cost-of-illness study will identify the total excess costs 
independently attributable to diabetes. However, the approach is often restricted by data 
availability and any cost-of-illness study needs to be tailored to make the best use of the 
available data.  
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Table 2.1 – Cost-of-illness methodologies
Methodological Approach Description Advantages/disadvantages 
 
Total Costs 
 
Sum-all medical Identifies individuals with disease of interest and sums 
all health expenditure. 
- Captures all costs regardless of whether associated 
with disease or not. 
- Do not provide useful or meaningful estimates to 
inform policy. 
- Can overestimate costs of disease. 
 
Sum-diagnosis specific Identifies costs relating directly to disease of interest. 
 
- Includes disease-specific expenditure only. 
- Can underestimate costs, especially for diseases with 
comorbidities.  
Excess Costs 
 
Disease attributable  Identifies costs using attributable fraction 
methodology.  
Identifies the comorbidities caused by the disease of 
interest and applies population attributable fractions 
for each comorbidity to aggregate cost data. 
- Reliant on robust and appropriately specified 
attributable fractions. 
- Can underestimate costs due to inability to capture 
costs that do not appear directly associated with the 
disease of interest or where quantifiable associations 
are not available.  
 
Incremental analysis Compares excess costs in people with the disease of 
interest to those without 
Can be achieved using either a matching or 
regression-based approach 
 
- Allows for the identification of the excess costs 
independently attributable to the disease of interest. 
- Provides policy-relevant estimates. 
- Dependent on wide range of data availability for 
people with and without disease of interest 
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2.9 Cost-of-diabetes studies 
The most common method used in cost of diabetes studies is the sum-all medical approach 
(11). However, by adopting this method, studies capture all healthcare costs regardless of 
whether they are associated with diabetes or not. Such estimates fail to identify service use 
that can be attributed diabetes and thus, do not provide useful or meaningful estimates to 
inform policy. The number of studies estimating the excess costs associated with diabetes 
has increased in recent years (11,85,86). The disease attributable methodology is also 
commonly used, although mainly in the USA.  This method underestimates service use and 
costs associated with diabetes due to its inability to capture use that does not appear directly 
attributable to diabetes (92,93). For instance, mental health co-morbidities in people with 
diabetes increase health service utilisation (94). Due to its reliance on established 
quantifiable causal associations, disease-attributable methodology will not capture such 
excess service use. Furthermore, this method is reliant on robust and appropriately specified 
population attributable fractions which are not always available.  
The use of the incremental cost approach yields the most accurate and policy-relevant 
estimates of the cost of diabetes as it allows for the identification of the excess costs 
attributable to the diabetes (11,92,93). This approach allows for the control of important 
confounding factors and thus the identification of the excess costs independently 
attributable to diabetes (11,92,93). However, consideration of appropriate covariates is 
essential. For instance, if the aim is to estimate total excess costs attributable to diabetes 
adjusting for the presence of macrovascular and microvascular complications will lead to an 
attenuation in costs and provide an estimate of the costs attributable to diabetes 
independent of the presence of complications. Few studies have applied the incremental 
costs approach to examine the cost of diabetes (11). Of the studies adopting this approach, 
many have focused on specific hospital-based samples or have used routine healthcare data 
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to estimate direct costs. These studies may result in an overrepresentation of people with 
diabetes and also people with diabetes-related complications. Furthermore, due to data 
availability constraints, many incremental cost studies control for gender and age only (95). 
Honeycutt et al. demonstrate that controlling for age and gender only can result in an 
overestimation of diabetes-related service use and costs (92). Worldwide, there is a lack of 
accurate, comprehensive and comparable estimates of costs attributable to diabetes (5). 
Valid and reliable incremental cost estimates for diabetes are required at a regional and 
country level to improve the accuracy of global cost of diabetes estimates (5,10).  To date, 
the only estimate for the economic burden of diabetes in Ireland comes from the CODEIRE 
study published in 2006 (96). Using data from 1999/2000, CODIERE uses a sum-all medical 
approach for a hospital based sample of Irish adults aged over 30 years with diabetes. They 
do not estimate indirect costs.  
Due to wide variations in methodologies, comparisons across studies are hindered (11). 
However, despite this, there are a number of commonalities across international studies that 
provide insight into the economic burden of diabetes. Hospital in-patient costs account for 
the majority of direct expenditure associated with diabetes, followed by medication costs 
(97–105). Diabetes complications have a substantial impact on both direct and indirect 
diabetes costs (106–109). The Cost of Diabetes in Europe – Type II (CODE-2) study reported 
that in patients with both microvascular and macrovascular complications, the total cost of 
management was increased by 250% compared those without complications (110). More 
recent estimates are similar. In Denmark, the majority of costs were incurred among patients 
with major complications in 2011 (106). In Poland, the direct cost of hospital complication 
treatment were more than five times the direct costs of hospital treatment of people without 
complications (109). In studies assessing the direct and indirect costs, the ratio between the 
two varies and with the inclusion of differing cost categories and different methodologies, 
comparisons are limited. However, it is evident that indirect costs account for a significant 
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proportion of diabetes costs. Global estimates report that 34.7% (95% CI: 34.7, 35.0) of the 
total economic burden of diabetes is attributable to indirect costs (5). This varied from 40.0% 
in high-income countries to 33.5% in low-income countries. Higher estimates have been 
reported in some European countries, with over half the costs attributable to indirect costs 
in the UK and Poland (107,109). 
 
2.9.1 Rising costs of diabetes  
Should previous trends in diabetes prevalence and mortality continue, it is estimated that by 
2030, the global economic burden of diabetes will increase to $2.5 trillion (95% CI: 2.4, 2.6) 
(7). This translates to an increase in costs as a share of global GDP to 2.2%. Major increases 
in the proportion of GDP attributable to diabetes costs are predicted for all world regions, 
between 2015 and 2030.   
While global projections estimate an inevitable increase in the economic burden of diabetes 
between 2015 and 2030, country-specific data, demonstrating increasing costs, is only 
available for a small number of high-income countries (7). Evidence of the increasing cost of 
diabetes is largely based on research in the USA (8,9,97,107,111). The economic costs of 
diabetes, calculated by the American Diabetes Association, increased by 26% in the five-year 
period 2012 to 2017 (8). The increase is driven by increasing numbers of people with diabetes 
but also rising costs of medical care per person with diabetes (9,97). In the USA, medical 
spending attributable to diabetes per person doubled between 1987 and 2011 (9). 
Furthermore, each additional year with diabetes increases annual medical expenditure 
(112). As mortality rates in people with diabetes decline and years lived with diabetes 
increase, this has implications for the future costs of diabetes.  
Medication costs have been identified as the primary driver of increasing medical 
expenditure on diabetes (8,9). Over half the increase in medical expenditure is due to rising 
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prescription costs (9). It is suggested that the observed increase in pharmaceutical 
expenditure can be attributed to a combination of increasing diabetes prevalence, 
advancements in clinical guidelines advocating long-term glycaemic control and the upsurge 
of new expensive medical treatments (8–10). As of 2016, there were at new least 171 new 
drug therapies in development for the treatment and management of diabetes and its 
related complications (113). With an emphasis on maintaining glycaemic control, the number 
of classes of glucose-lowering drugs developed over the previous two decades has more than 
tripled (114). Novel and innovative treatments are expensive and concern has been raised 
about whether the benefits of these medications outweigh their significantly higher costs 
(115).  While empirical data is scarce, it is predicted these treatments contribute to rising 
medication costs associated with diabetes and the continued advancement in diabetes-
related medical technology will increase per capita medical expenditure per year 
(9,10,31,116). 
 
2.10 Public health policy response to diabetes 
 
The substantial economic burden of diabetes highlights the urgent need for cost-effective 
interventions (5). Estimates of the costs of diabetes provide insight into the measures and 
scale of investment required to address the societal and economic burden of diabetes. Rising 
medical costs per person with diabetes combined with increasing absolute cases of diabetes 
highlights the urgent need for cost-effective interventions to efficiently manage diabetes and 
its complications (12). In tandem with this, the prevention of diabetes is essential to curb the 
increasing prevalence, ensuring that the future costs of diabetes are curtailed and 
improvements in rates of morbidity and mortality are realised in economic terms. A multi-
level approach is required to tackle the burden of diabetes (14). A public health response to 
diabetes identifies three areas of prevention required to adequately address the burden of 
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diabetes (10,13–18). Primary prevention employs a population-wide approach with the aim 
of intervening before a disease occurs. Population based interventions aim to shift the 
distribution of risk factors in the entire population. Secondary prevention targets those at 
risk of developing the disease of interest, while tertiary prevention strategies manage and 
treat the disease once it has manifested with the aim to prevent disease-related 
complications. Effective interventions for diabetes exist across this continuum of prevention. 
For diabetes, the most progress has been made in the area of tertiary prevention, evident 
from the attenuation in relative risks for diabetes-related complications. In terms of 
preventing the onset of diabetes, attention has focused on the secondary prevention of 
diabetes in those at high risk or with pre-diabetes (10,13,14,117).  
 
2.10.2 Lessons of the paradox 
Despite significant strides made in the tertiary prevention of diabetes, improvements in 
population health are being negated by the increasing numbers of people with diabetes (13). 
Unless the incidence is curbed, the absolute numbers of people with diabetes will continue 
to increase and future costs of diabetes will not be curtailed.  The most robust and consistent 
evidence on cost-effective secondary prevention interventions exists for structured lifestyle 
interventions and intervention with metformin in those with pre-diabetes (17,118–121). 
Such interventions have been proven to be clinically effective and cost-effective in reducing 
diabetes incidence in high risk groups. However, they are limited by the challenges in 
identifying those in whom the intervention may be beneficial at population level (16,17). The 
secondary prevention of diabetes through effective structured lifestyle interventions is an 
essential aspect of intermediate efforts to stabilise diabetes prevalence. However, recent 
evidence has demonstrated that the impact on diabetes prevalence from this approach alone 
would be modest and that while they may result in slowing of increasing prevalence rates, 
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the prevalence of diabetes will continue to grow (122,123). Focusing efforts on the secondary 
prevention of diabetes is essential in the short to intermediate term but a longer-term 
strategy that widens its focus beyond those with high risk is required (12).  
Investment in effective primary prevention interventions is necessary to permanently alter 
increasing prevalence (122,123). While the ‘high risk’ approach outlined above aims to 
protect susceptible individuals, the population approach seeks to control the causes of 
incidence (124). Diabetes has a long incubation period and is intrinsically linked with 
sedentary lifestyles, physical inactivity, dietary intake and obesity (1,31). Focusing solely on 
those with pre-diabetes provides an interim expedient but will alone not stem increasing 
prevalence (124). An “upstream” or whole population approach shifts the focus from relative 
risk towards absolute risk, providing opportunities to address the current driving factors of 
the increasing economic burden of diabetes (14). Population-level interventions consider the 
role of broader social and environmental risk factors associated with diabetes incidence. 
However, primary prevention has been described as the weak link in the public health 
response to diabetes (13).  
Hospital inpatient costs and prescription costs are identified as substantial contributors to 
the economic burden of diabetes and the costs are significantly higher in those with 
diabetes-related complications (97–105). Tertiary prevention measures aim to reduce 
diabetes complications and prevent avoidable hospital admissions and therefore have the 
potential to result in significant cost-savings in the short term.  
 
2.11 Translation into policy and implementation in practice 
Valid estimates of the potential impact of public health interventions are essential to allow 
policy-makers make informed decisions about the cost-benefit trade-off between them. The 
use of biased designs results in inappropriate policies and confusion among policy-makers, 
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scientists and the public (24). Furthermore, where robust evidence on effective interventions 
exist, the translation of evidence into policy and the subsequent implementation into 
practice is not always achieved (117). The impact of interventions is influenced by policy 
decisions including legislative change, for example, a sugar-sweetened beverage tax and 
health system changes such as, drug reimbursement decisions or financial 
reimbursement/remuneration for structured chronic disease management. Although 
research has provided evidence for preventing or delaying type 2 diabetes, health policy 
decisions can influence the potential impact on the burden of diabetes (26).   
Three effective interventions spanning the prevention continuum have been recommended 
in recent Irish health policy; one primary prevention strategy and two potential interventions 
addressing the tertiary prevention of diabetes. The secondary prevention of diabetes, as 
defined above, has not been addressed in national health policy. Firstly, the primary 
prevention of diabetes has been addressed in healthy government policy tackling sugar-
sweetened beverage consumption. As a substantial body of evidence supports an association 
between sugar-sweetened beverage consumption and incident type 2 diabetes, population 
health interventions targeting consumption can potentially play an important role in primary 
prevention (125). Such interventions have been implemented in numerous countries 
worldwide, largely in the form of fiscal policies, with the UK and Ireland introducing a tax on 
sugar-sweetened beverages in April 2018 (19–21). Two effective tertiary prevention 
interventions have also been recommended; firstly, the provision of funding for structured 
care for people with type 2 diabetes in primary care through an initiative called the “cycle of 
care” and secondly, the provision of bariatric surgery (22,23). International consensus now 
exists that structured management of uncomplicated diabetes in primary care with suitable 
organisational support constitutes good quality diabetes care. There is growing evidence that 
primary care led structured diabetes management is associated with improved outcomes for 
patients (126,127). Integrated diabetes care has been shown to reduce preventable 
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hospitalisations for diabetes-related complications (128). Structured approaches to diabetes 
care demonstrate improvements in glycaemic control and cardiovascular risk factors 
(129,130). Similarly, the clinical and cost-effectiveness of bariatric surgery makes it another 
important tertiary prevention option for diabetes (131). Bariatric surgery is associated with 
reductions in the use of medications and in overall health care costs in patients with type 2 
diabetes (132). However, for these policies to have meaningful impacts on the burden of 
diabetes in Ireland, the translation of evidence into policy and the implementation into 
practice essential.   
 
2.12 Summary 
Diabetes places a substantial burden on health systems and national economies (5). With the 
absolute numbers of diabetes cases increasing globally and evidence of rising medical 
expenditure per person with diabetes, the growth in economic burden will continue in 
coming years (4,7,9). Cost-of-illness estimates quantify the economic burden of diabetes and 
identify potential areas of cost-saving. They are used to inform and motivate policy-makers 
to address the burden of disease.  
There is wide variation in the methodological approaches employed to estimate the costs of 
diabetes (11). Worldwide, there is a lack of accurate, comprehensive and comparable 
estimates of costs attributable to diabetes (5). The most recent estimates of the economic 
burden of diabetes in Ireland are from 1999/2000 and are limited to the direct hospital costs 
in people with diabetes (96). Chapters three and four will provide recent, comprehensive 
and robust estimates of the costs of diabetes in Ireland.  
Hospital costs and prescription costs account for the vast majority of the direct costs of 
diabetes. Medication costs have been identified as the primary driver of increasing medical 
expenditure on diabetes (8,9), with over half the increase in medical expenditure due to 
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rising prescription costs (9).  Chapter five of this thesis will explore trends in prescription 
costs in Ireland and in particular assess the impact of novel blood glucose-lowering 
treatments on expenditure.  
The increasing economic burden of diabetes and trends in the descriptive epidemiology of 
diabetes have important implications for health policies aiming to address the burden. 
Effective interventions across the prevention continuum are necessary with primary, 
secondary and tertiary prevention playing important roles in addressing the different facets 
of the epidemic. Furthermore, although research has provided evidence for preventing or 
delaying type 2 diabetes, health policies determine their potential impact on the burden of 
diabetes (26).  
Three effective interventions spanning the prevention continuum have been recommended 
in recent Irish health policy; a sugar-sweetened beverage levy, dedicated remuneration for 
structured care for type 2 diabetes in primary care and the provision of bariatric surgery. 
Chapter six will explore the potential impact of the recently introduced sugar-sweetened 
beverage levy in curbing type 2 diabetes incidence in Ireland. Chapters seven and eight 
explore the potential for structured care for type 2 diabetes in primary care and the provision 
of bariatric surgery to reduce the burden of diabetes in Ireland, as provided for in Irish health 
policy.  
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3. Health Service Utilisation and Related Costs Attributable to 
Diabetes 
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3.1 Abstract 
Introduction  
Worldwide, there is a lack of accurate, comprehensive and comparable estimates of the 
health service use and costs associated with diabetes. This study aims to estimate the health 
service use and direct healthcare costs attributable to diabetes using best available data and 
methods. 
 
Methods 
A nationally representative sample of adults aged ≥50 years was analysed (n=8,107). Health 
service use in the previous 12-months included the number of General Practitioner (GP) 
visits, out-patient department visits, hospital admissions, and Accident and Emergency (A&E) 
attendances. Multivariable negative binomial regression estimated associations between 
diabetes and frequency of visits. Average marginal effects were applied to unit costs for each 
health service and extrapolated to the total population, calculating the incremental costs 
associated with diabetes. 
 
Results 
The prevalence of diabetes was 8.0% (95% CI:7.4%, 8.6%). In fully adjusted models, diabetes 
was associated with additional health service use. Compared to those without diabetes, 
people with diabetes have on average 1.49 (95% CI:1.10, 1.88) additional GP visits annually. 
Diabetes was associated with an 87% increase in out-patient visits, 52% increase in hospital 
admissions and 33% increase in A&E attendances (p<0.001). The incremental cost of this 
additional service use, nationally, is an estimated €88,894,421 annually, with hospital 
admissions accounting for 67% of these costs. 
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Conclusion 
Using robust methods, we identify substantial increased service use attributable to diabetes 
across the health system. Our findings demonstrate the urgent need to invest in the 
prevention and management of diabetes. 
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3.2 Introduction 
The number of people with diabetes has increased four-fold in the past 35 years and it is now 
the seventh leading cause of years lived with disability worldwide (2,4). The impact of 
diabetes on health systems and national economies is of growing concern. In 2015, the global 
cost of diabetes was estimated to be US$1.31 trillion, with direct medical costs accounting 
for two thirds of the costs (5). Increasing prevalence combined with rising per capita medical 
expenditure indicate that the burden of diabetes on health systems will continue to escalate 
(9). An understanding of the health service use and related costs associated with diabetes is 
necessary to inform national policies and the allocation of scarce resources. It is also essential 
in identifying and evaluating methods of cost saving.  
Worldwide, there is a lack of accurate, comprehensive and comparable estimates of the 
health service use and costs attributable to diabetes (5). This is largely due to the variation 
in methodologies employed (11). Furthermore, the approach used affects the policy 
relevance of the estimates. There are three main methodological approaches; sum-all 
medical approach, disease-attributable approach and incremental cost analysis. The most 
common method applied for estimating cost of diabetes is the sum-all medical approach 
(11). This method fails to identify service use attributable to diabetes and thus, does not 
identify costs that can be avoided by diabetes prevention or management interventions. As 
a result, the sum-all medical approach does not provide meaningful estimates to inform 
policy decisions. Another common method used is the disease-attributable approach, 
whereby attributable fractions for conditions associated with diabetes are applied to health 
service use data to identify the proportion attributable to diabetes (11). This method 
underestimates service use and costs associated with diabetes due to its inability to capture 
use that does not appear directly attributable to diabetes (11,92). For instance, mental 
health co-morbidities in people with diabetes increase health service utilisation (94). 
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However, due to its reliance on established quantifiable causal associations, disease-
attributable methodology will not capture such excess service use.  
More recent studies adopt an incremental costing approach. This method identifies the 
incremental health service use and costs for people with diabetes compared to those 
without, therefore capturing all costs associated with diabetes. The incremental costing 
approach also allows for consideration of other factors known to influence health service use 
including age, sex, ethnicity, education, socio-economic status, health status and lifestyle 
factors (133). Thus, it is possible to estimate health service use that is independently 
associated with diabetes (92,112). To provide more precise estimates of the global cost of 
diabetes, there is an urgent need for valid and reliable country-level data (5). This study aims 
to provide robust estimates of health service use and direct healthcare costs attributable to 
diabetes, from a societal perspective, by applying an incremental cost approach with 
appropriate adjustment using a nationally representative sample of a community-dwelling 
adults, aged 50 years and over, with and without diabetes. 
 
3.3 Methods 
Study design 
A cross-sectional analysis of data from the first wave of The Irish Longitudinal Study of Ageing 
(TILDA) was conducted. TILDA is a nationally representative prospective cohort study of 
community-dwelling adults aged 50 years and over in the Republic of Ireland (134). The 
sampling frame used for TILDA was the Irish Geodirectory, a comprehensive and up-to-date 
list of all residential addresses in Ireland. A multistage probability sampling design was used, 
with each residential address in the country having an equal probability of selection (134). 
Eligible addresses were defined as any household with a person aged ≥50 years. All 
household residents aged ≥50 years were eligible to participate in the study. The estimated 
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number of eligible households was 10,129. Of these, 6,282 households participated 
(response rate 62%) and 8,175 individuals were recruited. Ethical approval was obtained 
from Trinity College Dublin Research Ethics Committee. 
 
Data Collection 
Data collection occurred between October 2009 and November 2011. Participants were 
visited in their home by trained interviewers who used computer-assisted personal 
interviewing (CAPI). This included detailed questions about socio-demographics, physical 
and mental health, self-reported doctor-diagnosis of chronic conditions and health service 
use.  
 
Variable definition 
The outcome of interest was self-reported health service use. Participants were asked about 
the frequency of visits to General Practitioner (GP) services, outpatient department visits, 
hospital admissions and Accident and Emergency (A&E) attendances in the past 12 months. 
They were also asked whether they had attended any of the following ancillary state services 
in the 12 months preceding the survey; dietician, chiropody, optician, public health or 
community nurse, or psychology/counselling services. Individuals were classified as having 
diabetes if they self-reported a previous doctor-diagnosis of diabetes. To distinguish 
between people with type 1 and type 2 diabetes, we defined those who were aged less than 
50 years at diabetes diagnosis and reported injecting insulin, but not taking oral 
hypoglycaemic agents, as having type 1 diabetes. All others were classified as having type 2 
diabetes. Participants who reported a doctor-diagnosis of diabetes during the CAPI were 
asked the question ‘Has a doctor ever told you that you have any of the following conditions 
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related to your diabetes?’. The conditions listed were: leg ulcer, protein in urine, lack of 
feeling and tingling pain in legs and feet due to nerve damage, damage to the back of your 
eye. Any participant who answered yes to any of the above was considered to have a 
microvascular complication. Any participant who self-reported a doctor diagnosis of heart 
attack (myocardial infarction), heart failure (congestive cardiac failure), stroke 
(cerebrovascular accident) and mini stroke (transient ischaemic attack) were considered to 
have macrovascular complications. Other variables of interest included age (in years), 
gender, marital status (yes/no), education (primary, secondary, third level), location 
(urban/rural), healthcare cover (means tested public health insurance, private health 
insurance, both, neither), self-reported health status (excellent, very good, good, fair, poor) 
and other chronic conditions deemed not to be associated with diabetes. These conditions 
were lung disease, asthma, arthritis, osteoporosis, cancer, Parkinson’s disease and peptic 
ulcer disease.  
 
Statistical analysis 
Health service utilisation was compared across populations with and without diabetes. The 
differences in the proportion of people attending each health service was analysed using 
Pearson’s chi-square test. Independent samples t-test was used to analyse the difference in 
the mean number of visits to each service. Logistic regression was used to model the 
association between diabetes and attendance at ancillary state services. Negative binomial 
regression models were used to analyse the association between diabetes and the frequency 
of health service use. Poisson, negative binomial, zero-inflated Poisson and zero-inflated 
negative binomial regression models were explored. Model selection was informed by 
Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) statistics and by 
comparing predicted and observed probabilities, with negative binomial regression being 
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selected as the most appropriate model (Supporting Information, Appendix 1) (135). Average 
marginal effects were calculated, providing an estimate of the excess number of 
visits/admissions attributable to diabetes on average. The average marginal effects were 
computed using the post-estimation command, margins dydx, in Stata. This calculates a 
predicted probability for each case with the fixed and observed values of variables, and then 
averages the predicted values (136).   
The Anderson framework for the societal and individual determinants of health care 
utilisation was used to inform the selection of appropriate variables to include in the 
multivariable regression models, with the aim of identifying the independent effect of 
diabetes on health service use (137). The Anderson framework categorises determinants as 
either predisposing, enabling or need factors. Any variables that could potentially mediate 
the association between diabetes and health service use were omitted. Multivariable 
regression was used to first adjust for predisposing factors (age, gender and marital status), 
then enabling factors (education, healthcare cover and location) and finally need factors 
(other chronic conditions).  
Sampling weights were applied to all data analyses to adjust for differential non-response 
and to reduce the potential for participation or selection bias (134). Complete data was 
available for 99.1% of the sample and so a complete case analysis was carried out. Analysis 
was carried out in Stata v.12 for windows (StataCorp, College Station, TX, USA) using the 
survey function (svy).  
 
Calculation of costs 
The average marginal effects for significant associations were applied to unit costs for the 
relevant health service. A societal perspective was adopted, applying average unit costs of 
€50 for a GP visit, €160 for an out-patient department visit, €5,030 for a hospital in-patient 
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admission and €183 for an A&E attendance previously calculated for Ireland (138,139). These 
costs were extrapolated to the total population with diabetes to calculate the incremental 
health service costs. The total population with diabetes was estimated by applying the 
prevalence of diabetes in the sample to the most recent Irish census figures (2016). Cost 
estimates are reported in Euro and US dollars (USD) and were inflated to represent costs for 
2016 using the Consumer Price Index (CPI) Inflation Calculator for Ireland (140). To reflect 
uncertainty in the estimates of average unit costs, a sensitivity analysis was conducted 
whereby these estimates were varied by +/- 20% (141).  
 
3.4 Results  
Of the 8,107 participants included in the analysis, 51.9% were female and 41.5% were aged 
65 years or older. The prevalence of diabetes was 8.0% (95% CI: 7.4, 8.6), only 11 participants 
had type 1 diabetes. Among people with diabetes, 15.8% (95% CI: 13.0, 19.2) reported a 
macrovascular complication, while 26.3% (95% CI: 22.7, 30.3) reported a microvascular 
complication.  
There were significant differences between the population with and without diabetes (Table 
3.1). People with diabetes were older, had a lower proportion of females, lower levels of 
educational attainment and lower self-reported health status. They were also more likely to 
be covered by public health insurance. There was significantly higher service utilisation 
among people with diabetes for all health services, except psychology/counselling services. 
Those with diabetes reported an average of 5.8 GP visits in the past 12 months compared to 
3.8 visits among those without diabetes (p<0.001). 60.8% (95% CI: 56.7, 64.8) of people with 
diabetes reported attending an out-patient department in the last year compared to 39.1% 
(95% CI: 37.7, 40.5) of people without diabetes. A higher proportion of people with diabetes 
also reported being admitted to hospital in the previous 12 months (19.8%, 95% CI: 16.7, 
40 
 
23.2) than those without diabetes (12.4%, 95% CI: 11.6, 13.2). Similar variations were 
observed for A&E attendances, with 20.5% (95% CI: 17.3, 24.1) of people with diabetes 
attending A&E compared to 14.9% (95% CI: 14.0, 15.8) of people without. 
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Table 3.1 - Characteristics of population by diabetes diagnosis 
 Population without 
diabetes  
% (n=7486)  
Population with 
diabetes 
% (n=621) 
P value 
Female 53 42 <0.001 
Age 
50-64 
65-74 
75+ 
 
60  
23 
17  
 
44 
32  
25  
 
 
 
<0.001 
Rural residence  44  40  0.12 
Married 66  63  0.11 
Education 
None/primary 
Secondary 
Third level 
 
37  
44  
19 
 
50  
37  
13  
 
 
 
<0.001 
Health care cover 
Medical card 
Private health insurance only 
Dual cover 
No cover 
 
35  
38  
16  
11  
 
50 
25  
19  
7  
 
 
 
 
<0.001 
Diabetes-related condition 
Macro vascular 
Micro vascular 
Other chronic illness* 
 
8 
- 
47  
 
16  
26  
51  
 
<0.001 
 
0.07 
Self-reported health 
Excellent/very good 
Good 
Fair/poor 
 
55  
30  
15 
 
33  
32  
36  
 
 
 
<0.001 
GP visits 
Attended past year  
Mean (SD)  no. visits past year  
 
87  
3.8 (4.1) 
 
96  
5.8 (5.1) 
 
<0.001 
<0.001 
Outpatient department 
Attended past year  
Mean (SD) no. visits past year  
 
39  
1.1 (2.1) 
 
61 
2.2 (2.7) 
 
<0.001 
<0.001 
Hospital admissions 
Admitted in past year  
Mean (SD) no. admissions past 
year 
 
12 
0.2 (0.6) 
 
20  
0.3 (.08) 
 
<0.001 
<0.001 
A&E attendance  
Attended in past year  
Mean (SD)  no. visits past year 
 
15  
0.2 (0.7)  
 
21 
0.3 (0.8) 
 
<0.001 
0.01 
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Access to ancillary state 
service  
Dietician  
Chiropody services 
Optician 
Public health/community 
nurse 
Psychology/counselling 
services 
 
0.6  
4  
12  
6  
0.8  
 
11 
16  
21  
12  
1.2  
 
<0.001 
<0.001 
<0.001 
<0.001 
0.40 
  *lung disease, asthma, arthritis, osteoporosis, cancer, Parkinson’s disease and peptic ulcer 
disease 
 
There were large statistically significant differences in the proportion of people attending all 
ancillary state services in the previous year between the two populations, other than 
attendance at a psychologist or counsellor (Table 3.1). The proportion of people with 
diabetes attending these services did not exceed 21%. Table 3.2 documents the adjusted 
odds ratios for attending ancillary state services for people with diabetes compared to those 
without. The odds of people with diabetes attending a dietician were 19.2 times that of the 
odds in people without diabetes (95% CI: 12.4, 29.6). People with diabetes were 4 times more 
likely to attend a chiropodist than those without (95% CI: 3.0, 5.5). Diabetes was also 
significantly associated with an approximately 60% increased odds of attendance at an 
optician or public health nurse, with odds ratios of 1.58 (95% CI: 1.27, 1.96) and 1.57 (95% 
CI: 1.17, 2.10), respectively.  
Table 3.2 - Adjusted odds ratios for the association between diabetes diagnosis and 
ancillary service use in previous 12-month period 
1Models adjusted for age, gender, marital status, urban/rural location, education, healthcare cover, 
chronic conditions.  
 
Ancillary service Adjusted odds ratio (95% CI)1 P-value 
Dietician 19.2 (12.4, 29.6) <0.001 
Chiropody  4.06 (3.00, 5.50) <0.001 
Optician 1.58 (1.27, 1.96) <0.001 
Public health/community nurse 1.57 (1.17, 2.10) 0.003 
Psychology/counselling service 1.47 (0.66, 3.27) 0.34 
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The incidence rate ratio (IRR) and average marginal effects (AME) from the multivariable 
negative binomial regression models are presented in Table 3.3. There were statistically 
significant positive associations between diabetes and the frequency of GP visits, out-patient 
department visits, hospital admissions and A&E attendances. Adjustment for important 
confounding variables resulted in an attenuation of the IRR point estimates. In the fully 
adjusted models, people with diabetes had a higher rate of GP visits with an IRR of 1.39 (95% 
CI:1.29, 1.50). A similar pattern was observed for out-patient department visits and hospital 
admissions. Diabetes was associated with an 87% increase in out-patient department visits 
and a 52% increase in hospital admissions (p<0.001). A&E attendance was also associated 
with diabetes (IRR: 1.33; 95% CI:1.06, 1.66). On average, 1.49 (95%  CI:1.10, 1.88) additional 
GP visits were attributable to diabetes in a 12-month period and approximately one 
additional out-patient visit (0.97; 95% CI:0.73, 1.21).
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Table 3.3 - Multivariable negative binomial regression results 
IRR – Incidence Rate Ratio, AME – Average Marginal Effect  
Model 1 – crude association 
Model 2 – adjusted for age, gender, marital status 
Model 3 – adjusted for age, gender, marital status, education, healthcare cover, location 
Model 4 – adjusted for age, gender, marital status, education, healthcare cover, location, chronic conditions. 
Health 
service 
Model 1 – Crude Model 2 - Predisposing Model 3 - Enabling Model 4 - Need 
 IRR AME IRR AME IRR AME IRR AME 
GP visits 1.53 
(1.42, 1.64) 
p<0.001 
1.99 
(1.58, 2.40) 
p<0.001 
1.50 
(1.38, 1.62) 
p<0.001 
1.88 
(1.45, 2.32) 
p<0.001 
1.38 
(1.28, 1.49) 
p<0.001 
1.46 
(1.08, 1.84) 
p<0.001 
1.39 
(1.29, 1.50) 
p<0.001 
1.49 
(1.10, 1.88) 
p<0.001 
Outpatient 
department 
1.93 
(1.73, 2.17) 
p<0.001 
1.04 
(0.81, 1.27) 
p<0.001 
1.91 
(1.70, 2.14) 
p<0.001 
1.01 
(0.79, 1.24) 
p<0.001 
1.77 
(1.58, 1.99) 
p<0.001 
0.87 
(0.65, 1.08) 
p<0.001 
1.87 
(1.65, 2.11) 
p<0.001 
0.97 
(0.73, 1.21) 
p<0.001 
Hospital 
admission 
1.68 
(1.35, 2.09) 
p<0.001 
0.12 
(0.06, 0.19) 
p<0.001 
1.58 
(1.26, 1.98)  
p<0.001 
0.11 
(0.04, 0.17)  
p=0.001 
1.49 
(1.20, 1.85) 
p<0.001 
0.09 
(0.03, 0.15) 
p=0.002 
1.52 
(1.21, 1.91) 
p<0.001 
0.10 
(0.03, 0.16) 
p=0.002 
A&E 
attendance 
1.42 
(1.15, 1.77)  
p=0.001 
0.09 
(0.03, 0.16)  
p=0.006 
1.41 
(1.13, 1.77)  
p=0.002 
0.09 
(0.02, 0.16)  
p=0.008 
1.34 
(1.07, 1.68)  
p=0.01 
0.08 
(0.01, 0.14)  
p=0.02 
1.33 
(1.06, 1.66)  
p=0.01 
0.07 
(0.01, 0.14) 
p=0.03  
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The population-based cost estimates for the incremental health service use associated with 
diabetes are presented in Table 3.4. The total population in Ireland in 2016, aged 50 years 
or over, was 1,446,460. The prevalence of diabetes in this sample was applied, estimating 
that 115,717 adults aged 50 years or over have diabetes, in Ireland. The incremental health 
service use associated with diabetes is estimated to cost €88,894,421 per annum. Hospital 
admissions account for the majority of this spending, costing an estimated €60,002,517. The 
results of the sensitivity analysis are displayed in Table 3.5. By varying the unit cost estimates 
by +/- 20%, the cost of the incremental health service use associated with diabetes fluctuates 
from €71,115,537 to €106,673,305. 
 
Table 3.4 – Total incremental health service costs attributable to diabetes 
Health service Direct costs  
(95% Confidence Interval) 
 Euro USD 
GP visits 8,886,425  
(6,560,448 – 11,212,403) 
 
10,358,107 
(7,645,924 – 13,069,288) 
Out-patient department 
visits 
18,512,617  
(13,932,175 – 23,093,058) 
 
21,578,491 
(16,239,483 – 26,917,499) 
Hospital admissions 60,002,517  
(18,000,755 – 96,004,027) 
 
69,939,533 
(20,981,860 – 111,903,253) 
A&E attendances 1,492,862  
(213,266 – 2,985,725) 
 
1,740,095 
(248,585 - 3,480,191) 
Total 88,894,421  
(38,706,645 – 133,295,212) 
 
103,616,226 
(45,116,852 – 155,370,232) 
USD – United States Dollars 
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Table 3.5 – Sensitivity analysis - total incremental health service costs attributable to 
diabetes 
Health service Direct costs, € 
(95% Confidence Interval) 
 -20% +20% 
GP visits 7,109,140 
(5,248,359, 8,969,922) 
 
10,663,710 
(7,872,538, 13,454,883) 
 
Out-patient department 
visits 
14,810,093 
(11,145,740, 18,474,446) 
 
22,215,140 
(16,718,612, 27,711,669) 
 
Hospital admissions 48,002,013 
(14,400,604, 76,803,221) 
 
72,003,020 
(21,600,906, 115,204,832) 
 
A&E attendances 1,194,290 
(170,613, 2,388,580) 
 
1,791,435 
(255,919, 3,582,870) 
 
Total 71,115,537 
(30,965,316, 106,636,169) 
106,673,305 
(46,447,974, 159,954,254) 
 
  
 
 
3.5 Discussion 
 
Using a large nationally-representative population based study, we provide robust estimates 
of health service use and related costs attributable to diabetes. We identify substantial 
increased service use associated with diabetes across the health system. Due to the high 
costs of hospital admissions, hospitalisation costs place the largest burden on the health 
service accounting for more than two thirds of the total costs attributable to diabetes. 
Diabetes was associated with a 39% increase in GP visits and an 87% increase in out-patient 
department visits. This translated to an additional 1.49 GP visits on average per annum and 
approximately one additional out-patient visit. Due to the higher unit cost of out-patient 
visits, the associated costs are more than twice that of primary care costs. With ageing 
populations and the increasing burden of chronic disease, greater attention has been paid to 
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coordinating patient care according to levels of disease complexity. There has been a shift 
towards multidisciplinary shared management of complex cases of diabetes across primary 
and secondary care settings, and structured management of people with uncomplicated 
diabetes in primary care with suitable organisational support (142). These findings suggest 
this shift in routine care settings could result in considerable cost savings.  
Diabetes diagnosis was associated with increased hospital admissions, in line with a number 
of international studies that document higher rates of hospitalisations in people with 
diabetes (143,144). While many studies only take age and gender into consideration, our 
findings add to the literature by indicating that, in a population based sample, diabetes 
remains associated with increased hospital admissions after controlling for a wide range of 
important potential confounders. Our analysis shows that diabetes was associated with a 
52% increase in admissions. Due to variations in study populations and methodological 
approaches, direct comparisons with previous studies are limited. One study conducted in 
Tayside, Scotland, reported a 100% increase in rates of hospital admissions in people with 
diabetes compared to those without (145). This is a crude estimate and the study population 
was significantly younger. 
Almost 70% of the health service costs associated with diabetes resulted from hospital 
admissions. Numerous studies report hospital admissions as the main driver of costs 
associated with diabetes and our findings highlight the need to provide effective 
interventions for the management of diabetes and related complications (97,99). Increased 
risk of hospitalisation in people with diabetes is attributable to macrovascular and 
microvascular complications (100,143). While significantly higher than the population 
without diabetes, it is concerning that less than a quarter of people with diabetes reported 
attending ancillary state services such as chiropody and dietetic services. A shortage of allied 
health professionals has previously been identified as a barrier to delivering diabetes care in 
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Ireland (146). International guidelines identify these services as part of routine care for 
people with diabetes (147). Such services, specifically foot care services and dietetic 
interventions for people with diabetes, are effective in preventing complications and 
subsequently reducing healthcare expenditure (148). While these services may be available 
privately, at a significant cost to the patient, it is imperative that such effective services are 
accessible to all people with diabetes.  
Addressing many of the limitations of previous studies, we provide robust estimates of 
health service utilisation attributable to diabetes. By adopting an incremental approach, we 
ensure that any excess health service use attributable to diabetes is identified, not just the 
service use that appears directly related to diabetes. For instance, this approach ensures that 
excess service use associated with mental health issues is captured in our results. A 
nationally-representative sample provides an appropriate comparison group to calculate 
incremental use and costs, avoiding the overrepresentation of people with diabetes and 
diabetes-related complications. To date, studies have largely relied on hospital-based 
samples or administrative healthcare data (11).  Unlike much of the existing literature on the 
cost of diabetes, we specifically address the issue of endogeneity (11). Our study accounts 
for important confounding variables that have previously been recognised as predictors of 
service use, identifying the costs that can be independently attributed to diabetes (133). The 
adjustment for such factors led to the attenuation of our estimates. Most incremental 
studies control for gender and age only due to data availability constraints (5,11,100,104), 
and so may overestimate service use and costs attributable to diabetes. Furthermore, any 
variables identified as potential mediating factors were omitted from the analyses ensuring 
that the findings were not an underestimation of the true association between diabetes and 
health service use. To date, the only nationally representative studies adopting the 
incremental costing approach and adjusting for additional factors were conducted in the USA 
(9,112).  
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While we cannot infer causality due to the cross-sectional nature of the data, almost 90% of 
the cohort had attended the GP in the previous year. Thus, the potential for reverse causality 
whereby those who attend the GP are more likely to be diagnosed with diabetes and 
diabetes-related complications is reduced. Furthermore, less than one percent of the cohort 
had undiagnosed diabetes on the basis of HbA1c measurement (149). While the reliance on 
self-report doctor diagnoses may potentially introduce misclassification bias and result in 
inaccurate estimates, evidence demonstrates that self-report is a suitable measure for 
estimating the prevalence of chronic conditions including diabetes when compared to 
medical records (150).  Health service utilisation is also based on self-report introducing 
potential for measurement bias. However, recent studies suggest there is no evidence of 
differential recall bias according to demographics or health status (151). This method is 
widely used in health services research. The data were weighted to adjust for differential 
non-response with the aim to minimise the potential for selection bias and improve the 
representativeness of the findings. However, our estimates are only representative of the 
excess health service use and costs associated with diabetes in community-dwelling adults 
aged 50 years and older and so do not represent costs for the total population. It is estimated 
that less than 1.6% of the adult population aged 50 years and older in Ireland are in long-
term residential care (152).  It is also important to note that cost estimates are based on 
average unit costs per visit/admission. Diabetes-related admissions are more expensive and 
as a result our cost estimates are likely to be an underestimation of the true costs of hospital 
admissions (99). The cost estimates also only refer to additional service use for GP and 
hospital services. Due to data limitations, we were unable to calculate the costs associated 
with ancillary service use or community care. Although we employ a societal perspective in 
calculating the associated costs, our estimates represent the direct medical costs and do not 
consider the indirect costs associated with excess health service use. The accuracy of our 
estimates could be improved in further research by applying the demonstrated methods to 
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individual level cost data. The challenge, however, is to find a data source with all necessary 
information. In the absence of a unique identifier in Ireland, this was not possible.  
In conclusion, our findings demonstrate that diabetes is associated with substantial 
additional health service use and costs, with hospital admissions accounting for more than 
two thirds of the cost burden. We highlight areas for potential cost-savings in the context of 
finite healthcare resources, such as a shift in routine management to primary care and 
improved access to effective ancillary services such as foot care services and dietetic 
interventions (148). We provide robust informative estimates for policy-makers by 
identifying additional health service use and costs that are attributable to diabetes. Effective 
interventions aimed specifically at both diabetes prevention and management therefore 
have the potential to directly impact on these health care costs. The challenge is to identify 
cost-effective interventions, examine the trade-offs between them and determine how to 
best implement them. 
  
  
 
 
O'Neill, K. N. 2018. The economic burden of diabetes in Ireland. PhD Thesis, 
University College Cork. 
 
Please note that Chapters 4,5 & 6 (pp. 51-111) are unavailable due to a 
restriction requested by the author.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CORA Cork Open Research Archive http://cora.ucc.ie  
 
112 
 
 
7. Cycle of Care for people with diabetes: an equitable 
initiative? 
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7.1 Abstract 
 
Introduction 
In 2015, the diabetes “cycle of care” was launched. This national initiative financially 
remunerates General Practitioners for structured care for people with type 2 diabetes. 
However, eligibility for the scheme is limited to those with means-tested public health 
insurance. We aim to investigate the coverage of the cycle of care and to describe the socio-
demographic and clinical profile of the population who are not currently eligible. 
 
Methods 
Cross-sectional analysis of wave one (2009-2011) of The Irish LongituDinal study on Ageing 
(TILDA). Individuals were classified as having type 2 diabetes if they self-reported a previous 
doctor diagnosis or if they reported the use of oral hypoglycaemic agents.  Estimates were 
applied to the 2016 census figures estimating absolute population eligible/non-eligible for 
the scheme.  Pearson’s chi-square test was used for the comparison of categorical variables 
across eligibility status while Independent samples t-test was used for continuous data.  
 
Results 
Of the 8,107 TILDA participants, 609 had type 2 diabetes (prevalence: 7.9% [95% CI: 7.3%, 
8.5%]). While the majority of people aged over 50 years with type 2 diabetes are covered by 
the cycle of care, 31.6% (95% CI: 27.8, 35.6) are not eligible for the scheme, equating to 
36,567 (95% CI: 32,170, 41,196) individuals with type 2 diabetes. People not eligible were 
less likely to be on insulin and more likely to be managing their diabetes without medication.  
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 Conclusion 
A third of people over 50 years of age, with type 2 diabetes, are not eligible for the cycle of 
care. Current eligibility criteria for the cycle of care does not identity people on the basis of 
clinical need but rather on income.  
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7.2 Introduction 
 With rising prevalence and burgeoning healthcare costs, diabetes embodies many of the 
challenges facing health systems. The prevalence of doctor diagnosed diabetes in Ireland has 
increased from 2.2% of the adult population in 1998 to 5.2% in 2015 (46). In adults aged 50 
years and older, the prevalence of type 2 diabetes is 8.5% (47). Healthcare costs attributable 
to diabetes in those aged over 50 years are estimated at €89 million per annum with hospital 
admissions accounting for almost 70% of costs (153). Out-patient department visits 
attributable to diabetes cost an estimated €18.5 million per annum.    
International consensus now exists that structured management of uncomplicated diabetes 
in primary care with suitable organisational support constitutes good quality diabetes care. 
There is growing evidence that primary care led structured diabetes management is 
associated with improved outcomes for patients (126,127). Recent guidance on integrated 
care for diabetes in Ireland recommends that patients with uncomplicated type 2 diabetes 
are to be managed in primary care and patients with complicated type 2 diabetes managed 
between primary and secondary care (22). The management of type 1 diabetes remains in 
secondary care. Uncomplicated patients are defined as patients not on insulin but treated by 
diet or glucose lowering agents only, controlled HbA1c and no diabetes-related 
complications (22). 
In 2015, the diabetes “cycle of care” was launched. This is the first national initiative to 
financially remunerate General Practitioners (GPs) for providing structured care for people 
with type 2 diabetes. GPs are remunerated for providing two structured diabetes review 
visits per year. The initiative also establishes formal requirements for registering, recording 
and reporting processes of care. However, GPs will only be remunerated for patients entitled 
to the General Medical Services scheme or the GP-visit scheme. Eligibility for these schemes 
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is means-tested.  We aim to investigate the coverage of the cycle of care and to describe the 
population who are not currently eligible for the initiative. 
 
7.3 Methods 
A cross-sectional analysis of wave one (2009-2011) of The Irish LongituDinal study on Ageing 
(TILDA) was conducted. TILDA is a population-based prospective cohort study of community-
dwelling adults aged 50 years and over (231). The sampling frame is the Irish Geodirectory, 
which is a comprehensive and up-to-date list of all residential addresses in Ireland. A 
multistage probability sampling design was used. Participants completed a computer-
assisted personal interview (CAPI). Individuals were classified as having diabetes if they self-
reported a previous doctor diagnosis or if they reported the use of oral hypoglycaemic 
agents. Type 1 diabetes was defined as those who were aged less than 50 years at diabetes 
diagnosis and reported injecting insulin, but not taking oral hypoglycaemic agents. All others 
were classified as having type 2 diabetes. Participants who reported a doctor diagnosis of 
diabetes during the CAPI were asked the question ‘Has a doctor ever told you that you have 
any of the following conditions related to your diabetes?’. The conditions listed were: leg 
ulcer (peripheral vascular disease), protein in urine (served as a proxy for elevated urine 
albumin creatinine ratio), lack of feeling and tingling pain in legs and feet due to nerve 
damage (diabetic neuropathy), damage to the back of your eye (diabetic retinopathy). These 
were defined as microvascular complications. Participants were considered as having a 
macrovascular complication if they self-reported a doctor-diagnosis of any of the following; 
heart attack (myocardial infarction), heart failure (congestive cardiac failure), stroke 
(cerebrovascular accident) or mini stroke (transient ischaemic attack). During the CAPI, 
participants were also asked about their health cover. People who reported either having a 
medical card or a doctor-visit card are eligible for the cycle of care. Self-reported health 
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service use in the previous 12 months included number of GP visits, out-patient department 
visits, hospital admissions and attendance at ancillary services.  
 
Pearson’s chi-square test was used for the comparison of categorical variables across 
eligibility status while independent samples t-test was used for continuous data. The 
proportion of people who are eligible for the cycle of care was applied to the most recent 
census figures (2016) to estimate the absolute numbers of people covered and not covered 
by the scheme. Survey weights were applied to the analysis to reflect the complex sampling 
design and to adjust for participation bias (134). Analysis was carried out in Stata v. 12 for 
windows (StataCorp, College Station, TX, USA) using the survey function (svy). 
 
7.4 Results  
A total of 8,175 participants from 6,282 households completed the CAPI (response rate: 
62%). Of these, 8,107 had complete data and were included in the analysis. Almost 70% of 
people with type 2 diabetes, aged 50 years and over, are covered by the cycle of care (Table 
7.1). However, 31.6% (95% CI: 27.8-35.6) of people are not eligible for the scheme. In 2016, 
we estimate that 36,567 people, aged 50 years and over, were not eligible for the cycle of 
care scheme.  
 
 
 
 
 
118 
 
 
Table 7.1 - Cycle of Care eligibility 
Cycle of Care % 
(95% CI) 
Population Estimate 2016 
N (95% CI) 
Eligible 68.5 (64.4, 72.2) 79,267 (74,523, 83,548) 
Non-eligible 31.6 (27.8, 35.6) 36,567 (32,170, 41,196) 
 
 
Table 7.2 shows the characteristics of the population eligible for the cycle of care and those 
not eligible. There was a significantly higher proportion of females in the eligible population 
compared to those not covered by the scheme. The age breakdown between the groups also 
differed. Those eligible for the cycle of care were older with 34.2% aged over 75 years 
compared to only 4.1% of those not eligible. A quarter of people not eligible under the cycle 
of care had completed third level education, compared to just 7.4% of those who were 
eligible. The proportion of people living in urban locations did not differ significantly between 
the groups. While a higher proportion of the eligible population reported fair or poor health, 
this was not statistically significant. Similarly, were no significant differences in the 
prevalence of diabetes complications between the groups. There were significant 
differences, however, in diabetes treatment. Among those eligible for the cycle of care, 
17.4% were on insulin compared to 9.8% of people not eligible. A significantly higher 
proportion of non-eligible people reported no medical treatment for their diabetes (27.4% 
compared to 14.7%). 
Those eligible for the cycle of care reported a mean number of 6.7 GP visits in the past 12 
months, compared with 3.8 visits in the those not eligible (p<0.001). There was no significant 
difference in the proportion of people attending outpatient departments in the previous 12 
months between the two groups (p=0.36). The mean number of visits to an outpatient 
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department per 12 months was 2.4 in the eligible group and 1.6 in the non-eligible group 
(p<0.001).    
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Table 7.2 - Characteristics of the population eligible and non-eligible for the cycle of care 
 Eligible 
% (95% CI) 
(n=403) 
Non-eligible 
% (95% CI) 
(n=206) 
P value 
Female 47.2 (42.4-51.9) 30.8 (24.8-37.5) <0.001 
Age 
50-64 
65-74 
75+ 
 
31.4 (27.0-36.2) 
34.2 (29.8-39.0) 
34.2 (29.5-39.2) 
 
69.7 (63.2-75.6) 
26.2 (20.8-32.4) 
4.1 (2.0-8.1) 
 
 
 
<0.001 
Self-reported health 
Excellent/very good 
Good 
Fair/poor 
 
31.9 (27.5-36.7) 
29.5 (25.1-34.3) 
38.6 (33.8-43.6) 
 
34.7 (28.4-41.6) 
36.6 (30.3-43.4) 
28.7 (22.5-35.7) 
 
 
 
0.06 
Education 
None/primary 
Secondary 
Third level 
 
60.4 (55.4-65.2) 
32.2 (27.7-37.1) 
7.4 (5.6-9.7) 
 
28.3 (22.1-35.4) 
46.4 (39.7-53.2) 
25.3 (20.1-31.4) 
 
 
 
<0.001 
Diabetes Management 
Insulin 
Tablets only 
No medication 
 
17.4 (14.0-21.5) 
67.9 (63.0-72.4) 
14.7 (11.6-18.5) 
 
9.9 (6.3-15.0) 
62.8 (55.9-69.2) 
27.4 (21.6-34.0) 
 
<0.001 
Diabetes-related condition 
Macro vascular 
Micro vascular 
 
17.4 (14.0-21.4) 
28.1 (23.7-33.1) 
 
13.4 (9.1-19.3) 
22.7 (17.2-29.2) 
 
0.21 
0.16 
GP 
Attended past year 
Mean (SD) no. visits past year 
 
98.1 (96.3-99.0) 
6.7 (5.2) 
 
91.8 (86.8-95.0) 
3.8 (3.9) 
 
<0.001 
<0.001 
OPD 
Attended past year  
Mean (SD) no. visits past year 
 
62.1 (57.0-66.9) 
2.4 (2.8) 
 
57.9 (50.3-65.1) 
1.6 (2.4) 
 
0.35 
0.001 
Hospital admissions 
Admitted in past year   
Mean (SD) no. admissions 
past year 
 
22.4 (18.4-26.9) 
0.4 (0.8) 
 
14.6 (10.4-20.2) 
0.2 (0.6) 
 
0.03 
0.01 
AE admissions  
Admitted in past year 
Mean (SD) no. admissions 
past year  
 
21.9 (18.0-26.5) 
0.3 (0.8) 
 
17.9 (13.2-23.6) 
0.3 (0.8) 
 
0.23 
0.44 
Access to ancillary state 
service  
Dietician 
Chiropody services 
Optician 
Public health/community 
nurse 
Psychology/counselling 
services 
 
12.3 (9.2-16.2) 
19.8 (15.9-24.4) 
27.0 (22.7-31.7) 
15.8 (12.4-19.9) 
1.0 (0.4-2.3) 
 
9.5 (5.9-15.0) 
6.8 (4.0-11.2) 
7.0 (4.1-11.7) 
2.7 (1.2-6.0) 
1.6 (0.5-5.3) 
 
0.35 
<0.001 
<0.001 
<0.001 
0.47 
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7.5 Discussion 
This study describes the proportion, demographics, health status and healthcare utilisation 
of people with type 2 diabetes according to their eligibility for the cycle of care initiative. 
Almost one third of people over the age of 50 years are not eligible for the initiative. They 
are more likely to be male, to be younger and to have higher levels of educational attainment 
than those covered by the scheme. There were no significant differences in self-reported 
health. However, there were significant differences in diabetes management and health 
service use. 
The aim of the cycle of care is to provide financial remuneration to GPs for providing 
structured care for people with type 2 diabetes in primary care. National guidelines for 
integrated care identify those with uncomplicated type 2 diabetes as the most suitable to be 
managed in primary care (22). Our findings indicate that those currently not eligible for the 
scheme are more likely to fit the outlined criteria of uncomplicated diabetes and therefore 
suitable for structured care in a primary care setting. The prevalence of diabetes-related 
complications in the non-eligible population was lower than the eligible population, although 
this was not statistically significant. We find that almost double the proportion of the non-
eligible population manage their diabetes without medication. Furthermore, a significantly 
lower proportion of the non-eligible population were on insulin. As it currently stands, the 
cycle of care eligibility is not based on clinical need but is solely means-tested. Integrated 
diabetes care has been shown to reduce preventable hospitalisations for diabetes-related 
complications (128). Structured approaches to diabetes care demonstrate improvements in 
glycaemic control and cardiovascular risk factors (129,130). However, if integrated diabetes 
care is to result in clinically and cost-effective care, it must be provided in the most 
appropriate setting to all people with diabetes (148). 
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In Ireland, attendance at out-patient clinics is free at the point of access creating a perverse 
incentive for non-eligible individuals to seek routine diabetes care in secondary care. The roll 
out of the cycle of care to all people with type 2 diabetes would remove the financial barriers 
that currently exist to managing uncomplicated diabetes at the right time and in the right 
place. For integrated care to be implemented, the financing has to be aligned with the care 
pathways. 
Using a nationally representative sample, we provide robust estimates of the number of 
people aged 50 years and older who are currently not eligible for the cycle of care scheme. 
There are some limitations to be noted. Our estimates only include people aged over 50 
years and so the total number of non-eligible people is likely to much higher. Self-reported 
doctor diagnoses may introduce misclassification bias and result in inaccurate estimates. 
However, a number of studies have demonstrated that self-report is a suitable method to 
determine the prevalence of diabetes compared to medical records (150,232). The self-
reported doctor diagnosis of diabetes may underestimate the true prevalence of diabetes as 
it does not measure undiagnosed diabetes. However, the prevalence of undiagnosed 
diabetes has been shown to be low in this cohort (149). As TILDA does not contain 
information on diabetes specific health service, we were unable to explore attendance rates 
at outpatient departments compared to GP visits for routine diabetes care.   
Our findings highlight the inequity of the cycle of care scheme, particularly for younger 
people with type 2 diabetes. While a welcome initiative and an important step in the 
implementation of integrated care in Ireland, eligibility for the scheme needs to be based on 
clinical criteria rather than income-based in order for the true benefits to be realised.  If 
integrated diabetes care is to result in cost-effective care, it is essential that all those likely 
to benefit from the scheme are eligible.  
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8. Unmet Need for Bariatric Surgery 
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8.1 Abstract 
 
Introduction 
With the rising prevalence of severe obesity and type 2 diabetes, bariatric surgery offers a 
clinical and cost-effective treatment for carefully selected patients. Despite this, provision of 
surgical services varies significantly between countries. We aim to inform health service 
planning by estimating the number of people who would potentially benefit from bariatric 
surgery.  
 
Methods  
We applied two separate evidence-based criteria sets for eligibility for bariatric surgery. For 
the first set of criteria, we considered those with body mass index (BMI) ≥40kg/m² or 
≥35kg/m² and one or more of the following; type 2 diabetes, hypertension, previous 
myocardial infarction (MI) or sleep apnea. For the second set of criteria, we considered 
patients with type 2 diabetes and BMI ≥35kg/m², with one or more of the following; previous 
MI, elevated urine albumin-creatinine ratio, retinopathy, neuropathy or peripheral vascular 
disease. Prevalence estimates were applied to census figures for 2011, estimating absolute 
numbers meeting the criteria. 
 
Results 
 Among adults aged ≥50 years, 7.97% (95% CI: 7.23-8.78), representing 92,573 (95% CI: 
83,978–101,981) people, met criteria one and 0.97% (95% CI :0.73-1.28), representing 
11,231 (95% CI: 8,471–14,890) people, met criteria two. With fewer than 1/100,000 
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population publicly funded surgeries taking place annually, current service provision meets 
much less than 0.1% of the need. 
Conclusion 
While many adults who fulfil the eligibility criteria for bariatric surgery may not want or 
require it, the current level of need for bariatric surgical services is not being met. A strategy 
to develop and expand the provision of bariatric care is urgently needed. 
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8.2 Introduction 
With the prevalence of severe obesity and type 2 diabetes continuing to rise (4,233–235), 
the increasing evidence on the clinical and cost-effectiveness of bariatric surgery makes it an 
attractive treatment option (236,237). A Cochrane review investigating the effect of bariatric 
surgery for overweight and obesity found surgery to be more clinically effective in the 
treatment of severe obesity than other non-surgical interventions (238). While most trials 
only follow participants for up to three years (132), data from observational studies with 10-
20 year follow-up show the benefits of surgery (131,238). The Swedish Obese Subjects 
prospective case-control study, indicates the benefits of bariatric surgery in maintaining 
weight loss for 20 years (239). Compared with usual care, bariatric surgery is associated with 
a long-term reduction in overall morbidity and mortality (239,240). The largest benefit of 
bariatric surgery is observed among people with type 2 diabetes (240), with international 
diabetes organisations now calling for the inclusion of metabolic surgery among anti-
diabetes interventions for people with type 2 diabetes and obesity (237).  Substantially 
higher diabetes remission rates are observed among people with type 2 diabetes after 
bariatric surgery (adjusted odds ratios for remission after two years was 8.42; P<0.001 and 
3.45; P<0.001 after ten years) (239) . In the UK national registry of bariatric surgical patients 
with diabetes, operated on between 2011 and 2013, 65% achieved good glycemic control, 
returning to a state of no indication of diabetes without medication (241). This represents a 
large reduction in direct healthcare cost associated with diabetes. The cost-effectiveness of 
bariatric surgery is most notable in patients with high direct health care costs secondary to 
the complications of obesity such as diabetes (131). A UK health technology assessment 
found for patients with diabetes and a body mass index (BMI) of 30-39kg/m2 the 
incremental-cost-effective-ratio was £1367 per QALY gained (242). For patients with type 2 
diabetes (ranging from newly diagnosed to those requiring multimodal therapies), the costs 
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of surgery will be recuperated within three years (239,243). This can potentially be further 
improved in the subgroup of patients with type 2 diabetes with the highest direct healthcare 
costs, such as those requiring expensive insulin or GLP-1 analogues or the subgroup of 
patients with established complications of diabetes such as micro and macrovascular disease 
(244).   
Despite the global obesity and diabetes epidemics and the demonstrated clinical and cost-
effectiveness of bariatric surgery, there is large variation in service provision between 
countries. The rate of bariatric surgery in North America is 44 per 100,000 population, while 
Sweden performs 78 surgeries per 100,000 population. In comparison, the rate of surgery is 
<10 per 100,000 in the UK or Germany (245).  Periodic assessment of bariatric surgery rates 
is an important source of knowledge to healthcare providers and governments (246). Further 
to this, in order to inform health policy and resource allocation, an estimate of the 
prevalence of eligibility for bariatric surgery would be helpful. Bariatric surgical procedures 
are not commonly performed in Ireland.  There is currently no national registry of bariatric 
surgical patients, so robust information about how many procedures are done is limited. 
However, only two public bariatric centres exist nationally and between them fewer than 50 
procedures are done per annum, equivalent to fewer than 1/100,000 population publicly 
funded surgeries taking place annually. Ireland has a two tier health system, whereby all 
citizens are entitled to health care under the public system, funded mainly through general 
taxation. Private health insurance acts as duplicate cover, providing faster access to care 
(247). While an unknown number of bariatric surgeries are carried out in the private sector, 
this provision is dependent on individuals’ ability to pay.  
Ireland has one of the highest rates of obesity in Europe, with one in four adults estimated 
to already suffer with obesity (247). The prevalence of doctor-diagnosed diabetes has 
increased from 2.2% of the adult population in 1998 to 5.2% in 2015 (47). The overall 
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prevalence of type 2 diabetes among adults aged over 50 years in Ireland is 8.5% (47). We 
sought to estimate the number of people potentially eligible for bariatric surgery in Ireland 
based on established clinical criteria and then to refine the number of potentially eligible 
patients by identifying those who suffer from the diseases with high morbidity, mortality and 
healthcare cost, that respond best to bariatric surgery.  
 
8.3 Methods 
We applied two separate sets of criteria to identify those potentially eligible for bariatric 
surgery. The first set of criteria, based on UK guidelines (131), included a BMI ≥40 kg/m2 or a 
BMI ≥35kg/m² and one or more of the following conditions; type 2 diabetes, hypertension, 
previous myocardial infarction (MI) and sleep apnea. The second set of criteria applied only 
to those patients with type 2 diabetes and BMI ≥35kg/m², who had one or more of the 
following; previous MI, elevated urine albumin-creatinine ratio, retinopathy, neuropathy or 
peripheral vascular disease. This second set of criteria was used to identify the cohort of 
patients in whom the largest benefits and cost-savings from bariatric surgery are observed 
(242,244). 
 
We conducted a cross sectional analysis of the first wave (2009-2011) of The Irish 
LongituDinal Study on Ageing (TILDA) to estimate the proportion of people eligible for 
bariatric surgery. TILDA is a nationally representative cohort study of community-dwelling 
adults aged 50 years and over. The sampling frame is the Irish Geodirectory, which is a 
comprehensive and up-to-date list of all residential addresses in Ireland. A multistage 
probability sampling design was used, with each residential address in the country having an 
equal probability of selection.  All household residents aged ≥50 years were eligible to 
participate in the study. Participants completed a computer-assisted personal interview 
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(CAPI) administered by trained social interviewers which included questions on self-report 
doctor diagnosis of chronic conditions. Those who completed the CAPI were invited to attend 
a health assessment either at the study centre or in their home (231). During the health 
assessment, trained nurses objectively measured participants’ weight and height. These 
measures were used to calculate BMI. Only those who completed the health assessment are 
included in the analysis. 
 
Individuals were classified as having diabetes if they self-reported a previous doctor 
diagnosis. Type 1 diabetes was defined as those who were aged less than 50 years at diabetes 
diagnosis and reported injecting insulin, but not taking oral hypoglycemic agents. All others 
were classified as having type 2 diabetes. Participants were asked “Has a doctor ever told 
you that you have any of the conditions on this card?”, which included high blood pressure 
and heart attack (including MI or coronary thrombosis). Those who responded “yes” were 
considered to have the named condition. Participants were asked “How likely are you to doze 
off or fall asleep during the day?” with four different response options; 0=would never doze; 
1=slight chance of dozing; 2=moderate chance of dozing; and 3=high chance of dozing. This 
question was considered a surrogate for the Epworth Sleepiness Scale (248). For the purpose 
of this analysis, those who responded with “high chance of dozing” were classified as having 
sleep apnea. Participants who reported a doctor diagnosis of diabetes during the CAPI were 
asked the question ‘Has a doctor ever told you that you have any of the following conditions 
related to your diabetes?’. The conditions listed were: leg ulcer, protein in urine, lack of 
feeling and tingling pain in legs and feet due to nerve damage, damage to the back of your 
eye. Those who responded “yes” were considered to have peripheral vascular disease, 
elevated urine albumin-creatinine ratio, diabetic neuropathy or diabetic retinopathy, 
respectively. 
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Survey weights were applied to the analysis to reflect the complex sampling design and to 
adjust for participation bias. Based on comparisons with the Irish census and the 2010 
Quarterly National Household Survey, a weight was constructed adjusting for differences in 
educational attainment, age, sex, marital status and geographic location. The survey weights 
applied also accounted for non-response bias in the health assessment sample, as previously 
described (134). The number of participants meeting the eligibility criteria for the two sets 
of criteria were calculated and expressed as a percentage with corresponding 95% 
confidence intervals, using Poisson regression. Prevalence estimates were applied to the 
most recent Irish census figures (2011) to determine absolute numbers meeting these 
criteria. Based on evidence from the UK national registry of bariatric surgical patients, a 
diabetes remission rate of 65% was applied to model the number of people with type 2 
diabetes and microvascular complications (criteria 2) with potential remission of diabetes 
following surgery (241). Due to the crude measure used for sleep apnea, a sensitivity analysis 
was conducted excluding those who were defined as eligible for surgery based solely on 
having sleep apnea. Analysis was carried out in Stata v.12 for windows (StataCorp, College 
Station, TX, USA) using the survey function (svy). 
 
8.4 Results 
A total of 8,175 participants from 6,282 households completed the CAPI (response rate: 
62%). Of these, 5,873 (71%) participants completed the health assessment and were 
included in the analysis. The cohort comprised of 51.7% females and the mean age was 62.9 
years. 21.2% (95% CI: 20.1, 2.4) had a normal BMI and 42.7% (95% CI: 41.4, 44.1) had a BMI 
between 25kg/m² and 29.9kg/m². 25.2% (95% CI: 24.1, 26.4) of the population had moderate 
obesity while 7.7% (95% CI: 7.0, 8.5) and 2.7% (95% CI: 2.3, 3.1) had severe and morbid 
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obesity, respectively. The prevalence of type 2 diabetes was 7.74% (95% CI: 7.08, 8.45) and 
the prevalence of doctor-diagnosed hypertension was 37.9% (95% CI: 36.5, 39.3). 
Under criteria one, 444 participants were eligible for bariatric surgery (patients with a BMI 
≥40 or ≥35kg/m² and one or more of the following conditions; type 2 diabetes, hypertension, 
previous MI or sleep apnea). This accounted for 7.97% (95% CI: 7.23, 8.78) of the population 
(Table 8.1). In the sensitivity analysis excluding those eligible for surgery based solely on 
having sleep apnea, this reduced to 7.42% (95% CI: 6.72, 8.19).  
 
Table 8.1 - Distribution of clinical conditions among TILDA participants for criteria one 
Condition N % (95% CI) Population Estimates  
N (95% CI) 
BMI ≥40kg/m² 145 2.66 (2.25, 3.13)  
    
BMI ≥35kg/m² and:     
Type 2 diabetes 112 2.06 (1.70, 2.49)  
Hypertension 336 6.08 (5.43, 6.79)  
Previous MI 37 0.67 (0.48, 0.94)  
Sleep apnea 119 2.19 (1.81, 2.65)  
    
Any 444 7.97 (7.23, 8.78) ᵃ 92,573 (83,978 – 101,981) 
ᵃCategories of participants are not mutually exclusive 
TILDA – The Irish LongituDinal study of Aging 
BMI – Body mass index 
MI – Myocardial infarction 
 
 
There were 112 (2.06% [95% CI: 1.70, 2.49) participants with a BMI ≥35kg/m² and type 2 
diabetes. Under the second set of criteria, 50 participants were eligible for bariatric surgery 
(patients with a BMI ≥35kg/m², type 2 diabetes and one or more of the following 
complications; previous MI, elevated urine albumin creatinine ratio, retinopathy, 
neuropathy, and peripheral vascular disease). This accounted for 0.97% (95% CI: 0.73, 1.28) 
of the population (Table 8.2).   
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Table 8.2 - Distribution of complications among TILDA participants with BMI ≥35kg/m² 
and type 2 diabetes (criteria two) 
Condition N % (95% CI) Population Estimates  
N (95% CI) 
Previous MI 15 0.29 (0.17, 0.50)  
Protein in urine 14 0.25 (0.15, 0.41)  
Retinopathy 17 0.36 (0.22, 0.58)  
Neuropathy 21 0.39 (0.25, 0.60)  
Peripheral vascular disease 10 0.19 (0.10, 0.35)  
    
Any 50 0.97 (0.73, 1.28)ᵃ 11,231 (95% CI: 8,471, 14,890) 
ᵃCategories of participants are not mutually exclusive 
TILDA – The Irish LongituDinal study of Aging 
BMI – Body mass index 
MI – Myocardial infarction 
  
 
The total proportion of people eligible for bariatric surgery under the two sets of criteria 
were applied to the 2011 Irish census figures to estimate the absolute numbers with 
potential indication for bariatric surgery in Ireland. The total population aged ≥50 years was 
1,161,512. The total number of people with potential indication for bariatric surgery under 
the first set of criteria, was 92,573 (95% CI: 83,978, 101,981). Under the second set of criteria, 
11,231 (95% CI: 8,471, 14,890) people were eligible for bariatric surgery. 
The UK national registry of patients with diabetes operated on between 2011 and 2013, 
shows 65% had acceptable glycaemic control without medication after surgery (241). By 
applying these results to Irish patients with complicated type 2 diabetes (criteria 2), we 
estimated that prioritising bariatric surgery for this cohort could result in an estimated 7,301 
patients achieving good glycaemic control, without requiring medication for up to two years 
after surgery. 
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8.5 Discussion 
It is evident that a substantial proportion of older Irish adults are potentially eligible for 
bariatric surgery. While many adults who fulfil the criteria may not want or be suitable for 
bariatric surgery, these findings highlight the high level of need for such services in Ireland. 
With an estimated 1/100,000 population publically funded surgeries taking place annually, 
our findings indicate that current public service provision of bariatric surgery in Ireland meets 
much less than 0.1% of the need. This mirrors the situation in other countries, such as the 
UK where it is estimated that 2.5 million people are eligible for surgery with less than 10,000 
surgeries occurring annually (131).  
Obesity poses a major challenge for public health. Public health strategies focus on the 
prevention of obesity and lifestyle interventions. However, it is clear that the treatment of 
morbid obesity needs to be recognised as a fundamental aspect in tackling the obesity 
epidemic. A strategy to develop bariatric care in Ireland seems warranted, given the 
previously established efficacy and cost-effectiveness of bariatric surgery. This effective 
intervention increases life-expectancy and increases the odds of diabetes remission, leading 
to a reduction in direct healthcare expenditure (131). The challenge will be to implement a 
strategy that can show a return on investment within three years, but which will have an 
acceptable budget impact in the first year (243). This may be achieved by focusing on those 
patients that would benefit most from surgery while simultaneously having the highest direct 
healthcare cost such as those with established complications of diabetes (criteria two) who 
are using expensive drugs to treat their diabetes.  Our findings demonstrate that by 
increasing the rates of surgery in Ireland in line with other European countries, such as 
France (57/100,000), the intervention will be more accessible, at least, to this population 
subgroup (245). 
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A strength of this study is the large national population based sample. The objective 
measurement of BMI reduces the potential for misclassification bias. The data are weighted 
to adjust for differential non-response, minimising the potential for selection bias and 
improving the representativeness of the findings. A number of limitations should be noted. 
Firstly, the reliance on self-reported doctor diagnoses may introduce misclassification bias 
and result in inaccurate estimates. However, a number of studies have demonstrated that 
self-report is a suitable method to determine the prevalence of type 2 diabetes, hypertension 
and previous MI compared to medical records (150,232). The self-reported doctor diagnosis 
of diabetes may underestimate the true prevalence of type 2 diabetes as it does not measure 
undiagnosed diabetes. However, the prevalence of undiagnosed diabetes is low in this 
cohort (149). Moreover, such an underestimation in the prevalence of diabetes would likely 
lead to an underestimation of the true prevalence of eligibility for bariatric surgery also. As 
there was no validated measure for sleep apnoea in TILDA, our assessment of its prevalence 
is relatively crude and may have lacked adequate specificity. However, sleep apnoea 
prevalence, using this measure, was similar to prevalence estimates in other cohorts of older 
adults (249,250). Moreover, a sensitivity analysis, whereby sleep apnoea was omitted from 
the eligibility criteria, showed no significant difference in the prevalence of eligibility for 
surgery. Thus, our estimates of the prevalence of bariatric surgical eligibility are likely to be 
conservative and clearly limited to those aged 50 years and older. The true numbers eligible 
for bariatric surgery in Ireland are likely to be higher.  
 
In conclusion, 7.97% of older Irish adults are eligible for bariatric surgery according to recent 
guidelines but current service provision meets less than 0.1% of this need. This huge gap 
between need and service highlights the urgent need for the provision of clinical and cost-
effective interventions to treat people with severe obesity. Our findings ought to be 
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considered by policy makers and should be used to guide resource allocation. One strategy 
to limit the budget impact is to focus on the 0.97% of patients, eligible under criteria two, 
that have very large and immediate impacts on their health and healthcare cost. The 
provision of bariatric surgery to those in greatest need has the potential to improve both 
patient outcomes and reduce direct healthcare expenditure quickly. 
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Appendix 1 – Supplementary Data for Chapter 3 
 
Table S1 – Evidence for Model Selection 
 
AIC - Akaike Information Criterion  
BIC - Bayesian Information Criterion  
 Poisson Negative Binomial Zero-inflated Poisson Zero-inflated Negative 
Binomial 
GP visits 
AIC 
BIC 
Mean difference between 
observed and predicted count 
 
44973.985 
45057.991 
0.035 
 
37896.424 
37987.430 
0.023 
 
43761.648 
43929.660 
0.036 
 
37876.907 
38051.919 
0.023 
Out-patient department  
AIC 
BIC 
Mean difference between 
observed and predicted count 
 
30296.569 
30380.574 
0.057 
 
22843.915 
22934.921 
0.005 
 
24775.994 
24944.006 
0.020 
 
22694.836 
22869.849 
0.005 
Hospital admission 
AIC 
BIC 
Mean difference between 
observed and predicted count 
 
9031.183 
9115.189 
0.012 
 
8034.123 
8125.129 
0.002 
 
8209.350 
8377.361 
0.004 
 
8203.378 
8028.366 
0.002 
A&E attendance 
AIC 
BIC 
Mean difference between 
observed and predicted count 
 
9999.863 
10083.869 
0.013 
 
8986.221 
9077.227 
0.002 
 
9191.499 
9359.510 
0.004 
 
8986.277 
9161.289 
0.002 
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Figure S1 – Residual plot: GP visits per annum  
  
PRM – Poisson Model 
NBRM – Negative Binomial Model 
ZIP – Zero-inflated Poisson Model 
ZINB – Zero-inflated Negative Binomial Model 
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Figure S2 – Residual plot: Outpatient department visits per annum 
 
PRM – Poisson Model 
NBRM – Negative Binomial Model 
ZIP – Zero-inflated Poisson Model 
ZINB – Zero-inflated Negative Binomial Model 
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Figure S3 – Residual plot: Hospital admissions per annum 
 
PRM – Poisson Model 
NBRM – Negative Binomial Model 
ZIP – Zero-inflated Poisson Model 
ZINB – Zero-inflated Negative Binomial Model 
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Figure S4 – Residual plot: A&E attendances per annum  
 
PRM – Poisson Model 
NBRM – Negative Binomial Model 
ZIP – Zero-inflated Poisson Model 
ZINB – Zero-inflated Negative Binomial Model 
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Appendix 2 – Supplementary Data for Chapter 5 
 
Diabetes-specific items Other items 
 
Drugs used in diabetes A10 
Insulins – A10A 
1. A10AB01  
2. A10AB04  
3. A10AB05  
4. A10AB06  
5. A10AC01  
6. A10AD01  
7. A10AD05  
8. A10AD30  
9. A10AE01  
10. A10AE04  
11. A10AE05  
12. A10AE06 
 
Blood glucose-lowering drugs – A10B 
Metformin – A10BA02 
Glibenclamide – A10BB01  
Glicazide – A10BB09  
Glimepiride – A10BB12 
Metformin and Pioglitazone – A10BD05 
Metformin and Sitaliptin – A10BD07  
Metformin and Vildagliptin – A10BD08 
Metformin and Saxagliptin – A10BD10 
Metformin and Linagliptin – A10BD11  
Metformin and Dapaglifozin – A10BD15  
Metformin and Canagliflozin – A10BD16  
Metformin and Empagliflozin – A10BD20  
Acarbose – A10BF01  
Pioglitazone – A10BG03  
Sitagliptin – A10BH01 
Vildagliptin – A10BH02  
Saxagliptin – A10BH03  
Linagliptin – A10BH05  
Canagliflozin – A10BK02  
Repaglinide – A10BX02  
Nateglinide – A10BX03  
Exenatide – A10BJ01  
Liraglutide – A10BJ02  
Dapafliglozin – A10BK01  
Empagliflozin - A10BK03  
Dulaglutide – A10BJ05 
 
Diagnostic agents – V04 
 
Antithrombotic agents – B01 
Warfarin - B01AA03  
Clopidogrel - B01AC04  
Acetylsalicylic Acid – B01AC06 (*Aspirin - 
Antithrombotic)  
Dabigatran Etexilate – B01AE07  
Apixaban – B01AF02  
Rivaroxaban – B01AF01  
Edoxaban – B01AF03  
 
Cardiovascular system - C 
Cardiac therapy – C01 
Glyceryl Trinitrate - C01DA02  
Isosorbide Dinitrate – C01DA08  
Isosorbide Mononitrate – C01DA14  
 
Antihypertensives – C02 
Methyldopa – C02AB01  
Clonidine – C02AC01  
Prazosin – C02CA01  
Indoramin – C02CA02  
Doxazosin – C02CA04  
Hydralazine – C02DB02  
Minoxidil – C02DC01  
 
Diuretics – C03 
Bendroflumethiazide – C03AA01 
Bendroflumethiazide and Potassium – 
C03AB01 Xipamide – C03BA10  
Indapamide – C03BA11  
Furosemide – C03CA01  
Bumetanide – C03CA02  
Piretanide – C03CA03  
Spironolactone – C03DA01  
Eplerenone – C03DA04 
Hydrochlorothiazide & Potassium Sparing 
Agents – C03EA01  
Furosemide & Potassium Sparing Agents – 
C03EB01 
 
Beta blocking agents – C07 
Propranolol – C07AA05 
Sotalol – C07AA07  
Metoprolol – C07AB02  
Atenolol – C07AB03  
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Blood glucose/Ketones test strips, urine 
test strips etc., (but not Meters) – V04  
 
All other non-therapeutic agents – V07 
Insulin needles and syringes – V07  
Lancets – V07  
Dextrose Gel  
Injection swabs  
Control solutions for use with meters.  
Infusion sets and appliances required for 
use with Insulin pumps (e.g. Medtronic 
Minimed Sets, though not the actual 
Insulin Pumps) – V07  
Consumable Items required for use with 
Insulin Pumps  
Batteries for Insulin Pumps - V07AY92 
Bisoprolol – C07AB07  
Celiprolol – C07AB08  
Nebivolol – C07AB12  
Labetalol – C07AG01  
Carvedilol – C07AG02  
Timolol and Thiazides – C07BA06  
Nebivolol and Thiazides – C07BB12  
Atenolol and other Diuretics – C07CB03   
Atenolol and other Antihypertensives – 
C07FB03  
 
Calcium channel blockers – C08 
Amlodipine – C08CA01  
Felodipine – C08CA02  
Nifedipine – C08CA05  
Nimodipine – C08CA06  
Nilvadipine – C08CA10  
Lercanidipine – C08CA13 
Verapamil – C08DA01  
Diltiazem – C08DB01  
 
Agents acting on the renin-angiotensin 
system – C09 
Captopril – C09AA01   
Enalapril – C09AA02  
Lisinopril – C09AA03  
Perindopril – C09AA04  
Ramipril – C09AA05  
Quinapril – C09AA06  
Benazepril – C09AA07  
Cilazapril – C09AA08  
Trandolapril – C09AA10  
Zofenopril – C09AA15  
Captopril and Diuretics – C09BA01  
Enalapril and Diuretics – C09BA02  
Lisinopril and Diuretics – C09BA03  
Perindopril and Diuretics – C09BA04  
Ramipril and Diuretics – C09BA05  
Quinapril and Diuretics – C09BA06  
Enalapril and Lercanidipine – C09BB02 
Perindopril and Amlodipine – C09BB04 
Ramipril and Felodipine – C09BB05  
Perindopril, Amlodipine and Indapamide – 
C09BX01  
Perindopril and Bisoprolol – C09BX02  
Losartan – C09CA01  
Eprosartan – C09CA02  
Valsartan – C09CA03  
Irbesartan – C09CA04  
Candesartan – C09CA06  
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Telmisartan – C09CA07 
Olmesartan Medoxomil – C09CA08  
Azilsartan Medoxomil – C09CA09  
Losartan and Diuretics – C09DA01  
Eprosartan and Diuretics – C09DA02  
Valsartan and Diuretics – C09DA03  
Irbesartan and Diuretics – C09DA04 
Candesartan and Diuretics – C09DA06 
Telmisartan and Diuretics – C09DA07 
Olmesartan Medoxomil and Diuretics – 
C09DA08  
Valsartan and Amlodipine – C09DB01 
Olmesartan Medoxomil & Amlodipine – 
C09DB02  
Telmisartan and Amlodipine – C09DB04 
Valsartan, Amlodipine & 
Hydrochlorothiazide – C09DX01  
Olmesartan Medoxomil, Amlodipine & 
Hydrochlorothiazide – C09DX03  
Aliskiren – C09XA02  
Aliskiren and Hydrochlorothiazide – 
C09XA52  
 
Lipid modifying agents – C10 
Simvastatin – C10AA01  
Pravastatin – C10AA03  
Fluvastatin – C10AA04  
Atorvastatin – C10AA05 
Rosuvastatin – C10AA07  
Gemfibrozil – C10AB04  
Fenofibrate – C10AB05  
Colestyramine – C10AC01  
Colesevelam – C10AC04  
Ezetimibe – C10AX09  
Simvastatin and Ezetimibe – C10BA02 
Atorvastatin and Ezetimibe – C10BA05 
Atorvastatin, Acetylsalicylic Acid and 
Ramipril – C10BX06  
 
Other 
Glucagen Hypokit. – H04AA01  
Gabapentin - N03AX12  
Amitriptyline – N06AA09 
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Supplementary Figure 1 - Trends in (A) average prescription costs and (B) number of items, 
2011-2015 
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Supplementary Figure 2 - Trends in (A) average prescription costs and (B) number of items, 
2011-2015 
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Appendix 3 – Research Output and Dissemination  
A.3.1 Peer-reviewed publications 
Year  Publication 
2018 O’Neill KN, McHugh SM, Tracey ML, Fitzgerald AP, Kearney PM. Health 
service utilization and related costs attributable to diabetes. Diabetic Med 
2018:1–8. doi:10.1111/dme.13806. 
2017 O’Neill KN, Finucane FM, le Roux CW, Fitzgerald AP, Kearney PM. Unmet 
need for bariatric surgery. Surg Obes Relat Dis 2017;13:1052–6. 
doi:10.1016/j.soard.2016.12.015. 
2016 Tracey ML, Gilmartin M, O’Neill K, Fitzgerald AP, McHugh SM, Buckley CM, et 
al. Epidemiology of diabetes and complications among adults in the Republic 
of Ireland 1998-2015: a systematic review and meta-analysis. BMC Public 
Health. 2016;16(1):1-13. 
2015  McHugh S, Tracey ML, Riordan F, O’Neill K, Mays N, Kearney PM. Evaluating 
the implementation of a national clinical programme for diabetes to 
standardise and improve services: a realist evaluation protocol. 
Implementation Science: IS. 2015;11:107. 
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A3.2 Conference Presentations 
Year  Title   Conference  
2018 Impact of Population Shifts in Sugar 
Sweetened Beverage Consumption on 
Type 2 Diabetes Incidence: A 
Comparative Risk Assessment Study 
Oral  European Congress of 
Epidemiology, Lyon, 
July 2018 
2018 Trends in Diabetes-related Prescription 
Costs in Ireland 
Oral  SPHeRE Network 
Annual Conference, 
Dublin, January 2018 
2017 Impact of Sugar Sweetened Beverage 
Consumption on Type 2 Diabetes 
Incidence in Ireland 
Oral  Jacqueline Horgan 
Bronze Medal Meeting, 
Dublin,  
2017 Impact of Sugar-Sweetened Beverages 
on Type 2 Diabetes Incidence in 
Ireland 
Poster  World Congress of 
Epidemiology, Saitima, 
Japan, August 2017 
2017 Impact of Sugar-Sweetened Beverages 
on Type 2 Diabetes Incidence in 
Ireland 
Moderated 
Poster 
European Association 
for the Study of 
Diabetes Annual 
Meeting, Lisbon, 
September 2017 
2017 Health Service Utilisation and Related 
Costs Associated with Diabetes 
Oral  SPHeRE Network 
Annual Conference, 
Dublin, January 2017 
2017 Health Service Utilisation and Related 
Costs Associated with Diabetes 
Rapid Fire  AUDGPI Annual 
meeting, Limerick, 
March 2017 
2016 Urgent need for bariatric surgery in 
Ireland (acknowledgment for top 
presentation in session) 
Moderated 
Poster 
Society of Social 
Medicine, 60th Annual 
Scientific Meeting, 
York, September, 2016 
2016 Health Service Utilisation and Related 
Costs Associated with Diabetes 
Poster  National Health Service 
Research Institute 
Research Day, UCC, 
November, 2016 
2016 Unmet Need for Bariatric Surgery Oral  National Health Service 
Research Institute 
Research Day, UCC, 
November, 2016 
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Appendix 4 – Extra credit modules or other completed training  
Year  Course 
Extra-credit modules, University College Cork 
2018 PG7048 Generic and Transferable Skills Portfolio 
2017 PG7016 Systematic Reviews for the health sciences 
2016 PG7021 An Introduction to the Ethics of Health Research 
Other training completed during PhD 
2018 Data Analysis in R – University College Cork 
2017 Advanced Modelling Summer School – Leeds University, UK 
2017 Cochrane Systematic Review Course - University College Cork 
2016 Mediation analysis: challenges and novel approaches - University of Bristol, UK 
2016 Masterclass in health economics and policy - NUI Galway 
2016 NVIVO qualitative software training, UCC 
2016 Symposium on Evidence Synthesis in Health Professions Education, UCC 
2016 How to turbo charge your writing, UCC (Hugh Kearnes) 
2016 Designing Effective Interventions for Health Behaviour Change, NUIG 
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Appendix 5 – Teaching contributions and student supervision 
 
 
 
  
Academic Year  Module Role 
2017-2017  ST1001/ST1002 Introduction to Health Statistics Tutor 
2017-2018  EH2007 Health Information Systems II Tutor 
2017-2018 EH3012 Data Management Tutor 
2017-2018 BSc Public Health and Health Promotion  Mentor 
2016-2017 ST1001/ST1002 Introduction to Health Statistics Tutor 
2016-2017 EH2007 Health Information Systems II Tutor 
2016-2017 EH3012 Data Management Tutor 
2016-2017 BSc Public Health and Health Promotion Mentor 
2105-2016 EH2007 Health Information Systems II Tutor 
2015-2016 BSc Public Health and Health Promotion Mentor 
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Academic Year  Student Project supervision 
2017-2017  Niamh Bambury MPH thesis:  Trends in incidence of ischaemic stroke in 
people with and without diabetes in Ireland 2005-
2015 
2017-2018  Treasa Kelleher MPH thesis:  Modifiable predictors of incident 
depression in multimorbid older adults: results from 
The Irish Longitudinal Study on Ageing 
2017-2018 Sarah Buggy MPH thesis: Associations between maternal well-
being and infant dietary intake at 18 months, in a low-
income context 
2016-2017 Grainne O’Sullivan MPH thesis: Is childcare at 9 months and 3 years of 
age associated with weight status at 5 years of age in 
children in Ireland?  
2016-2017 Aisling O’Brien MPH thesis:  prevalence of diabetes and its related 
microvascular and macrovascular complications in 
nationally representative, community dwelling older 
adults (aged ≥50) in Ireland, England and the United 
States of America (USA). 
2016-2017 Aileen Callanan HRB summer student:  Evaluation of policy changes to 
the Dental Treatment Services Scheme (DTSS) and its 
impact on dental service use for older Irish adults with 
diabetes. 
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Appendix 6 – Published Papers 
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Abstract
Aims To estimate the health service use and direct healthcare costs attributable to diabetes using best available data and
methods.
Methods A nationally representative sample of adults aged ≥50 years was analysed (n=8107). Health service use in the
previous 12 months included the number of general practitioner visits, outpatient department visits, hospital admissions,
and accident and emergency department attendances. Multivariable negative binomial regression was used to estimate
the associations between diabetes and frequency of visits. Average marginal effects were applied to unit costs for each
health service and extrapolated to the total population, calculating the incremental costs associated with diabetes.
Results The prevalence of diabetes was 8.0% (95% CI: 7.4, 8.6). In fully adjusted models, diabetes was associated with
additional health service use. Compared to those without diabetes, people with diabetes have, on average, 1.49 (95% CI:
1.10, 1.88) additional general practitioner visits annually. Diabetes was associated with an 87% increase in outpatient
visits, a 52% increase in hospital admissions and a 33% increase in accident and emergency department attendances
(P<0.001). The incremental cost of this additional service use, nationally, is an estimated €88,894,421 annually, with
hospital admissions accounting for 67% of these costs.
Conclusion Using robust methods, we identified substantially increased service use attributable to diabetes across the
health system. Our findings highlight the urgent need to invest in the prevention and management of diabetes.
Diabet. Med. 35, 1727–1734 (2018)
Introduction
The number of people with diabetes has increased fourfold in
the past 35 years and it is now the seventh leading cause of
years lived with disability worldwide [1,2]. The impact of
diabetes on health systems and national economies is of
growing concern. In 2015, the global cost of diabetes was
estimated to be US$1.31 trillion, with direct medical costs
accounting for two-thirds of the costs [3]. Increasing preva-
lence combined with rising per capita medical expenditure
indicate that the burden of diabetes on health systems will
continue to escalate [4]. An understanding of the health
service use and related costs associated with diabetes is
necessary to inform national policies and the allocation of
scarce resources. It is also essential for identifying and
evaluating methods of cost saving.
Worldwide, there is a lack of accurate, comprehensive and
comparable estimates of the health service use and costs
attributable to diabetes [3]. This is largely due to the
variation in methodologies employed [5]. Furthermore, the
approach used affects the policy relevance of the estimates.
There are three main methodological approaches: the sum-all
medical approach; the disease-attributable approach; and
incremental cost analysis. The most common method applied
for estimating the cost of diabetes is the sum-all medical
approach [5]. This method fails to identify service use
attributable to diabetes and, thus, does not identify costs that
can be avoided by diabetes prevention or management
interventions. As a result, the sum-all medical approach does
not provide meaningful estimates to inform policy decisions.
Another common method used is the disease-attributable
approach, whereby attributable fractions for conditions
associated with diabetes are applied to health service use
data to identify the proportion attributable to diabetes [5].
This method underestimates service use and the costs
associated with diabetes because of its inability to capture
use that does not appear directly attributable to diabetes
[5,6]. For instance, mental health comorbidities in people
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with diabetes increase health service utilisation [7]; however,
because of its reliance on established quantifiable causal
associations, disease-attributable methodology will not cap-
ture such excess service use.
More recent studies adopt an incremental costing
approach. This method identifies the incremental health
service use and costs for people with diabetes compared to
those without, therefore capturing all costs associated with
diabetes. The incremental costing approach also allows for
the consideration of other factors known to influence health
service use, including age, sex, ethnicity, education, socio-
economic status, health status and lifestyle factors [8]. Thus,
it is possible to estimate health service use that is indepen-
dently associated with diabetes [6,9]. To provide more
precise estimates of the global cost of diabetes, there is an
urgent need for valid and reliable country-level data [3]. This
study aims to provide robust estimates of health service use
and direct healthcare costs attributable to diabetes from a
societal perspective by applying an incremental cost
approach, with appropriate adjustment, using a nationally
representative sample of a community-dwelling adults, aged
≥50 years, with and without diabetes.
Methods
Study design
A cross-sectional analysis of data from the first wave of The
Irish Longitudinal Study of Ageing (TILDA) was conducted.
TILDA is a nationally representative prospective cohort
study of community-dwelling adults aged ≥50 years in the
Republic of Ireland [10]. The sampling frame used for
TILDA was the Irish Geodirectory, a comprehensive and up-
to-date list of all residential addresses in Ireland. A multi-
stage probability sampling design was used, with each
residential address in the country having an equal probability
of selection [10]. Eligible addresses were defined as any
household with a person aged ≥50 years. All household
residents aged ≥50 years were eligible to participate in the
study. The estimated number of eligible households was
10 129. Of these, 6282 households participated (response
rate 62%) and 8175 individuals were recruited. Ethical
approval was obtained from the Trinity College Dublin
Research Ethics Committee.
Data collection
Data collection occurred between October 2009 and Novem-
ber 2011. Participants were visited in their home by trained
interviewers who used computer-assisted personal interview-
ing. This included detailed questions about sociodemograph-
ics, physical and mental health, self-reported doctor-
diagnosis of chronic conditions and health service use.
Variable definition
The outcome of interest was self-reported health service use.
Participants were asked about the frequency of visits to
general practitioner (GP) services, outpatient department
visits, hospital admissions and accident and emergency
department (A&E) attendances in the past 12 months. They
were also asked whether they had attended any of the
following ancillary state services in the 12 months preceding
the survey: dietitian; chiropody; optician; public health or
community nurse; or psychology/counselling services. Indi-
viduals were classified as having diabetes if they self-reported
a previous doctor diagnosis of diabetes. To distinguish
between people with Type 1 and Type 2 diabetes, we defined
those who were aged <50 years at diabetes diagnosis and
reported injecting insulin, but who were not taking oral
hypoglycaemic agents, as having Type 1 diabetes. All others
were classified as having Type 2 diabetes. Participants who
reported a doctor diagnosis of diabetes during the computer-
assisted personal interviewing were asked the question, ‘Has a
doctor ever told you that you have any of the following
conditions related to your diabetes?’. The conditions listed
were: leg ulcer, protein in urine, lack of feeling and tingling
pain in legs and feet due to nerve damage, damage to the back
of the eye. Any participant who answered ‘yes’ to any of the
above was considered to have a microvascular complication.
Any participant who self-reported a doctor diagnosis of heart
attack (myocardial infarction), heart failure (congestive
cardiac failure), stroke (cerebrovascular accident) and mini
stroke (transient ischaemic attack) was considered to have
macrovascular complications. Other variables of interest
included age (in years), gender, marital status (yes/no),
education (primary, secondary, third level), location (urban/
rural), healthcare cover (means tested public health insurance,
private health insurance, both, neither), self-reported health
status (excellent, very good, good, fair, poor) and other
chronic conditions deemed not to be associated with diabetes.
What’s new?
• Addressing many of the limitations of previous studies,
our paper is one of the first European studies to
quantify the excess health service use and costs inde-
pendently attributable to diabetes.
• After accounting for important determinants of health
service use, diabetes was associated with substantial
additional health service use and costs across the health
system. Hospital admissions account for two-thirds of
the cost burden.
• We provide informative estimates for policy-makers,
identifying the costs that can be directly targeted by
diabetes prevention and management interventions and
by highlighting areas for potential cost savings in the
context of finite healthcare resources.
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These conditions were lung disease, asthma, arthritis, osteo-
porosis, cancer, Parkinson’s disease and peptic ulcer disease.
Statistical analysis
Health service utilization was compared across populations
with and without diabetes. The differences in the proportion
of people attending each health service was analysed using
Pearson’s chi-squared test. An independent samples t-test
was used to analyse the difference in the mean number of
visits to each service. Logistic regression was used to model
the association between diabetes and attendance at ancillary
state services. Negative binomial regression models were
used to analyse the association between diabetes and the
frequency of health service use. Poisson, negative binomial,
zero-inflated Poisson and zero-inflated negative binomial
regression models were explored. Model selection was
informed by Akaike Information Criterion and Bayesian
Information Criterion statistics and by comparing predicted
and observed probabilities, with negative binomial regression
being selected as the most appropriate model (Appendix S1)
[11]. Average marginal effects were calculated, providing an
estimate of the excess number of visits/admissions attribu-
table to diabetes on average. The average marginal effects
were computed using the post-estimation command, margins
dydx, in STATA. This calculates a predicted probability for
each case with the fixed and observed values of variables, and
then averages the predicted values [12].
The Anderson framework for the societal and individual
determinants of healthcare utilization was used to inform the
selection of appropriate variables to include in the multi-
variable regression models, with the aim of identifying the
independent effect of diabetes on health service use [13]. The
Anderson framework categorizes determinants as either
predisposing, enabling or need factors. Any variables that
could potentially mediate the association between diabetes
and health service use were omitted. Multivariable regression
was used to first adjust for predisposing factors (age, gender
and marital status), then enabling factors (education, health-
care cover and location) and finally need factors (other
chronic conditions).
Sampling weights were applied to all data analyses to
adjust for differential non-response and to reduce the
potential for participation or selection bias [10]. Complete
data were available for 99.1% of the sample and so a
complete case analysis was carried out. Analysis was carried
out in STATA v.12 for windows (StataCorp, College Station,
TX, USA) using the survey function (svy).
Calculation of costs
The average marginal effects for significant associations were
applied to unit costs for the relevant health service. A societal
perspectivewas adopted, applying average unit costs of€50 for
a GP visit, €160 for an outpatient department visit, €5,030 for
a hospital inpatient admission and €183 for an A&E atten-
dance, previously calculated for Ireland [14,15]. These costs
were extrapolated to the total population with diabetes to
calculate the incremental health service costs. The total
population with diabetes was estimated by applying the
prevalence of diabetes in the sample to the most recent Irish
census figures (2016). Cost estimates are reported in Euro and
US dollars (USD) and were inflated to represent costs for 2016
using the Consumer Price Index (CPI) Inflation Calculator for
Ireland [16]. To reflect uncertainty in the estimates of average
unit costs, a sensitivity analysis was conducted whereby these
estimates were varied by  20% [17].
Results
Of the 8107 participants included in the analysis, 51.9% were
female and 41.5% were aged ≥65 years. The prevalence of
diabetes was 8.0% (95% CI: 7.4, 8.6), only 11 participants had
Type 1 diabetes. Among people with diabetes, 15.8% (95%CI:
13.0, 19.2) reportedamacrovascular complication,while26.3%
(95% CI: 22.7, 30.3) reported a microvascular complication.
There were significant differences between the population
with and without diabetes (Table 1). People with diabetes
were older, included a lower proportion of women, lower
levels of educational attainment and lower self-reported health
status. They were also more likely to be covered by public
health insurance. There was significantly higher service
utilization among people with diabetes for all health services,
except psychology/counselling services. Those with diabetes
reported an average of 5.8 GP visits in the past 12 months
compared with 3.8 visits among those without diabetes
(P<0.001). Of people with diabetes, 60.8% (95% CI: 56.7,
64.8) reported attending an outpatient department in the last
year compared with 39.1% (95% CI: 37.7, 40.5) of those
without diabetes. A higher proportion of people with diabetes
also reported being admitted to hospital in the previous 12
months [19.8% (95% CI: 16.7, 23.2)] than those without
diabetes [12.4% (95% CI: 11.6, 13.2)]. Similar variations
were observed for A&E attendances, with 20.5% (95% CI:
17.3, 24.1) of people with diabetes attending A&E compared
with 14.9% (95% CI: 14.0, 15.8) of people without diabetes.
When stratified by public health insurance coverage, similar
patterns were observed (Appendix S2).
There were large statistically significant differences in the
proportion of people attending all ancillary state services in the
previous year between the two populations, other than
attendance at a psychologist or counsellor (Table 1). The
proportion of peoplewith diabetes attending these services did
not exceed 21%. Table 2 documents the adjusted odds ratios
for attending ancillary state services for people with diabetes
compared to those without. The odds of people with diabetes
visiting a dietitian were 19.2 times those of people without
diabetes (95%CI: 12.4, 29.6). People with diabetes were four
times more likely to visit a chiropodist than those without
(95% CI: 3.0, 5.5). Diabetes was also significantly associated
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with ~60% increased odds of attendance at an optician or
public health nurse, with odds ratios of 1.58 (95% CI: 1.27,
1.96) and 1.57 (95% CI: 1.17, 2.10), respectively.
The incidence rate ratios (IRRs) and average marginal
effects from the multivariable negative binomial regression
models are presented in Table 3. There were statistically
significant positive associations between diabetes and the
frequency of GP visits, outpatient department visits, hospital
admissions and A&E attendances. Adjustment for important
confounding variables resulted in an attenuation of the IRR
point estimates. In the fully adjusted models, people with
diabetes had a higher rate of GP visits, with an IRR of 1.39
(95% CI: 1.29, 1.50). A similar pattern was observed for
outpatient department visits and hospital admissions. Dia-
betes was associated with an 87% increase in outpatient
department visits and a 52% increase in hospital admissions
(P<0.001). A&E attendance was also associated with
diabetes (IRR 1.33; 95% CI: 1.06, 1.66). On average, 1.49
(95% CI: 1.10, 1.88) additional GP visits were attributable
to diabetes in a 12-month period and approximately one
additional outpatient visit [0.97 (95% CI: 0.73, 1.21)].
The population-based cost estimates for the incremental
health service use associated with diabetes are shown in
Table 4. The total population in Ireland in 2016 aged ≥50
years was 1 446 460. The prevalence of diabetes in this
sample was applied, estimating that 115 717 adults aged ≥50
years had diabetes in Ireland. The incremental health service
use associated with diabetes was estimated to cost
€88,894,421 per annum. Hospital admissions accounted
for the majority of this spending, costing an estimated
€60,002,517. The results of the sensitivity analysis are shown
in Table 5. By varying the unit cost estimates by  20%, the
cost of the incremental health service use associated with
diabetes fluctuated from €71,115,537 to €106,673,305.
Discussion
Using a large nationally representative population-based
study, we provide robust estimates of health service use and
related costs attributable to diabetes. We identify substantial
increased service use associated with diabetes across the
health system. Due to the high costs of hospital admissions,
hospitalization costs place the largest burden on the health
service, accounting for more than two-thirds of the total
costs attributable to diabetes.
Diabetes was associated with a 39% increase in GP visits
and an 87% increase in outpatient department visits. This
translated to an additional 1.49 GP visits on average per
Table 1 Characteristics of population by diabetes diagnosis
Population
without
diabetes
(n=7486)
%
Population
with
diabetes
(n=621)
% P
Women 53 42 <0.001
Age
50–64 years 60 44
65–74 years 23 32
≥75 years 17 25 <0.001
Rural residence 44 40 0.12
Married 66 63 0.11
Education
None/primary 37 50
Secondary 44 37
Third level 19 13 <0.001
Healthcare cover
Medical card 35 50
Private health insurance
only
38 25
Dual cover 16 19
No cover 11 7 <0.001
Diabetes-related condition
Macrovascular 8 16 <0.001
Microvascular - 26
Other chronic illness* 47 51 0.07
Self-reported health
Excellent/very good 55 33
Good 30 32
Fair/poor 15 36 <0.001
GP visits
Attended past year 87 96 <0.001
Mean (SD) no. visits past
year
3.8 (4.1) 5.8 (5.1) <0.001
Outpatient department visits
Attended past year 39 61 <0.001
Mean (SD) no. visits past
year
1.1 (2.1) 2.2 (2.7) <0.001
Hospital admissions
Admitted in past year 12 20 <0.001
Mean (SD) no. admissions
past year
0.2 (0.6) 0.3 (.08) <0.001
A&E attendance
Attended in past year 15 21 <0.001
Mean (SD) no. visits past
year
0.2 (0.7) 0.3 (0.8) 0.01
Access to ancillary state service
Dietitian 0.6 11 <0.001
Chiropody services 4 16 <0.001
Optician 12 21 <0.001
Public health/community
nurse
6 12 <0.001
Psychology/counselling
services
0.8 1.2 0.40
A&E, accident and emergency department; GP, general prac-
titioner; SD, standard deviation.
*Lung disease, asthma, arthritis, osteoporosis, cancer, Parkin-
son’s disease and peptic ulcer disease.
Table 2 Adjusted odds ratios for the association between diabetes
diagnosis and ancillary service use in previous 12-month period
Ancillary service
Adjusted odds
ratio (95% CI)* P
Dietitian 19.2 (12.4, 29.6) <0.001
Chiropody 4.06 (3.00, 5.50) <0.001
Optician 1.58 (1.27, 1.96) <0.001
Public health/community nurse 1.57 (1.17, 2.10) 0.003
Psychology/counselling service 1.47 (0.66, 3.27) 0.34
*Models adjusted for age, gender, marital status, urban/rural
location, education, healthcare cover, chronic conditions.
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annum and approximately one additional outpatient visit.
Because of the higher unit cost of outpatient visits, the
associated costs were more than twice those of primary care
costs. With ageing populations and the increasing burden of
chronic disease, greater attention has been paid to coordi-
nating patient care according to levels of disease complexity.
There has been a shift towards multidisciplinary shared
management of complex cases of diabetes across primary and
secondary care settings, and structured management of
people with uncomplicated diabetes in primary care with
suitable organizational support [18]. The present findings
suggest this shift in routine care settings could result in
considerable cost savings.
Diabetes diagnosis was associated with increased hospital
admissions, in line with a number of international studies
that document higher rates of hospitalizations in people with
diabetes [19,20]. While many studies only take age and
gender into consideration, our findings add to the literature
by indicating that, in a population-based sample, diabetes
remains associated with a higher number of hospital admis-
sions after controlling for a wide range of important
potential confounders. Our analysis shows that diabetes
was associated with a 52% higher number of admissions.
Because of variations in study populations and methodolog-
ical approaches, direct comparisons with previous studies are
limited. One study conducted in Tayside, Scotland, reported
a 100% higher rate of hospital admissions in people with
diabetes compared to those without [21]. This was a crude
estimate and the study population was significantly younger.
Almost 70% of the health service costs associated with
diabetes resulted from hospital admissions. Numerous stud-
ies report hospital admissions as the main driver of costs
associated with diabetes and our findings highlight the need
to provide effective interventions for the management of
diabetes and related complications [22,23]. Increased risk of
hospitalization in people with diabetes is attributable to
macrovascular and microvascular complications [19,24].
While significantly higher than the population without
diabetes, it is concerning that less than one-quarter of people
with diabetes reported attending ancillary state services, such
as chiropody and dietetic services. A shortage of allied health
professionals has previously been identified as a barrier to
delivering diabetes care in Ireland [25]. International guide-
lines identify these services as part of routine care for people
with diabetes [26]. Such services, specifically foot care
services and dietetic interventions for people with diabetes,
are effective in preventing complications and subsequently
reducing healthcare expenditure [27]. While these services
may be available privately, at a significant cost to the patient,
it is imperative that such effective services are accessible to all
people with diabetes.
Addressing many of the limitations of previous studies, we
provide robust estimates of health service utilization attri-
butable to diabetes. By adopting an incremental approach,
we ensured that any excess health service use attributable toTa
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diabetes was identified, not just the service use that appeared
directly related to diabetes. For instance, this approach
ensured that excess service use associated with mental health
issues was captured in our results. A nationally representative
sample provides an appropriate comparison group to calcu-
late incremental use and costs, avoiding the overrepresenta-
tion of people with diabetes and diabetes-related
complications. To date, studies have largely relied on
hospital-based samples or administrative healthcare data
[5]. Unlike much of the existing literature on the cost of
diabetes, we specifically address the issue of endogeneity [5].
The present study accounts for important confounding
variables that have previously been recognized as predictors
of service use, identifying the costs that can be independently
attributed to diabetes [8]. The adjustment for such factors led
to the attenuation of our estimates. Most incremental studies
control for gender and age only, because of data availability
constraints [3,5,24,28], and so may overestimate service use
and costs attributable to diabetes. Furthermore, any variables
identified as potential mediating factors were omitted from
the analyses ensuring that the findings were not an under-
estimation of the true association between diabetes and
health service use. To date, the only nationally representative
studies adopting the incremental costing approach and
adjusting for additional factors were conducted in the USA
[4,9].
While we cannot infer causality because of the cross-
sectional nature of the data, almost 90% of the cohort had
attended the GP in the previous year. Thus, the potential for
reverse causality whereby those who attend the GP are more
likely to be diagnosed with diabetes and diabetes-related
complications is reduced. Furthermore, <1% of the cohort
had undiagnosed diabetes on the basis of HbA1c measure-
ment [29]. While the reliance on self-report doctor diagnoses
may potentially introduce misclassification bias and result in
inaccurate estimates, evidence shows that self-report is a
suitable measure for estimating the prevalence of chronic
conditions including diabetes when compared to medical
records [30]. Health service utilization is also based on self-
report, introducing potential for measurement bias. How-
ever, recent studies suggest there is no evidence of differential
recall bias according to demographics or health status [31].
This method is widely used in health services research. The
data were weighted to adjust for differential non-response
with the aim of minimizing the potential for selection bias
and improving the representativeness of the findings; how-
ever, our estimates are only representative of the excess
health service use and costs associated with diabetes in
community-dwelling adults aged ≥50 years and so do not
represent costs for the total population. It is estimated that
<1.6% of the adult population aged ≥50 years in Ireland are
in long-term residential care [32]. It is also important to note
that cost estimates are based on average unit costs per visit/
admission. Diabetes-related admissions are more expensive
and as a result our cost estimates are likely to be an
underestimation of the true costs of hospital admissions [22].
Table 4 Total incremental health service costs attributable to diabetes
Health service
Direct costs (95% CI)
Euro USD
GP visits 8,886,425 (6,560,448–11,212,403) 10,358,107 (7,645,924–13,069,288)
Outpatient department visits 18,512,617 (13,932,175–23,093,058) 21,578,491 (16,239,483–26,917,499)
Hospital admissions 60,002,517 (18,000,755–96,004,027) 69,939,533 (20,981,860–111,903,253)
A&E attendances 1,492,862 (213,266–2,985,725) 1,740,095 (248,585–3,480,191)
Total 88,894,421 (38,706,645–133,295,212) 103,616,226 (45,116,852–155,370,232)
A&E, accident and emergency department; GP, general practitioner; USD, US dollars.
Table 5 Sensitivity analysis: total incremental health service costs attributable to diabetes
Health service
Direct costs, € (95% CI)
–20% +20%
GP visits 7,109,140 (5,248,359, 8,969,922) 10,663,710 (7,872,538, 13,454,883)
Outpatient department visits 14,810,093 (11,145,740, 18,474,446) 22,215,140 (16,718,612, 27,711,669)
Hospital admissions 48,002,013 (14,400,604, 76,803,221) 72,003,020 (21,600,906, 115,204,832)
A&E attendances 1,194,290 (170,613, 2,388,580) 1,791,435 (255,919, 3,582,870)
Total 71,115,537 (30,965,316, 106,636,169) 106,673,305 (46,447,974, 159,954,254)
A&E, accident and emergency department; GP, general practitioner.
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The cost estimates also only refer to additional service use for
GP and hospital services. As a result of data limitations, we
were unable to calculate the costs associated with ancillary
service use or community care. Although we took a societal
perspective in calculating the associated costs, our estimates
represent the direct medical costs and do not consider the
indirect costs associated with excess health service use. The
accuracy of our estimates could be improved in further
research by applying the demonstrated methods to individ-
ual-level cost data. The challenge, however, is to find a data
source with all the necessary information. In the absence of a
unique identifier in Ireland, this was not possible.
In conclusion, our findings show that diabetes is associated
with substantial additional health service use and costs, with
hospital admissions accounting for more than two-thirds of
the cost burden. We highlight areas for potential cost savings
in the context of finite healthcare resources, such as a shift in
routine management to primary care and improved access to
effective ancillary services, such as foot care services and
dietetic interventions [27]. We provide robust informative
estimates for policy-makers by identifying additional health
service use and costs that are attributable to diabetes.
Effective interventions aimed specifically at both diabetes
prevention and management therefore have the potential to
have a direct impact on these healthcare costs. The challenge
is to identify cost-effective interventions, examine the trade-
offs between them, and determine how best to implement
them.
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Abstract Introduction: With the rising prevalence of severe obesity and type 2 diabetes (T2D), bariatric
surgery offers a clinical and cost-effective treatment for carefully selected patients. Despite this, the
provision of surgical services varies signiﬁcantly between countries.
Objective: To inform health service planning by estimating the number of people who would
potentially beneﬁt from bariatric surgery.
Setting: Nationally representative sample of community-dwelling older adults.
Methods: We applied two separate evidence-based criteria sets for eligibility for bariatric surgery.
For the ﬁrst set of criteria, we considered those with body mass indexZ40 kg/m2 orZ35 kg/m2
and one or more of the following: T2D, hypertension, previous myocardial infarction, or sleep
apnea. For the second set of criteria, we considered patients with T2D and body mass indexZ35
kg/m2, with one or more of the following: previous myocardial infarction, elevated urine albumin-
creatinine ratio, retinopathy, neuropathy, or peripheral vascular disease. Prevalence estimates were
applied to census ﬁgures for 2011, estimating absolute numbers meeting the criteria.
Results: Among adults agedZ50 years, 7.97% (95% conﬁdence interval [CI]: 7.23, 8.78),
representing 92,573 people (95% CI: 83,978, 101,981), met criteria one and 0.97% (95% CI: 0.73,
1.28), representing 11,231 people (95% CI: 8471, 14,890), met criteria two. With fewer than
1/100,000 population publicly funded surgeries taking place annually, current service provision
meets much less than 0.1% of the need.
Conclusions: While many adults who fulﬁll the eligibility criteria for bariatric surgery may not want or
require it, the current level of need for bariatric surgical services is not being met. A strategy to develop
and expand the provision of bariatric care is urgently needed. (Surg Obes Relat Dis 2017;13:1052–1056.)
r 2017 American Society for Metabolic and Bariatric Surgery. All rights reserved.
Keywords: Bariatric surgery eligibility; Severe obesity; Type 2 diabetes
With the prevalence of severe obesity and type 2 diabetes
(T2D) continuing to rise [1–4], the increasing evidence on
the clinical and cost-effectiveness of bariatric surgery makes
it an attractive treatment option [5,6]. A Cochrane review
investigating the effect of bariatric surgery for overweight
and obese patients found surgery to be more clinically
effective in the treatment of severe obesity than other
nonsurgical interventions [7]. While most trials only follow
participants for up to 3 years [8], data from observational
studies with 10- to 20-year follow-up show the beneﬁts of
surgery [7,9]. The Swedish Obese Patients prospective case-
control study demonstrates the beneﬁts of bariatric surgery
in maintaining weight loss for 20 years [10]. Compared
http://dx.doi.org/10.1016/j.soard.2016.12.015
1550-7289/r 2017 American Society for Metabolic and Bariatric Surgery. All rights reserved.
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with usual care, bariatric surgery is also associated with a
long-term reduction in overall morbidity and mortality
[10,11]. The largest beneﬁt of bariatric surgery is observed
among people with T2D [11], with international diabetes
organizations now calling for the inclusion of metabolic
surgery among antidiabetes interventions for people with
T2D and obesity [6]. Substantially higher diabetes remis-
sion rates are observed among people with T2D after
bariatric surgery (adjusted odds ratios for remission after
2 years was 8.42 (Po .001) and 3.45 (Po .001) after 10
years) [10]. In the UK national registry of bariatric surgical
patients, 65% of patients with diabetes achieved good
glycemic control after surgery, returning to a state of no
indication of diabetes without medication [12]. This repre-
sents a large reduction in direct healthcare costs associated
with diabetes. The cost-effectiveness of bariatric surgery is
most notable in patients with high direct healthcare costs
secondary to the complications of obesity, such as diabetes
[9]. A UK health technology assessment found that for
patients with diabetes and a body mass index (BMI) of
30–39 kg/m2 the incremental-cost-effective-ratio was £1367
($1684) per quality-adjusted life-year gained [13]. For
patients with T2D (ranging from newly diagnosed to those
requiring multimodal therapies), the costs of surgery will be
recuperated within 3 years [10,14]. This can potentially be
further improved in the subgroup of patients with T2D with
the highest direct healthcare costs, such as those requiring
expensive insulin or GLP-1 analogues or the subgroup of
patients with established complications of diabetes such as
micro- and macrovascular disease [15].
Despite the global obesity and diabetes epidemics and the
demonstrated clinical and cost-effectiveness of bariatric sur-
gery, there is large variation in service provision between
countries. The rate of bariatric surgery in North America is
44 per 100,000 people, while Sweden performs 78 surgeries
per 100,000 people. In comparison, the rate of surgery iso10
per 100,000 in the UK or Germany [16]. Periodic assessment
of bariatric surgery rates is an important source of knowledge
to healthcare providers and governments [17]. Furthermore, to
inform health policy and resource allocation, an estimate of the
prevalence of eligibility for bariatric surgery would be helpful.
Bariatric surgical procedures are not commonly performed in
Ireland. There is currently no national registry of bariatric
surgical patients, so robust information about how many
procedures are done is limited. However, only two public
bariatric centers exist nationally and between them fewer than
50 procedures are done per annum, equivalent to less than 1
publicly funded surgery taking place annually per 100,000
people. Ireland has a two-tier health system, whereby all
citizens are entitled to healthcare under the public system,
funded mainly through general taxation. Private health insur-
ance acts as duplicate cover, providing faster access to care
[18]. While an unknown number of bariatric surgeries are
carried out in the private sector, this provision is dependent on
individuals’ ability to pay.
Ireland has one of the highest rates of obesity in Europe,
with 1 in 4 adults estimated to suffer with obesity [18].
The prevalence of doctor diagnosed diabetes has increased
from 2.2% of the adult population in 1998 to 5.2% in 2015
[19]. The prevalence of T2D among adults aged over 50
years in Ireland is 8.5% [20]. We sought to estimate the
number of people potentially eligible for bariatric surgery
in Ireland based on established clinical criteria and then to
reﬁne the number of potentially eligible patients by
identifying those who suffer from the diseases with high
morbidity, mortality, and healthcare cost, that respond best
to bariatric surgery.
Methods
We applied two separate sets of criteria to identify those
potentially eligible for bariatric surgery. The ﬁrst set
of criteria, based on UK guidelines [9], included a
BMIZ40 kg/m2 or a BMIZ35 kg/m2 and one or more
of the following conditions: T2D, hypertension, previous
myocardial infarction (MI), and sleep apnea. The second set
of criteria applied only to those patients with T2D and
BMIZ35 kg/m2, who had one or more of the following
conditions; previous MI, elevated urine albumin-creatinine
ratio, retinopathy, neuropathy, or peripheral vascular dis-
ease. This second set of criteria was used to identify the
cohort of patients in whom the largest beneﬁts and cost-
savings from bariatric surgery are observed [13,15].
We conducted a cross sectional analysis of the ﬁrst wave
(2009–2011) of The Irish Longitudinal Study on Ageing
(TILDA) to estimate the proportion of people eligible for
bariatric surgery. TILDA is a nationally representative
cohort study of community-dwelling adults aged 50 years
and over. The sampling frame is the Irish Geodirectory,
which is a comprehensive and up-to-date list of all
residential addresses in Ireland. A multistage probability
sampling design was used, with each residential address in
the country having an equal probability of selection. All
household residents agedZ50 years were eligible to
participate in the study. Participants completed a
computer-assisted personal interview (CAPI) administered
by trained social interviewers which included questions on
self-reporting doctor diagnosis of chronic conditions. Those
who completed the CAPI were invited to attend a health
assessment either at the study center or in their home [21].
During the health assessment, trained nurses objectively
measured participants’ weight and height. These measures
were used to calculate BMI. Only those who completed the
health assessment are included in the analysis.
Individuals were classiﬁed as having diabetes if they self-
reported a previous doctor diagnosis. Type 1 diabetes was
deﬁned as those who were aged less than 50 years at
diabetes diagnosis and reported injecting insulin, but not
taking oral hypoglycemic agents. All others were classiﬁed
as having T2D. Participants were asked “Has a doctor ever
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told you that you have any of the conditions on this card?”,
which included high blood pressure and heart attack
(including MI or coronary thrombosis). Those who
responded “yes” were considered to have the named
condition. Participants were asked “How likely are you to
doze off or fall asleep during the day?” with four different
response options: 0 ¼ would never doze; 1 ¼ slight chance
of dozing; 2 ¼ moderate chance of dozing; and 3 ¼ high
chance of dozing. This question was considered a surrogate
for the Epworth Sleepiness Scale [22]. For the purpose of
this analysis, those who responded with “high chance of
dozing” were classiﬁed as having sleep apnea. Participants
who reported a doctor diagnosis of diabetes during the
CAPI were asked the question “Has a doctor ever told you
that you have any of the following conditions related to
your diabetes?” The conditions listed were: leg ulcer,
protein in urine, lack of feeling and tingling pain in legs
and feet due to nerve damage, or damage to the back of
your eye. Those who responded “yes” were considered to
have peripheral vascular disease, elevated urine albumin-
creatinine ratio, diabetic neuropathy, or diabetic retinop-
athy, respectively.
Survey weights were applied to the analysis to reﬂect the
complex sampling design and to adjust for participation
bias. Based on comparisons with the Irish census and the
2010 Quarterly National Household Survey, a weight was
constructed adjusting for differences in educational attain-
ment, age, sex, marital status, and geographic location. The
survey weights applied also accounted for nonresponse bias
in the health assessment sample, as previously described
[23]. The number of participants meeting the eligibility
criteria for the two sets of criteria was calculated and
expressed as a percentage with corresponding 95% con-
ﬁdence intervals (CIs), using Poisson regression. Prevalence
estimates were applied to the most recent Irish census
ﬁgures (2011) to determine absolute numbers meeting these
criteria. Based on evidence from the UK national registry of
bariatric surgical patients, a diabetes remission rate of 65%
was applied to model the number of people with T2D and
microvascular complications (criteria two) with potential
remission of diabetes following surgery [12]. Due to the
crude measure used for sleep apnea, a sensitivity analysis
was conducted excluding those who were deﬁned as
eligible for surgery based solely on having sleep apnea.
Analysis was carried out in Stata v.12 for windows
(StataCorp, College Station, TX, USA) using the survey
function (svy).
Results
A total of 8,175 participants from 6,282 households
completed the CAPI (response rate: 62%). Of these, 5,873
(71%) participants completed the health assessment and
were included in the analysis. The cohort comprised 51.7%
females and the mean age was 62.9 years. Of the
participants, 21.2% (95% CI: 20.1, 22.4) had a normal
BMI and 42.7% (95% CI: 41.4, 44.1) had a BMI between
25 kg/m2 and 29.9 kg/m2. In assessing obesity, 25.2% (95%
CI: 24.1, 26.4) of the population had moderate obesity
while 7.7% (95% CI: 7.0, 8.5) and 2.7% (95% CI: 2.3, 3.1)
had severe and morbid obesity, respectively. The prevalence
of T2D was 7.74% (95% CI: 7.08, 8.45) and the prevalence
of doctor diagnosed hypertension was 37.9% (95% CI:
36.5, 39.3).
Under criteria one, 444 participants were eligible for
bariatric surgery (patients with a BMIZ40 or Z35 kg/m2
and one or more of the following conditions: T2D, hyper-
tension, previous MI, or sleep apnea). This accounted for
7.97% (95% CI: 7.23, 8.78) of the population (Table 1). In
the sensitivity analysis excluding those eligible for surgery
based solely on having sleep apnea, this reduced to 7.42%
(95% CI: 6.72, 8.19). There were 112 (2.06%; 95% CI:
1.70, 2.49) participants with a BMIZ35 kg/m2 and T2D.
Under the second set of criteria, 50 participants were
eligible for bariatric surgery (patients with a BMI
Z35 kg/m2, T2D, and one or more of the following
complications: previous MI, elevated urine albumin
creatinine ratio, retinopathy, neuropathy, and peripheral
vascular disease). This accounted for 0.97% (95% CI:
0.73, 1.28) of the population (Table 2).
The total proportion of people eligible for bariatric
surgery under the two sets of criteria were applied to the
2011 Irish census ﬁgures to estimate the absolute numbers
with potential indication for bariatric surgery in Ireland. The
total population aged Z50 years was 1,161,512. The total
number of people with potential indication for bariatric
surgery under the ﬁrst set of criteria, was 92,573 (95% CI:
83,978, 101,981). Under the second set of criteria, 11,231
(95% CI: 8471, 14,890) people were eligible for bariatric
surgery.
The UK national registry of bariatric surgical patients
with diabetes, operated on between 2011 and 2013, shows
65% had acceptable glycemic control without medication
after surgery [12]. By applying these results to Irish patients
Table 1
Distribution of clinical conditions among TILDA participants for
criteria one
Condition n % (95% CI) Population Estimate
n (95% CI)
BMIZ40 kg/m2 145 2.66 (2.25, 3.13)
BMIZ35 kg/m2 and:
Type 2 diabetes 112 2.06 (1.70, 2.49)
Hypertension 336 6.08 (5.43, 6.79)
Previous MI 37 0.67 (0.48, 0.94)
Sleep apnea 119 2.19 (1.81, 2.65)
Any* 444 7.97 (7.23, 8.78) 92,573 (83,978, 101,981)
BMI ¼ body mass index; MI ¼ myocardial infarction; TILDA ¼ The
Irish LongituDinal study of Aging.
*Categories of participants are not mutually exclusive.
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with complicated T2D (criteria two), we estimated that
prioritizing bariatric surgery for this cohort could result in
an estimated 7,301 patients achieving good glycemic
control, without requiring medication for up to two years
after surgery.
Discussion
It is evident that a substantial proportion of older Irish
adults are potentially eligible for bariatric surgery. While
many adults who fulﬁll the criteria may not want or be
suitable for bariatric surgery, these ﬁndings highlight the high
level of need for such services in Ireland. With an estimate of
less than 1 publicly funded surgery taking place annually per
100,000 people, our ﬁndings indicate that current public
service provision of bariatric surgery in Ireland meets much
less than 0.1% of the need. This mirrors the situation in other
countries, such as the UK, where it is estimated that 2.5
million people are eligible for surgery with less than 10,000
surgeries occurring annually [9].
Obesity poses a major challenge for public health. Public
health strategies focus on the prevention of obesity and lifestyle
interventions. However, it is clear that the treatment of morbid
obesity needs to be recognized as a fundamental aspect in
tackling the obesity epidemic. A strategy to develop bariatric
care in Ireland seems warranted, given the previously estab-
lished efﬁcacy and cost-effectiveness of bariatric surgery. This
effective intervention increases life-expectancy and increases the
odds of diabetes remission, leading to a reduction in direct
healthcare expenditure [9]. The challenge will be to implement
a strategy that can show a return on investment within 3 years,
but which will have an acceptable budget impact in the ﬁrst
year [14]. This may be achieved by focusing on those patients
who would beneﬁt most from surgery while simultaneously
having the highest direct healthcare cost, such as those with
established complications of diabetes (criteria two) who are
using expensive drugs to treat their diabetes. Our ﬁndings
demonstrate that by increasing the rates of surgery in Ireland in
line with other European countries, such as France (57/100,000
people), the intervention will be more accessible, at least, to this
population subgroup [16].
One strength of this study is the large national
population-based sample. The objective measurement of
BMI reduces the potential for misclassiﬁcation bias. The
data are weighted to adjust for differential nonresponse,
minimizing the potential for selection bias and improving
the representativeness of the ﬁndings. A number of limi-
tations should be noted, however. Firstly, the reliance on
self-reported doctor diagnoses may introduce misclassiﬁca-
tion bias and result in inaccurate estimates. However, a
number of studies have demonstrated that self-report is a
suitable method to determine the prevalence of T2D,
hypertension, and previous MI compared with accessing
medical records [24,25]. The self-reported doctor diagnosis
of diabetes may underestimate the true prevalence of T2D
as it does not measure undiagnosed diabetes. However, the
prevalence of undiagnosed diabetes is low in this cohort
[26]. Moreover, such an underestimation in the prevalence
of diabetes would likely lead to an underestimation of the
true prevalence of eligibility for bariatric surgery also. As
there was no validated measure for sleep apnea in TILDA,
our assessment of its prevalence is relatively crude and may
have lacked adequate speciﬁcity. However, sleep apnea
prevalence, using this measure, was similar to prevalence
estimates in other cohorts of older adults [27,28]. Moreover,
a sensitivity analysis, whereby sleep apnea was omitted
from the eligibility criteria, showed no signiﬁcant difference
in the prevalence of eligibility for surgery. Thus, our
estimates of the prevalence of bariatric surgical eligibility
are likely to be conservative and clearly limited to those
aged 50 years and older. The true numbers eligible for
bariatric surgery in Ireland are likely to be higher.
Conclusions
Of older Irish adults, 7.97% are eligible for bariatric
surgery according to recent guidelines. However, current
service provision meets less than 0.1% of this need. These
ﬁgures highlight the urgent need for the provision of clinical
and cost-effective interventions to treat people with severe
obesity. Our ﬁndings ought to be considered by policy-
makers and should be used to guide resource allocation.
One strategy to limit the budget impact is to focus on the
0.97% of patients, eligible under criteria two, who would
see very large and immediate impacts on their health and
healthcare cost. The provision of bariatric surgery to those
in greatest need has the potential to improve both patient
outcomes and reduce direct healthcare expenditure quickly.
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Abstract
Background: Accurate estimates of the burden of diabetes are essential for future planning and evaluation of services.
In Ireland, there is no diabetes register and prevalence estimates vary. The aim of this review was to systematically
identify and review studies reporting the prevalence of diabetes and complications among adults in Ireland between
1998 and 2015 and to examine trends in prevalence over time.
Methods: A systematic literature search was carried out using PubMed and Embase. Diabetes prevalence estimates
were pooled by random-effects meta-analysis. Poisson regression was carried out using data from four nationally
representative studies to calculate prevalence rates of doctor diagnosed diabetes between 1998 and 2015 and was
also used to assess whether the rate of doctor diagnosed diabetes changed over time.
Results: Fifteen studies (eight diabetes prevalence and seven complication prevalence) were eligible for inclusion. In
adults aged 18 years and over, the national prevalence of doctor diagnosed diabetes significantly increased from 2.2 %
in 1998 to 5.2 % in 2015 (p trend≤ 0.001). The prevalence of diabetes complications ranged widely depending on study
population and methodology used (6.5–25.2 % retinopathy; 3.2–32.0 % neuropathy; 2.5-5.2 % nephropathy).
Conclusions: Between 1998 and 2015, there was a significant increase in the prevalence of doctor diagnosed diabetes
among adults in Ireland. Trends in microvascular and macrovascular complications prevalence could not be examined
due to heterogeneity between studies and the limited availability of data. Reliable baseline data are needed to monitor
improvements in care over time at a national level. A comprehensive national diabetes register is urgently needed in
Ireland.
Keywords: Ireland, Prevalence, Trends, Diabetes, Microvascular, Macrovascular, Adults, Epidemiology
Background
Diabetes is a serious global public health issue which
has been described as the most challenging health
problem in the 21st century [1, 2]. Cases of diabetes
have progressively increased worldwide; between 1980
and 2008 there was a two-fold increase in the number
of adults with diabetes [3]. Type 2 diabetes is the main
driver of the epidemic, accounting for approximately
90 % of all cases [2]. The increasing burden of diabetes
is driven primarily by rising levels of obesity and an
ageing population [2, 4]. To date there is no national
surveillance programme, or national population-based
survey of diabetes in Ireland. Therefore it is difficult to
quantify or monitor the impact of diabetes at a national
level. Estimates from the International Diabetes Feder-
ation (2013) suggest that the prevalence of diabetes is
in line with global trends. In 2000, the IDF estimated
that the prevalence of diabetes was 3.2 % [5], this had
increased to 6.5 % in 2013 [2].
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Diabetes places a significant burden of care on the
individual, health care professionals and the wider health
system [1, 6]. Individuals with diabetes are two to four
times more likely to develop cardiovascular disease
relative to the general population and have a two to
five-fold greater risk of dying from these conditions [7, 8].
Diabetes is a significant cause of blindness in adults, non-
traumatic lower limb amputations and end-stage renal
disease resulting in transplantation and dialysis [2].
Understanding the epidemiology of diabetes is essential
to identify public health priorities. Accurate estimates of
the burden of diabetes are essential for future planning
and evaluation of services. While the IDF provides preva-
lence estimates for countries and regions, there are sub-
stantial variations in time trends as estimates are based on
imputations [9, 10]. To date, estimates of diabetes preva-
lence in Ireland have been largely based on data from the
2007 National Survey of Health and Lifestyles in Ireland
(SLÁN) [11]. Country specific prevalence rates have also
been reported in the grey literature [2]; however these es-
timates have been extrapolated using data from the UK.
The Euro Diabetes Index (2014) stated that there was a
lack of reliable data to monitor diabetes related complica-
tions in Ireland [12]. To date, a comprehensive overview
of the diabetes situation in Ireland has not been carried
out. Therefore the rationale for carrying out this system-
atic review is to provide a comprehensive understanding
of the diabetes situation in Ireland and to highlight
current gaps in existing knowledge to inform future re-
search. The aims of this review are (1) to systematically
identify and summarise studies describing the prevalence
of diabetes and the most common microvascular (retinop-
athy, neuropathy and nephropathy) and macrovascular
complications among adults in Ireland between 1998 and
2014; and (2) to explore trends in diagnosed diabetes
prevalence between 1998 and 2015.
Methods
This review was produced according to Preferred Report-
ing Items for Systematic reviews and Meta-Analyses
(PRISMA) guidelines for systematic reviews and meta-
analyses [13]. Key words and study eligibility criteria were
determined a priori.
Search strategy
Both peer-reviewed journal articles and reports were
considered for this review. A systematic literature search
was carried out in PubMed and Embase databases to
identify relevant studies reporting the prevalence of
diabetes, microvascular or macrovascular complica-
tions among adults within the Republic of Ireland.
Keywords and Medical Subject Headings (MeSH) terms
included Ireland, prevalence, diabetes, microvascular,
retinopathy, neuropathy, nephropathy, macrovascular and
cardiovascular disease. Keywords were combined using
the AND or OR operators (Additional file 1). Titles and
abstracts of the resulting literature were screened for
further consideration. Reference lists of articles were
also examined to identify potentially relevant studies.
In addition, a Google search was conducted using the
keywords prevalence, diabetes, retinopathy, neuropathy,
nephropathy and Ireland to identify relevant grey litera-
ture. Searches were carried out between January 2014
and March 2014. A second search was carried out in
December 2015 to ensure the review included all up to
date relevant information.
Inclusion criteria
Studies were eligible for inclusion if they met the follow-
ing criteria: (1) conducted in the Republic of Ireland
between 1998 and 2014; (2) cross-sectional study design
or baseline data from longitudinal studies; (3) prevalence
estimates reported for adults aged ≥ 18 years, including
men and women; (4) data provided on diabetes prevalence
(including a self-report of a previous doctor diagnosis and
undiagnosed diabetes) and/or the prevalence of micro-
vascular complications (retinopathy, neuropathy, nephropa-
thy) or macrovascular complications (myocardial infarction,
congestive heart failure, stroke or TIA) in persons with
diabetes; (5) if prevalence data were not reported, sufficient
detail to calculate the numerator and denominator was
provided; (6) the total sample size was ≥ 200; (7) adequate
information was reported on the methods used.
Exclusion criteria
Studies containing participants from Northern Ireland,
restricted to a specific sub-population (including hospital-
based studies), solely focused on type 1 diabetes, pre-
diabetes or gestational diabetes were excluded from this
review. Model estimates of prevalence were also excluded.
If multiple articles provided information on a single study,
the article detailing the most comprehensive data was
selected. Full text articles were retrieved for all potentially
eligible studies and were independently reviewed by three
authors (MT, MG, and KON).
Data abstraction and quality assessment
For each eligible study, three reviewers (MT, MG, and
KON) individually collected relevant information using a
structured data extraction form. The methodological
quality of each included study was assessed using a critical
appraisal checklist for studies used in systematic reviews
addressing questions of prevalence [14]. This appraisal
tool was developed to specifically examine the internal
and external validity of prevalence data included in sys-
tematic reviews. Methodological quality was considered
‘low’ if three or less criteria were met, ‘moderate’ if four to
six criteria were met and ‘high’ if seven to nine criteria
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were met. Articles were not excluded on the basis of
quality. Any inconsistencies in data abstraction and
quality assessment between reviewers were resolved
through consensus.
Statistical analysis
A meta-analysis was carried out using STATA version
13.1 (StataCorp, College Station, TX, USA). Studies
were grouped into four categories: diagnosed diabetes
among adults aged 18+ years; diagnosed and undiag-
nosed diabetes among adults aged 45+ years; diagnosed
diabetes among adults aged 45+ years; undiagnosed
diabetes among adults aged 45+ years. Pooled estimates
of diabetes prevalence and 95 % confidence intervals
(95 % CI) were calculated. Trends in pooled prevalence
could not be explored as there was a lack of available
data from different time points; therefore an overall
estimate was provided for each group. Heterogeneity
between studies was assessed by the Chi-square based
Q test and I2 statistic. Potential publication bias was
evaluated by the Begg’s test. A two-tailed p <0.05 was
regarded to be statistically significant. High heterogen-
eity was found among studies reporting diabetes preva-
lence (I2 ≥ 75 %, p-value < 0.01) hence, pooled estimates
were calculated using random-effects model using the
method of DerSimonian and Laird [15]. The results
from the meta-analysis were presented in a forest plot.
To determine the robustness of the results, a sensitivity
analysis, based on high quality studies, was carried out.
A meta-analysis of the prevalence of diabetes complica-
tions was inappropriate; factors which influence preva-
lence estimates (e.g. time since diabetes diagnosis, type
of diabetes, method of diagnosis) either varied between
studies or were not reported. Instead a narrative synthesis
provides a summary of relevant data.
Trends in diagnosed diabetes
As trends in diabetes prevalence could not be calculated
by meta-analysis, original datasets from four national
population based studies [16–19], identified during the
literature search were obtained and analysed. In each
dataset, diabetes was defined by a self-report of a previous
doctor diagnosis. A detailed description on study method-
ology can be found elsewhere [18, 20]. Using data from
these national surveys, multivariate Poisson regression
models were undertaken to impute annual gender and
age-specific (18–39 years, 40–69 years, ≥70 years) rates of
diagnosed diabetes and to assess trends over time. The
dependent variable was the number of cases of diagnosed
diabetes and the exposure variables were year of data
collection and age group. An interaction term between
calendar year and age group was considered to explore
whether the rates of change over time differed across age
groups; a non-significant interaction indicated a common
linear trend in prevalence. The predict command was
used post analysis to calculate the expected rates of diag-
nosed diabetes for each calendar year of the study. The
gender and age-specific predicted rates were applied to
2004–2015 population data so the absolute number of
diabetes cases could be obtained. Annual population esti-
mates were obtained from the Central Statistics Office
(CSO), Ireland [21]. A census took place in Ireland in
2002, 2006 and 2011; data for other study years were CSO
inter-censal estimates [21]. Prevalence was calculated by
dividing the number of expected cases of doctor diagnosis
of diabetes by the total study population and was expressed
as a percentage with 95 % CI. Prevalence estimates were
presented graphically in Excel.
Results
Study selection
Results of the literature search and the selection process
are summarised in Fig. 1. One report [22] provided two
estimates for diabetes prevalence from two separate
studies [16, 17]. In total, 15 studies were eligible for
inclusion; eight reporting estimates on diabetes preva-
lence and seven reporting estimates on complication
prevalence. Of the included studies, the methodological
quality was considered moderate in nine studies and
high in the remaining studies (Additional file 2).
Characteristics of selected studies
Characteristics of studies that reported the prevalence
of diabetes or diabetes complications are presented in
Tables 1 and 2. In all included studies, data collection
were carried out between 1998 and 2011. Studies varied in
terms of the study design, setting (national vs. regional),
sampling approach and study quality. Of the 8 studies
reporting on diabetes prevalence (Table 1), five articles
had been published in peer-reviewed journals [11, 23–26],
while three estimates were reported in two national re-
ports [22, 27]. Of the 7 studies reporting diabetes com-
plications (Table 2), six had been published in peer-
reviewed journals [28–33], while one audit [34] pro-
vided data on the prevalence of diabetes related complica-
tions. Five studies utilised an objective data source to
ascertain the prevalence of complications [28–30, 33, 34].
The diagnostic criteria for complications was unclear in
three studies [31, 31, 34] whereas the remaining four
used validated diagnostic criteria to identify cases
[28–30, 33], however these criteria differed between
studies reporting on the same complication.
Prevalence of diabetes in included studies
Table 3 reports the prevalence of diabetes by study. Indi-
vidual and summary estimates, based on a random-effects
meta-analysis are illustrated in Fig. 2. There was signifi-
cant heterogeneity in all groups. Sensitivity analysis only
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showed lower heterogeneity in combined prevalence rates
for undiagnosed and diagnosed diabetes among adults
aged over 45 years (I2 ≥ 25 %, p = 0.36); with a pooled
prevalence of 9.2 % (95 % CI: 8.6–9.8) (Additional file 3).
According to the Egger’s test, there was no evidence of
publication bias (p = 0.27).
Trends in the prevalence of diagnosed diabetes over time
In adults aged 18 years and over, the prevalence of diag-
nosed diabetes increased from 2.2 % (95 % CI: 1.7 %–
2.7 %) in 1998 to 5.2 % (95 % CI: 5.1 %–5.3 %) in 2015
(ptrend = <0.001); representing an absolute mean increase
of 0.17 % per year. In 2015, the incidence of diagnosed
diabetes was 0.2/100 population.
Figure 3 illustrates the age-specific prevalence of self-
reported diagnosed diabetes from 1998 to 2015. In adults
aged between 18 and 39 years, the prevalence of self-
reported doctor diagnosed diabetes remained stable
between 1998 and 2015 in both men and women;
ptrend >0.05. However, there was a significant increase in
Fig. 1 PRISMA flow chart depicting the selection process of articles included in the systematic review
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Table 1 Characteristics of studies reporting the prevalence of diabetes or related complications among adults in the Republic of Ireland, 1998–2011
Author Year of data
collection
Study design National or
regional
Setting Population Sampling frame Sampling method Sample size Males
(%)
Age
(years)
Study quality
(out of 9)
Diabetes prevalence
Sheily and
Kelleher [22]
1998 Cross-sectional National Household General population Electoral register Multistage sample 1632 47.7 55 7
Creagh
et al. [23]
1998 Cross-sectional Regional 17 GP practices Primary Care Patients Practice list Stratified random 1018 48.2 50–69 6
Census Statistic
Office (CSO) [27]
2001 Survey National Household General population Census Total sample 3917203 - 18 5
Sheily and
Kelleher [22]
2002 Cross-sectional National Household General population Electoral register Multistage sample 1745 41.7 55 7
Balanda
et al. [11]
2007 Cross-sectional National Household General population Geodirectory Multistage probability 10,364 49.5 18 8
Gallagher
et al. [24]
2009-2010 Cross-sectional National Database Patients covered by
GMS, LTI, DPS schemes
HSE-PCRS pharmacy
claims data base
Total sample
2009
2010
3493974
3490877
- 16 6
Leahy et al. [25] 2009-2011 Cross-sectional
analysis of
longitudinal
study
National Household &
designated
health centre
General population Geodirectory Multi-stage probability 5377 46.5 50 8
OConnor
et al. [26]
2010-2011 Cross-sectional Regional Primary care centre Patients Practice list Random 2047 49.2 50–69 8
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Table 2 Characteristics of studies reporting the prevalence of diabetes or complications among adults in the Republic of Ireland, 1998-2011
Author Year of data
collection
Study design National or
regional
Setting Population Sampling frame Sampling method Sample
size
Males
(%)
Age
(years)
Study quality
(out of 9)
Complication
prevalence
Kelliher
et al. [28]
2003 Cross-sectional National National Council
for Blind Ireland
(NCBI)
All person registered
blind
NCBI database Total sample 6826 - Adults 8
Buckley
et al. [29]
2009 Cross-sectional National Population People with diabetes Hospital In-Patient
Enquiry (HIPE) dataset
Total sample 723551 - 20 years 9
Marsden
et al. [34]
2008-2009 Audit Regional 20 general
practices
Patients with T1 & T2 DM
registered with diabetes
structure care programme
Practice patient list Every second
person from list
1071 51.9 63 (sd
13)
5
Hurley
et al. [30]
2008-2009 Cross-sectional
analysis of
longitudinal study
Regional General
practices with
diabetes nurse
Patients with T1 & T2 DM Practice diabetes
register
Researchers selected
eligible participants
563 60 64 (sd
13.4)
6
Farrell &
Moran [31]
2010 Cross-sectional Regional 30 general
practices
T2 DM Diabetes imitative
database
Stratified sampling 309 - - 5
Tracey
et al. [32]
2009-2011 Cross-sectional
analysis of
longitudinal study
National Household General population Geodirectory Multi-stage
probability
8175 53 50 8
McHugh
et al. [33]
2011 Cross-sectional Regional 30 general
practices
Patients with T1 & T2 DM Practice patient list All persons with
T1&T2DM invited
1542 57.3 65 (sd
13)
7
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Table 3 Prevalence of diabetes among adults in included studies, 1998-2011
Study Year of data
collection
Response
rate (%)
Sample size Age Diabetes
type
Diagnostic criteria Estimate Prevalence % (95 % CI)
Males Females Total
Sheily and
Kelleher [22]
1998 62 1632 55 years All SRa Diagnosed 6.1 4.3 5.4
Creagh et al. [23] 1998 69.1 1018 50–69 years 2 FPGb Diagnosed
Undiagnosed
Total
Total 65 years
-
-
-
13
-
-
-
7
2.8
1.2
3.9 (2.9–5.4)
-
CSO [27] July- Sept. 2001 - 3917203 18 years All SR Diagnosed
18 years
65 years
-
1.7
-
1.4
1.5
4.5
Sheily and
Kelleher [22]
2002 53 1745 55 years All SR Diagnosed 8.0 5.1 6.4
Balanda et al. [11] 2007 62 10,364 18 years All SR or medication use
or HbA1cc
Diagnosed
18–44 years
45+ years
Total 18 years
Undiagnosed ( 45 years)
Total (diagnosed & undiagnosed
45 years)
-
6.8 (5.7–7.9)
-
4.0 (1.6–6.3)
10.8 (8.2–13.4)
-
5.4 (4.3–6.6)
-
1.7 (0.3–3.0)
7.1 (5.3–8.9)
0.7 (0.5–0.9)
6.1 (5.5–6.9)
3.5 (3.1–3.9)
2.8 (1.4–4.1)
8.9 (7.3–10.5)
Gallagher et al.
[24]
2009
2010
- 3493974
3490877
18 years 2 At least 1 prescription
of diabetes medication
Diagnosed
2009
2010
-
-
-
-
2.8
3.1
Leahy et al. [25] 2009–2011 62 5377 50 years 2 SR or medication use
or HbA1cc
Diagnosed
Undiagnosed
Total (diagnosed & undiagnosed)
50–59 years
60–69 years
70–79 years
80+ years
-
-
11.8 (10.3–13.3)*
5.1 (4.0–7.0)
6.0 (5.0–8.0)
12.0 (8.0–14.0)
10.0 (5.0–15.0)
-
-
7.3 (6.0–8.5)*
4.0
14.0 (11.0–16.0)
17.0 (14.0–21.0)
25.0 (15.0–36.0)
8.6 (7.6–9.5)
0.9 (0.6–1.1)
9.5 (8.5–10.4)
5.0 (4.0–6.0)
-
-
16.0 (10.7–21.4)
OConnor et al.
[26]
2010-2011 67.9 2047 50–69 years 2 SR or medication use
or HbA1cc
Diagnosed
Undiagnosed
Total
6.8*
7.1*
11.1*
3.1*
2.7*
6.0*
5.0 (4.1–6.0)
3.5 (2.8–4.4)
8.5 (7.4–8.8)
*p for difference < 0.05
aSR self-reported data; bFasting plasma glucose (American Diabetes Association criteria (ADA, 1997); cHbA1c (ADA, 2010)
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prevalence among men aged 40 to 69 years between 1998
(3.5 % [95 % CI: 3.4–3.6 %]) and 2015 (6.6 % [95 % CI:
6.5–6.7 %]; ptrend <0.001). The prevalence of diabetes
also increased among women in the same age group
over the same time period (1998–2.5 % [95 % CI: 2.4–
2.5 %] to 2015- 4.2 % [95 % CI: 4.1–4.3 %]; ptrend
<0.001). In those aged 70 years and over, an upward
trend in prevalence among both men (1998–8.2 %
[95 % CI: 8.0–8.3 %] to 2015- 15.1 % [95 % CI: 14.8–
15.2 %]) and women (1998- 4.7 % [95 % CI: 4.5–4.8 %]
Fig. 2 Forest plot of individual and summary diabetes prevalence estimates of included studies
Fig. 3 Prevalence of self-reported doctor diagnosed diabetes among adults in RoI, 1998–2015
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to 2015- 10.7 % [95 % CI: 10.5–10.8 %]) was also observed;
ptrend <0.001.
Prevalence of microvascular and macrovascular
complications
Table 4 describes the prevalence of microvascular and
macrovascular complications in each included study.
Five out of seven studies reported the prevalence of retin-
opathy [27, 29–31, 33]. Among people with type 2 dia-
betes, a population based study reported the prevalence of
diabetic retinopathy to be 8.5 % in 2009–2011 [30]; a
regional study, carried out among primary care patients,
found a higher prevalence of 24.8 % [31]; however this
estimate included patients with type 1 and 2 diabetes and
was based on objective data. A similar estimate (25.6 %)
was reported in a comparable cohort of primary care
patients in a different region [33].
In terms of diabetes-related neuropathy, a divergence
in the reported prevalence between studies was also ob-
served. Data from 12 primary care centres in the West of
Ireland indicated a prevalence of past documented neur-
opathy to be 3 % [30]. On the other hand, a population-
based study reported a prevalence of 14.6 % [32]. These pa-
tients had similar average duration since diagnosis (7.8 years
[30] vs. 5.0 years [32]); however, the latter estimate was
based on self-reported data. Prevalence rates for leg
amputations were 1.7 % among primary care patients
with diabetes [30]. In contrast, the prevalence of non-
traumatic lower leg amputation was lower (0.2 %) in a
population-based study which utilised national hospital
discharge data [29].
With reference to nephropathy, prevalence among those
with type 2 diabetes was similar in two studies [31, 32]. In
the three studies presenting data on macrovascular compli-
cations, a marked difference in prevalence was observed. A
primary care audit reported a prevalence of 3.5 % in pa-
tients with type 1 and 2 diabetes [34]. In contrast, among
those with type 2 diabetes, a population based study re-
ported a higher prevalence of 15.1 % [32].
Discussion
This systematic review is the first study to compile all
available evidence reporting the prevalence of diabetes
(diagnosed and undiagnosed) and related complications
(microvascular and macrovascular) among adults in
Ireland between 1998 and 2015. Fifteen studies (eight
describing diabetes prevalence and seven describing
complication prevalence) were included.
Similar to other systematic reviews [35–37]; compar-
ability between studies was limited due to differences in
study population, sampling methods and diagnostic cri-
teria. Additionally, substantial statistical heterogeneity was
detected between studies reporting the prevalence of dia-
betes; therefore our pooled estimates have to be interpreted
with caution. Sensitivity analysis, based on study quality,
lowered the heterogeneity of combined prevalence rates
for undiagnosed and diagnosed diabetes among adults aged
over 45 years. However, this may reflect variability between
prevalence estimates rather than study quality. Trends
in diabetes prevalence could not be explored by meta-
analysis, therefore, original data from four population-
based national studies [16–19] were obtained to explore
time trends in doctor diagnosed diabetes prevalence
between 1998 and 2015. Over a seventeen year period,
we observed an important increase in the national preva-
lence of self-reported diagnosed diabetes in Ireland.
Consistent with previous research [38–40] trends in the
prevalence of self-reported diagnosed diabetes remained
constant in adults aged 18 to 39 years, while an increasing
prevalence was observed in the older age groups. We were
unable to distinguish between the various types of diabetes
in this review; however it can be assumed that type 2 dia-
betes is driving the increase in prevalence as it accounts
for 90 % of all diabetes cases [1, 2]. The prevalence of
diabetes was consistently higher in males compared to
females. Evidence suggests that men are at a higher risk of
developing type 2 diabetes as they develop diabetes at a
lower BMI, are more predisposed to central fat deposition
and are more prone to insulin resistance [41]. Therefore,
men are more likely to develop type 2 diabetes in response
to increasing levels of obesity [42]. On the other hand, the
higher prevalence in the male population may reflect pref-
erences in diagnostic methods. Evidence has highlighted
that the prevalence of FPG diagnosed diabetes is higher
among men, whereas women are more commonly diag-
nosed by a 2-h plasma glucose test [43]. While it is not
possible to determine the method of diabetes diagnosis in
this review; it is important to consider how these gender
differences may influence diagnosed diabetes prevalence
estimates over time.
Similar to diagnosed diabetes, trends in the prevalence
of undiagnosed diabetes could not be explored by meta-
analysis as only two nationally representative studies had
relevant data [11, 25]. The prevalence of undiagnosed
diabetes, based on HbA1c, decreased from 2.8 % in 2007
to 0.9 % in 2009–2011 among adults aged ≥45 years and
≥50 years, respectively. While the prevalence of diag-
nosed diabetes increased from 6.1 % in 2007 [11] to
8.6 % in 2009–2011 [25]. This shift from undiagnosed to
diagnosed diabetes prevalence has also been observed in
a study carried out in Germany [10]. This decrease in
undiagnosed diabetes prevalence may be attributable to
earlier detection of diabetes [10]. In Ireland, screening
high risk patients for type 2 diabetes has been encouraged
since the introduction of national guidelines for diabetes-
care in 2002 [44]. Another study based on 29144 adults
aged 45–75 years with private health insurance, reported
the prevalence of undiagnosed diabetes to be 1.8 % in
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Table 4 Prevalence of microvascular and macrovascular complications in included studies, 2003–2011
Author Year of
study
Response
rate (%)
Sample
size
Age Diabetes
type
Time since
diabetes
diagnosis
Data source Diagnostic method Type of complication Prevalence (%)
Total
Kelliher
et al. [28]
2003 - 6826 Adults All - National blind registry Visual acuity of <6/60 in
better eye/visual field
subtending angle of
20°/< less
Blindness due to diabetic retinopathy 4.7
Buckley
et al. [29]
2009 - 723,551 20 years All - Hospital discharge
data
ICD-10 codes Non-traumatic lower leg amputation 0.2
Marsden
et al. [34]
Nov 2008-
March 2009
72 1071 63 years
(sd 13)
T1: 7.5 %
T2: 92.3 %
15 years Electronic & paper
clinical notes & referral
letters
-
Risk classification score
ACR 2.5–25
ACR >25
-
-
-
-
Diabetic retinopathy
Foot ulcer
Microalbuminuria
Proteinuria
Myocardial Infarction
Heart Failure
Transient Ischemic Attack
Stroke
Total macrovascular
24.8
2.5
32.1
6.0
0.4
0.3
1.5
0.5
3.5
Hurley
et al. [30]
Feb 2008-
Sept 2009
68 563 64 years
(sd 13.4)
T1: 10 %
T2: 90 %
7.7 (8.2)
years
Clinical foot examination
& practice medical records
Scottish Intercollegiate
Guidelines Network risk
stratificationsystem &
previous doctor diagnosis
Documented diabetic neuropathy
Foot ulceration
Past amputation
Neuropathy symptoms at examination
3.0
3.7
1.7
32
Farrell &
Moran [31]
2010 - 309 - T2 - Chart review - Diabetic retinopathy
Neuropathy
Peripheral vascular disease
Chronic kidney disease
Cerebrovascular disease
6.5
12.3
12.9
5.5
5.2
Tracey
et al. [32]
2009–2011 62 655 50 years T2 5 (IQR 3–10)
years
SR previous doctor
diagnosis
- Diabetic retinopathy
Neuropathy
Leg ulcer
Nephropathy
Proteinuria
Total macrovascular
8.2 (6.2–10.9)
14.6 (11.4–18.2)
4.2 (2.8–6.4)
5.1 (3.4–7.6)
6.1 (4.3–8.6)
15.1 (12.2–18.4)
McHugh
et al. [33]
2011 GP = 94 %;
Screening
uptake = 43 %
1542 65 years
(sd 13)
T1: 4.9 %
T2: 85.6 %
- Eye examination & clinical
records
Fundus 45° digital
PASA-approved camera
Background (R1)
Pre proliferative (R2)
Proliferative (R3)
Any diabetic retinopathy
21.5 (19.5–23.6)
3.4 (2.6–4.5)
0.7 (0.4–1.3)
25.6 (23.5–27.9)
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2009–2012 [45]. However this estimate was derived from
FPG; evidence suggests that the use of HbA1c may under-
estimate diabetes prevalence compared with estimates
using FPG [38, 43, 46].
The prevalence of diabetes complications varied substan-
tially between studies therefore comparisons between stud-
ies have to be interpreted with caution. These variations
may be attributable to differences in disease duration or
study population (type 1 and type 2 diabetes vs. type 2 dia-
betes), study setting (primary care vs. population-based) or
heterogeneity in the criteria used to diagnose macrovascu-
lar and microvascular complications. Objective data de-
scribing the national prevalence of diabetic retinopathy
was not available however, regional data on diabetic retin-
opathy showed that approximately 25 % of primary care
patients with type 1 and type 2 diabetes had been diag-
nosed with this condition [33, 34]. This estimate is higher
than a previous hospital-based study based on patients
with type 2 diabetes (14.8 %) [47] and primary care data
from the UK (19.6 %) [48] but lower than global prevalence
estimates (34.6 %) [49]. Though, caution has to be applied
when interpreting the results as both regional studies in-
cluded in this review reported a low uptake rate of retinop-
athy screening at approximately 50 % [33, 34].
Additionally, characteristics between attenders and non-
attenders were not compared in either study; hence it is
possible that there were systematic differences between
the two groups. Healthier people are more likely to par-
ticipate in research; therefore the prevalence of diabetic
retinopathy may have been underestimated. As a na-
tional screening programme for diabetic retinopathy
was introduced in 2013 [50], future estimates based on
this national programme may be more reliable.
Limitations
The strengths and limitations of this systematic review
should be noted. Both peer-reviewed articles and esti-
mates detailed in the grey literature were included to limit
the impact of publication bias. Original data from four
national studies were obtained so trends in diagnosed
diabetes prevalence could be examined over a 17 year
period. Although response rates were below the optimal
rate of 70 %, the representativeness of each study has
been demonstrated previously [18, 51], so it can be
assumed that the results presented can be generalised
to the Irish population.
However, several limitations need to be acknowledged.
Firstly, studies included in this review were of moderate
to high quality; however, six of the included studies relied
on self-reporting to determine the prevalence of diagnosed
diabetes and one study relied on self-reporting to deter-
mine the prevalence of diabetes related complications.
This approach is prone to misclassification bias which
can result in an inaccurate estimation of prevalence
[52]. When compared to medical records, data from self-
report have been shown to underestimate the prevalence
of diabetic retinopathy [53]. However, moderate to high
levels of agreement between diabetes prevalence and self-
report have been shown in several studies [54–56]. Al-
though only data on self-reported diabetes were available,
results from trend analysis are in line with other developed
countries. Secondly, without the inclusion of undiagnosed
diabetes in our trend analysis, we acknowledge that diabetes
prevalence is underestimated. Finally, significant increases
in diagnosed diabetes prevalence were observed over time
but these increases may be attributed to heightened aware-
ness among patients, changes in clinical practices, including
increased screening for type 2 diabetes, and better survival
rates for patients with diabetes [57]. However, there is a
lack of data on mortality rates among people with diabetes
in Ireland; therefore it is not possible to determine whether
our increasing trends in prevalence are due to improved
health outcomes in those with diabetes.
Conclusion
This review provides the first comprehensive overview
of the burden of diabetes in Ireland. In the absence of a
national diabetes register, the findings in this review pro-
vide a robust estimate of the trends in prevalence of
doctor diagnosed diabetes among the adult population
in Ireland. Findings from this review are in accordance
with the Euro Diabetes Index (2014) [12]; there is a lack
of information relating to the prevalence of undiagnosed
diabetes, macrovascular and microvascular complications.
Interpretation of available data was limited due to incon-
sistencies in reporting, limited availability of objective data
and standardisation in diagnostic criteria. We suggest that
the true burden of diabetes in Ireland is underestimated
[58]. In 2010, the National Clinical Programme in Dia-
betes was established to improve and standardise patient
care in Ireland [59]. Reliable baseline data are needed to
monitor improvements in care over time at a national
level. Therefore, we suggest that a comprehensive national
diabetes register is urgently needed in Ireland.
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STUDY PROTOCOL Open Access
Evaluating the implementation of a
national clinical programme for diabetes to
standardise and improve services: a realist
evaluation protocol
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Abstract
Background: Over the last three decades in response to the growing burden of diabetes, countries worldwide
have developed national and regional multifaceted programmes to improve the monitoring and management of
diabetes and to enhance the coordination of care within and across settings. In Ireland in 2010, against a backdrop
of limited dedicated strategic planning and engrained variation in the type and level of diabetes care, a national
programme was established to standardise and improve care for people with diabetes in Ireland, known as the
National Diabetes Programme (NDP). The NDP comprises a range of organisational and service delivery changes to
support evidence-based practices and policies. This realist evaluation protocol sets out the approach that will be
used to identify and explain which aspects of the programme are working, for whom and in what circumstances to
produce the outcomes intended.
Methods/design: This mixed method realist evaluation will develop theories about the relationship between the
context, mechanisms and outcomes of the diabetes programme. In stage 1, to identify the official programme
theories, documentary analysis and qualitative interviews were conducted with national stakeholders involved in
the design, development and management of the programme. In stage 2, as part of a multiple case study design
with one case per administrative region in the health system, qualitative interviews are being conducted with
frontline staff and service users to explore their responses to, and reasoning about, the programme’s resources
(mechanisms). Finally, administrative data will be used to examine intermediate implementation outcomes such as
service uptake, acceptability, and fidelity to models of care.
Discussion: This evaluation is using the principles of realist evaluation to examine the implementation of a national
programme to standardise and improve services for people with diabetes in Ireland. The concurrence of
implementation and evaluation has enabled us to produce formative feedback for the NDP while also supporting
the refinement and revision of initial theories about how the programme is being implemented in the dynamic
and unstable context of the Irish healthcare system.
Keywords: Realist evaluation, Protocol, Diabetes, Implementation
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Background
Diabetes is a major public health and health service
challenge worldwide with global prevalence estimated
to increase from 2.8 % in 2000 to 4.4 % in 2030, an in-
crease from 171 million people to 366 million people in
30 years [1]. The most recent Global Burden of Disease
study estimates that diabetes is the seventh leading
cause of years lived with disability worldwide [2]. Dia-
betes is associated with reduced quality of life and life
expectancy [3, 4]. There are also significant societal and
health service costs associated with the condition; glo-
bal health expenditure on diabetes was estimates to be
at least US$376 billion in 2010, rising to US$490 billion
by 2030 [5].
Optimal diabetes care
The need for organised coordinated implementation of
strategies to improve diabetes care and reduce disease
burden has long been recognised. In 1989, health depart-
ments from across Europe, including Ireland, signed the
St. Vincent Declaration, a set of standards and goals to
improve diabetes care [6]. The onus was placed on indi-
vidual governments to implement strategies to meet the
agreed targets. Over the next three decades, a number of
countries developed national and regional multidimen-
sional programmes to improve the monitoring and man-
agement of diabetes and to enhance the coordination of
care within and across settings [7–10].
Consensus exists on what constitutes good quality dia-
betes care. Substantial evidence supports treatments to
manage diabetes and slow the progression of complica-
tions [11–15]. National and international guidelines rec-
ommend the regular monitoring and management of
blood glucose levels, blood pressure, kidney function,
body mass index and smoking status, as well as routine
foot surveillance, retinopathy screening and patient self-
management education [16–18]. At a system level, the
organisational features of high-quality diabetes care
include regular review, patient registration and recall
[19–21]. There has been a shift towards multidisciplin-
ary shared management of complex patients across
primary and secondary care settings, and structured
management of stable diabetes in primary care with
suitable organisational support [21, 22]. While quality
improvement strategies targeting professionals and pa-
tients improve diabetes care and patient outcomes,
strategies which target the entire system of chronic
disease management, such as case management, team
changes and patient registry, are associated with the
largest benefits [23].
Diabetes services in Ireland
Over the last two decades in Ireland, a plethora of pol-
icies and reports have repeatedly called for evidence-
based service developments seen in other countries [24].
A number of diabetes initiatives have emerged, led by
healthcare professionals, to improve diabetes care at a
local level but with inconsistent implementation of a
comprehensive diabetes service nationally. The balance
of care between primary and secondary care settings var-
ies and includes traditional hospital-based management,
shared care between GPs and hospitals, and structured
primary care-led management. Care in general practice
ranges from ad hoc opportunistic management to struc-
tured care characterised by patient registration, regular
recall and review coordinated by practice nurses [25]. A
national survey of GPs reported that less than half used
a patient register and diabetes guidelines or engaged in
routine recall of patients with diabetes. Less than 10 %
had a formal shared protocol or ever had a joint meeting
with the hospital diabetes team. There was deficient
access to allied health services such as podiatry, dietetics
and eye screening [26]. Within the hospitals, not all
diabetes services are led by an endocrinologist.
Endocrinology-led services in Ireland had more devel-
oped subspecialty clinics and greater access to specialist
allied health professionals. However, waiting times for
these services were longer and discharge rates to pri-
mary care were lower than for non-specialty led ser-
vices [27]. The provision of structured diabetes care in
general practice and shared care between settings has
produced favourable results in Ireland in terms of pro-
cesses and outcomes of care [28–31]. However, these
models of care are not common-place and there is a
dearth of information on the quality of routine diabetes
management at a national level.
The National Diabetes Programme: a complex
intervention to standardise care
Against this backdrop of variation in the type and qual-
ity of diabetes care, and a lack of dedicated strategic
national planning and programme implementation, in
2010, a clinical programme for diabetes was established
to standardise and improve care for people with diabetes
in Ireland, known as the National Diabetes Programme
(NDP) [32]. The NDP was one of a number of clinical
care programmes set up under the auspices of the
Directorate of Clinical Strategy and Programme in the
Health Service Executive (HSE), the national health ser-
vice in Ireland. The overarching goals of these pro-
grammes are to improve access to services, quality and
safety of care, and cost effectiveness. These goals are
achieved by bringing together representatives from vari-
ous clinical disciplines to develop standardised patient
pathways and evidence-based models of care [32]. Simi-
lar to the other programmes, the diabetes programme
has a defined governance structure with a national clin-
ical lead and programme manager, a clinical advisory
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group, and a national working group with the joint in-
volvement of healthcare providers in primary, secondary
and tertiary care [33]. There are also four regional Dia-
betes Services Implementation Groups (DSIGs), which
are multidisciplinary regional networks established to
inform the development and implementation of the
National Diabetes Programme.
The specific aim of the NDP is to ‘save the eyes, limbs
and lives of people with diabetes’ [33]. Like other large-
scale service delivery innovations [34], a change in
patient outcomes was to be achieved through the coor-
dinated reorganisation of existing services, and the intro-
duction of new services and supports for people with
diabetes. Dedicated work streams were established for
the implementation of a national retinopathy screening
programme, a national model of care for the screening
and treatment of diabetic foot disease, and a national
model of integrated care for the management of dia-
betes across primary, secondary and tertiary care set-
tings (Fig. 1).
Service innovations such as the NDP lead to both
intended and unintended consequences. Evaluation pro-
vides an opportunity not only to identify and track these
but also to identify multilevel barriers to implementation
and conditions that make success and sustainability
more likely. However, process evaluation is difficult to
apply to complex services spanning organisational
boundaries [35]. The NDP represents a number of com-
plex interventions introduced into a complex social sys-
tem, making it an appropriate subject for a realist
evaluation. The realist evaluation approach, developed
by Pawson and Tilley, goes beyond looking at whether a
programme works or not, to try and understand which
aspects of the programme work, for whom, in what cir-
cumstances [36, 37]. There is an inherent acknowledge-
ment that a programme will work differently in different
contexts; the aim is to understand what it is about a
programme that leads to different outcomes [38].
According to Pawson and colleagues, complex service
interventions are based on an underlying hypothesis of
Fig. 1 Intervention components of the National Programme for Diabetes
McHugh et al. Implementation Science  (2016) 11:107 Page 3 of 13
how the intervention will bring about an outcome [37,
39]. The first step of a realist evaluation is to identify
and articulate these theories, known as programme the-
ories. A programme provides a resource, an opportunity
or a constraint, that influences the decision-making
process of its intended target group. It is this decision-
making process that determines whether an outcome is
achieved or not; complex interventions are active, that is
they only work through stakeholders’ reasoning and re-
sponses. This underlying interaction between what a
programme provides and the reasoning of its intended
targets is known as a mechanism. Understanding and
explaining the often invisible implicit mechanisms are
core functions of a realist evaluation [37, 40]. Mecha-
nisms are argued to be triggered, to a greater or lesser
extent in certain favourable and unfavourable contexts,
leading to intended and unintended outcomes. The
programme theory articulates a theoretical relationship
between a context, mechanism and outcome, known as
a ‘C-M-O’ configuration [37].
In this paper, we present the protocol for an evaluation
of the NDP that adopts a realist approach. The aim of
the evaluation is to identify and explain which aspects of
the programme are working (or not working), for whom
and in what circumstances to produce outcomes. The
evaluation will examine three ongoing work streams of
the NDP which have been prioritised since its inception
in 2010: the introduction of a national diabetic retinop-
athy screening programme (initiated in 2013); the estab-
lishment of a national model of foot care for people with
diabetes (staff recruited in 2013); and the development
of a national model of integrated care for diabetes (staff
recruited in 2013). The aim of this paper is to outline in
detail the stages, methods and data being used in the
evaluation, as well as some of the challenges to, and op-
portunities for, providing formative feedback to the
NDP.
Methods/design
This prospective evaluation follows the research stages
outlined by Pawson and Tilley: (1) elicit and formulate
the programme theory underlying the NDP and its work
streams (national retinopathy screening programme, na-
tional foot care model and national model of integrated
care), (2) collect data to test these initial theories, (3)
analyse data to interrogate the theories and (4) interpret
analysis to refine or revise the initial programme theor-
ies [36] (Fig. 2).
Realist evaluation is method neutral and most studies
employ both quantitative and qualitative research
methods [41–44]. We are using mixed methods depend-
ing on the stage of the study and the theory component
(context, mechanism or outcome) under scrutiny; for ex-
ample documentary analysis and qualitative interviews are
considered useful for identifying the official programme
theory and context, qualitative interviews are also appro-
priate for exploring stakeholders’ responses to and reason-
ing about the programme (mechanisms), and quantitative
administrative data allow examination of outcomes such
as service uptake [37]. Table 1 summarises the methods
being used during data collection at stage 1 and stage 2.
Fig. 2 Realist research cycle (adapted with permission from [63])
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Stage 1: elicit and formulate the programme theory
Design
As a theory-based evaluation approach, the first step of the
realist evaluation is to clarify the ‘programme theory’; that
is how the NDP and its three work streams are expected to
cause or contribute to outcomes. The programme theory
articulates the relationship between a context, mechanism
and outcomes of the national programme components,
known as ‘C-M-O’ configurations.
Data collection
Three data sources were used to develop the initial
programme theory. Firstly, a documentary analysis was
carried out to establish the official programme theory, ex-
pectations and rationale for establishing the Programme.
Documents included published and unpublished material
such as strategy documents from interest groups, media
coverage, press releases, national service plans, NDP web-
site, and official documentation on the role and function
of the programmes. An additional file outlines the type
and source of documents (see Additional file 1). These
data were also useful for mapping the context in which
the programme was being designed and implemented.
Secondly and concurrently, we conducted qualitative
interviews with a purposive sample of stakeholders in-
volved at a national level in the design, development and
management of the Programme. All members of the na-
tional diabetes working group were invited to take part
(membership between July 2014 and January 2015) as
well as former clinical leads and programme managers.
The national diabetes working group comprises repre-
sentatives from endocrinology, general practice, diabetes
nurse specialists and practice nurses, dietetics, podiatry,
community pharmacy, public health, patient advocacy
and health service management. Members also represent
different parts of the country. Following an initial invita-
tion via email, all participants were contacted individu-
ally by a member of the research team (MT) to outline
the study and arrange a convenient time and place for
interview.
A semi-structured topic guide was developed informed
by initial findings from the documentary analysis and
previously published realist evaluations [38, 42]. The
topic guide was piloted with a convenience sample of
two participants involved in diabetes care, who were not
members of the national working group but were aware
of the work of the Programme. Minor amendments were
made to the prompts and probes used within the topic
guide. The topic guide addressed participants’ role in the
Programme, why the programme was established, the
planned changes and how they were being implemented,
progress to date, anticipated barriers and facilitators, and
expected outcomes (see Additional file 2).
Face-to-face interviews were conducted (by MT) with
19 participants between July 2014 and January, 2015 (aver-
age duration 1 h). Participants received an information
Table 1 Data collection during stages 1 and 2 to formulate and refine programme theories
Stage Methods
Stage 1: Elicit and formulate the programme theory • Documentary analysis of published and unpublished documents pertaining
to the establishment, development and implementation of the National
Programme for Diabetes and the three programme interventions.
• Semi-structured interviews with national level programme developers (n = 19).
Stage 2: Data Collection Implementation of the National Programme for Diabetes
• Multiple case study design (n = 4 cases)
• Semi-structured interviews with theoretically sampled stakeholders in
each area (n = approx. 15 per case).
Further data for each case will be gathered through a number of sub-studies
conducted at a local and national level to build a rich case description and
allow for embedded analysis of each programme component.
Retinopathy screening programme
• Audit of registration, consent and uptake among a convenience sample of two
large primary care centres (n = 22 GPs, approx. 600 people with diabetes) and a
smaller rural practice in one region (n = 2 GPs, approx. 100 people with diabetes)
• Semi-structured interviews with people with diabetes from those practices
National foot care model
• Semi-structured interviews with podiatrists including those recruited as part of
the programme.
• Cross-sectional study of administrative activity data submitted by podiatrists as
part of the National Programme for Diabetes.
National model of integrated care
• National survey of Diabetes Nurse Specialists (DNSs) including those recruited
as part of the programme.
• Follow-up interviews and focus groups
• Cross-sectional analysis of administrative activity data submitted by DNSs recruited
as part of the National Programme for Diabetes
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sheet and signed a consent form prior to the interview.
These participants are implementers within their own
local diabetes service as well as being involved in the de-
sign of programme at a national level. Thus, in addition to
discussing planned implementation and expected out-
comes (official programme theory), participants discussed
their own experience of implementation, perceived out-
comes in their area, and barriers encountered. Data collec-
tion and analysis were iterative to allow the gathering of
further data on emergent themes and the topic guide was
modified to accommodate emergent lines of inquiry.
Thirdly, following a presentation of preliminary find-
ings, a short survey was conducted among attendees at
the annual conference held by the NDP (November,
2015). Attendees, including healthcare professionals, pa-
tient representatives, health service managers and policy
makers involved in or affected by the national programme,
were invited to complete open-ended questions about
which aspects of the national programme were working
well, which aspects were not working as well, and why.
Respondents were asked to indicate their professional role
and the area of the country in which they worked. Thirty
attendees completed the questionnaire (approximately
25 % response rate). Gathering the opinions of those in-
volved in implementation from around the country
allowed for further refinement and corroboration of the
initial programme theories based on national stakeholders’
accounts.
Data analysis
Interviews were audio-recorded, transcribed verbatim
and imported into NVivo 10 software [45]. The frame-
work approach [46] was used to systematically identify
contexts (C), mechanisms (M), and outcomes (O) in
the interview transcripts and documents, and chart
hypothetical relationships between them (C-M-O con-
figurations) to formulate programme theories for each
programme component.
The Framework approach is sufficiently open to allow
for novel themes to emerge inductively during analysis
[47]. First, transcripts were read and re-read (familiarisa-
tion), followed by open coding to identify contexts,
mechanisms and outcomes. Emergent concepts which
did not fit explicitly with the C-M-O framework were
also coded. Two researchers (MT and SMH) open-coded
three interviews of staff from different parts of the coun-
try. The research team then met to compare and contrast
codes, clarify understanding of contexts, mechanisms and
outcomes, and agree on an initial coding framework. Two
independent coders (FR, KON, researchers who had re-
cently joined the research team) were invited to analyse
four interviews (from different professional backgrounds
and locations) to further refine the coding framework.
This coding framework was applied to subsequent
transcripts by the research team. Framework development
was a dynamic process with regular meetings to discuss
new codes or merging existing codes, assumptions, and
ideas about C-M-O configurations.
Having openly coded all of the transcripts, data were
sorted and synthesised by theme bringing similar concepts
together (thematic charting). At this stage, themes were
sorted under the individual programme components: na-
tional working group (SMH), retinopathy screening (MT),
national foot care model (KON) and national model of
integrated care (FR). Each researcher led on the synthesis
of codes and development of themes for a different
programme intervention. This facilitated data manage-
ment but also enabled data immersion necessary to de-
velop a programme theory about the relationship between
contexts, mechanisms and outcomes for that intervention.
In some instances, participants themselves outlined partial
C-M-O configurations during interviews (e.g. between
contexts and outcomes, mechanisms and outcomes); these
relationships were refined or revised by examining other
participant interviews. However, in most cases, the re-
search team developed C-M-O configurations based on
the analysis of all interviews, starting with a synthesis of
the proposed outcomes and working backwards to build a
theory about the mechanism that led to that outcome and
the context that triggered the mechanism.
Open-ended responses to the conference survey were
coded using the same approach although emergent
themes tended to reiterate, and overlap with enabling
and disabling contexts identified during the interviews.
The themes were used to reinforce or refine the initial
C-M-O configurations.
Memos were used and shared throughout the analysis
to note assumptions, events and changes in the NDP,
coding definitions, hunches and early impressions [48].
The language and expressions of the participants were
maintained as far as possible, using in vivo codes, to
avoid losing the meaning and context. The results were
presented to the wider research team for discussion.
Stage 2: data collection to test programme theories
The aim of stage 2, which is currently underway, is to col-
lect data to test the C-M-O configurations developed in
stage 1. A multiple case study design is being used. Case
studies are often used in realist evaluation [34, 49–51]; this
approach emphasises the in-depth study of phenomena
in their real-life context, and the importance of theory
to inform the design, selection and interpretation of
case studies [52].
Case selection
A case was defined as a geographical area within one of
the four HSE administrative regions (Fig. 3).
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A number of criteria were used to select a case area.
Firstly, cases had to have received an intervention from
the NDP (retinopathy screening programme, integrated
care nurse and/or podiatrist). Second, it emerged during
stage 1 analysis that the presence or absence of a dia-
betes initiative (either a primary care-led diabetes initia-
tive, an existing community diabetes nurse specialist
(DNS) service, or an established diabetic retinopathy
(DR) screening initiative) was an important contextual
factor; therefore, we theoretically selected cases on this
basis. More detail on the underlying rationale for case
selection is available (see Additional file 3).
We mapped these criteria for all areas, starting with
the allocation of interventions by the NDP, and
discussed the selection of cases within the research
team. Table 2 outlines the final selection of four cases
and their characteristics.
Data collection
Within each case, multiple sources of data will be used
to test the C-M-O configurations developed in stage 1.
Qualitative Qualitative interviews will be undertaken
with key stakeholder groups purposively sampled in each
case and this work is ongoing. Table 3 outlines the ex-
pected number of participants per case. In each area,
local members of the regional DSIG will be invited to
participate. Participants will be invited to suggest other
Fig. 3 Map of administrative regions in the Health Service Executive (HSE)
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Table 2 Case study selection & sampling criteria
Case 1 Case 2 Case 3 Case 4
NDP interventions
• Received 2 components
Existing infrastructure and engagement
• Prior DR screening initiative delivered
in the community, open to patients in
a select number of general practices
(no universal access)
• Existing primary care diabetes initiative
with voluntary enrolment by some
general practices
NDP interventions
• Received 3 components
Existing infrastructure and engagement
• Previous population-based retinopathy
screening initiative offered to all general
practices in the area
• Existing primary care diabetes initiative
with voluntary participation from some
practices
• Community DNS
NDP interventions
• Received 3 components
Existing infrastructure and engagement
• Previous hospital service which provided eye
screening for those referred to service, no
population-based screening programme in
the community
• Existing primary care diabetes initiative
with voluntary participation from general
practices
• Community DNS
NDP interventions
• Received 3 components
Existing infrastructure and engagement
• Previous hospital service which provided eye
screening for those referred to service, no
population-based screening programme in
the community
• No existing primary care-led diabetes initiative
• Community DNS
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stakeholders such as health service managers that they
engage with. These managers may or may not be for-
mally involved with the DSIG but have a role in deploy-
ing and coordinating resources. Integrated care nurses
and podiatrists appointed as part of the implementation
of the NDP will be invited to participate in an interview
or focus group, as well as diabetes nurse specialists (hos-
pital and community-based) and podiatrists previously
in post. A purposive sample of GPs and practice nurses
will be recruited from practices enrolled/not enrolled in
primary care-led diabetes initiatives. Participants will be
recruited through educational meetings, continuing pro-
fessional development groups and local DSIGs. People
with diabetes will be recruited using a web-based entry
form and dedicated telephone line (participant portal).
To ensure we have patient representation specific to our
cases, we will ask participating healthcare professionals
to publicise our study and the participant portal to pa-
tients, and display sign-up posters in local clinics. People
with diabetes will also be recruited through local educa-
tion and awareness events run by a national patient ad-
vocacy group (Diabetes Ireland).
A theory-driven topic guide has been devised for inter-
views in stage 2, based on the programme theories de-
veloped during stage one. The topic guide has been
tailored to the stakeholder group being interviewed (hos-
pital specialist, GP, practice nurse, specialist nurse, po-
diatrist, person with diabetes). During the interview, we
will have an active and explicit role in explaining the
contexts and outcomes of interest, to ensure a shared
understanding of the terminology and purpose of the
questions. In the context of our developed theories, par-
ticipants will be invited to explain how their experience
fits with that theory and reflect on what may explain the
outcomes in their area [53]. The topic guide has been
piloted with a convenience sample of one GP and two
practice nurses, staff who would be most familiar with
or in receipt of most programme components. Written
consent will be obtained prior to each interview, and all
interviews will be audio-recorded and transcribed verba-
tim. Thematic analysis of the interviews will be guided
by the initial programme theories identified in stage 1.
However, analysis will be open to emergent themes to
facilitate further theory refinement.
Quantitative To assess programme outcomes, adminis-
trative data and healthcare professional surveys will be
analysed (see Table 1). For the national retinopathy
screening programme, the outcomes being examined are
registration, consent and uptake. These will be examined
using local audits of clinical records in general practice.
For the national foot care model, case-specific activity
data including the number and risk profile of patients
will be analysed. For the national model of integrated
care, a national survey of diabetes nurse specialists (in-
cluding integrated care nurses) is being conducted. This
will be supplemented with case-specific analysis of activ-
ity data, including the number of GPs engaging with the
integrated care nurse service and the number of patient
consultations.
Stage 3: analyse data to interrogate theories
In realist evaluation, the unit of analysis is the theories
hypothesising the mechanisms by which an intervention
produces certain outcomes in a particular context [54].
A matrix will be used to analyse and synthesise both the
qualitative and quantitative data available for each case
(administrative data, survey data, transcripts) [55, 56]. A
matrix will be constructed for each programme theory
relating to various programme components (retinopathy
screening, national foot care model, and national model
of integrated care). Following the example of O’Cathain
and colleagues [57], the columns of the matrix will con-
tain the contexts, mechanisms and outcomes for a given
theory. Each row in the matrix will represent a different
case (see Additional file 4 for an example). This ap-
proach will facilitate within-case analysis, highlighting
similarities or discrepancies between data sources which
may lead to further data collection or analysis [56]. It
will also facilitate cross-case analysis to identify patterns
across cases. NVivo 10 software will be used to store
and manage data [45].
Stage 4: interpret analysis to refine or revise the initial
programme theories
In light of the analysis in stage 3, the programme theor-
ies underpinning the NDP will be refined. The original
programme theories will be assessed against the evi-
dence emerging within cases and then between cases to
more accurately reflect the experiences of those deliver-
ing and receiving the changes introduced by the NDP,
and the outcomes realised in different contexts.
Table 3 Stage 2 sample per case
Number per case Total
DSIG member 2 8
Endocrinologist 1 4
General practitioner (GP) 2 8
Practice nurse 2 8
Diabetes nurse specialist/integrated
care nurse
2 8
Podiatrists 2 8
Ophthalmologist 1 4
Patient representative 2 8
Health service manager 1 4
Total 15 60
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Ethical considerations
This study has been approved by the Clinical Research
Ethics Committee of the Cork Teaching Hospitals. Each
participant in the study is asked for written informed
consent prior to conducting the interviews and focus
groups. Informed consent has also been sought from
survey participants, and data have been anonymised for
analysis and reporting. Permission has been granted by
the NDP to analyse activity data submitted to the
programme. Anonymity will be assured at each case
study site and all participants will be given a unique ID
number. Initial programme theories were presented to
members of the national working group for comment.
Results from later stages will be fed back to case study
participants in the form of a case report. Any potentially
identifiable information will be removed prior to report-
ing and publishing the findings.
Discussion
Realist evaluation, which allows for the study of context
and its influence on outcomes, is appropriate for exam-
ining the implementation of the NDP, given the history
of regional variation in diabetes services in Ireland. This
paper outlines the protocol for a mixed methods evalu-
ation to explore which aspects of the programme are
working, for whom and in which circumstances.
Geographic case studies are often difficult to define
[52], and this has been a particular challenge in this
study given the ill-defined boundaries of health services
in Ireland. Catchment areas for health services and hos-
pitals are often fluid, and the organisational structures
within the health service have gone through several re-
cent reconfigurations. Furthermore, the results of stage
1 of this study suggest variation in diabetes services
within regions and counties depending on the local re-
sources, infrastructure and engagement from stake-
holders such as GPs and local management. We have
selected cases for stage 2 on the basis of these prelimin-
ary findings. The aim of this study is to understand how
the NDP is working, for whom and in what circum-
stances. Therefore, the cases are considered instrumental
as opposed to intrinsic [58], that is they are being used
to gain a deeper understanding of programme imple-
mentation as a whole, as opposed to focusing on the
uniqueness of the individual case itself.
We have used a number of strategies to enhance the
rigour of this study. Data collection tools including topic
guides and surveys have been extensively piloted. Differ-
ent triangulation techniques will be used to strengthen
the validity of findings, including the use of mixed
methods, multiple data sources (interviews and docu-
ments) and researchers from different disciplinary per-
spectives (health services research, epidemiology, public
health, clinical medicine) [59]. While the limitations of
member checking as a strategy to verify overall re-
sults have been highlighted, it is considered appropri-
ate to enhance validity in case study research, as case
reports maintain the contextual information that al-
lows participants to relate their experiences to synthe-
sised results [52, 60].
Throughout this study, data will be collected and ana-
lysed concurrently within each stage to allow emergent
lines of enquiry to be explored [60]. The research team
has endeavoured to be responsive to the implementation
of the programme and changeable context in which it is
being rolled out. For example, in October 2015, the
Department of Health in Ireland agreed a new contract
with GPs which provided financial reimbursement for
two structured diabetes review visits in general practice
per year. This scheme is known as the Diabetes Cycle of
Care. Patients with type 2 diabetes who have a medical
card or a GP visit card, which entitles them to free GP
care in Ireland, are eligible to be registered by their GP
for the scheme. This is a significant influential factor
in the context of the NDP. Although not part of the
initial programme theories, given its recent introduc-
tion, we have adapted our topic guide to explore how
the introduction of this financial incentive may influ-
ence implementation.
Complex social interventions such as the NDP achieve
their outcomes by active input from various stake-
holders. Qualitative research is an important part of ex-
ploring the reasoning and responses of stakeholders to a
programme [37]. Similar to other realist evaluations [61],
the results of our interviews with national programme
stakeholders, who were also local implementers with
context-specific experience, further refined ‘official’
programme theories about which aspects are working, in
which circumstances and why. This evaluation builds on
previous work by the research team which analysed the
many diabetes care policies in Ireland, thereby providing
information on some of the contextual factors that pre-
ceded the national programme [24]. Pawson suggests that
by defining clearly the boundaries of case studies, eval-
uators are then able to harness the potential of admin-
istrative data, for example, relevant to quantifying the
outcomes of programmes in realist evaluation [37]. Col-
laboration with the NDP has enabled us to analyse such
administrative information where available. However, we
are limited by the lack of a diabetes register in Ireland or
national databases on the quality of diabetes care, and pa-
tients’ health service interactions and outcomes.
There is increasing interest in the evaluation of health
policy and health service implementation. In particular,
there is increasing emphasis on theory-based evaluations
which aim to establish the context and mechanisms that
facilitate successful implementation rather than simply
focusing on the achievement of specific endpoints [35].
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Realist evaluation has been used for this purpose to study
a diverse range of service changes including the introduc-
tion of an integrated care pathway for palliative care [41],
a multifaceted maternity care programme [49], ‘communi-
ties of practice’ [38], oncology teams [54] and quality
improvement in primary care [51]. There are very few
evaluations of the implementation of programmes or ser-
vice interventions in Ireland, and to our knowledge, this is
the first realist evaluation of a programme in Ireland.
The NDP is constantly moving between planning for
future work streams and ongoing implementation of the
current work streams. Therefore, the programme offers
a potentially unique opportunity to evaluate and inform
the implementation of changes in the Irish health system
as they emerge and evolve. For example, there has been
phased recruitment of integrated care diabetes nurse
specialists (known as integrated care nurses (ICNs)) to
support the implementation of the national model of in-
tegrated care as resources have been secured at national
level. A protocol has been developed to clarify the role
of the ICN, partly in response to barriers to implementa-
tion highlighted in the evaluation. There is close collabor-
ation between the national working group and research
team; the principal investigator (PK) is a member of the
working group which provides an opportunity to provide
formative feedback on implementation to those respon-
sible. Our results should also provide insights relevant to
the implementation of other clinical care programmes in
Ireland operating in similar contexts. Furthermore, we
hope that the findings will be relevant to programmes in
other countries, some of which are also evaluating imple-
mentation of new care programmes [62].
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